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Genetisk disposisjon for utvikling av svangerskapsforgiftning 
Genetiske assosiasjonsstudier i populasjonsbaserte kohorter og genekspresjonsstudier i 
decidua basalis vev 
 
Svangerskapsforgiftning (preeklampsi) kjennetegnes av høyt blodtrykk og protein i urinen etter 20. 
svangerskapsuke. Denne tilstanden oppstår i 2-8% av alle svangerskap, og er en av de viktigste årsakene 
til sykdom og død hos mor og foster. Til tross for intensiv forskning er årsakssammenhengene for 
utvikling av svangerskapsforgiftning fortsatt uklare. Vi vet at redusert blodgjennomstrømming 
i morkaken har en sentral rolle. Prosesser i decidua, som er den maternelle delen av morkaken og utgjør 
møtesonen mellom mor og foster, kan være avgjørende. Andre forhold virker også inn, som forhøyet 
kronisk inflammasjon hos mor. Forhøyet kronisk inflammasjon er også forbundet med overvekt, diabetes 
og forhøyet blodtrykk. Svangerskapsforgiftning kan ha konsekvenser på lengre sikt, blant annet er det en 
klar sammenheng mellom sykdommen og utvikling av hjerte-karsykdom senere i livet.  
 
Det er økt forekomst av svangerskapsforgiftning i enkelte familier. Epidemiologiske studier har vist at 
genetiske faktorer utgjør omtrent 50% av risikoen for sykdomsutvikling. Formålet med denne studien var 
å kartlegge genetisk disposisjon for utvikling av svangerskapsforgiftning.  
 
I studien ble det benyttet decidualt morkakevev fra kvinner med svangerskapsforgiftning, og/eller føtal 
veksthemming og kvinner med normale svangerskap samlet inn ved St. Olavs hospital og Haukeland 
universitetssykehus for å se på forskjell i genuttrykk mellom disse gruppene. RNA ble isolert, og en 
helgenomstranskripsjonsstudie med mer enn 48 000 transkripter fra alle kjente gener ble gjennomført. 
Deretter ble det foretatt nettverksanalyser for å se om de ulikt uttrykte genene påvirket hverandre. Videre 
har vi brukt data fra Helseundersøkelsen i Nord-Trøndelag (HUNT 2), Medisinsk fødselsregister og The 
Western Australian Pregnancy Cohort (Raine) Study til å sammenlikne gen-varianter mellom kvinner 
med svangerskapsforgiftning og normale svangerskap. Vi har også undersøkt om spesifikke gen-varianter 
på kromosom 2 kan disponere både for svangerskapsforgiftning og risikofaktorer for hjerte-karsykdom.  
 
Analysene av decidualt morkakevev viste at 455 transkripter var ulikt uttrykt hos kvinner med 
svangerskapsforgiftning sammenliknet med kvinner med normale svangerskap. Disse transkriptene 
omfattet både nye kandidatgener, for eksempel ARL5B og SLITRK4, og gener som tidligere var assosiert 
med svangerskapsforgiftning, for eksempel PLA2G7 og HMOX1. Sju signifikante reaksjonsveier som var 
assosiert med svangerskapsforgiftning ble identifisert. Disse var blant annet relatert til immunologiske 
mekanismer, utviklingen av blodkar, oksidativt stress, stress i endoplasmatisk retikulum (ER) og 
forstyrrelser i fettsyre-metabolismen. I videre analyser fant vi at stress i ER var særlig aktivert ved 
svangerskapsforgiftning med føtal vekstemming. Denne gruppen viste også ulikt uttrykk av STOX2, som 
kan være en medvirkende årsak til redusert blodgjennomstrømning i morkaken. Vi fant ut at fire gen-
varianter på kromosom 2 som tidligere er assosiert med svangerskapsforgiftning også kan være assosiert 
med risiko-faktorer for hjerte-karsykdom. 
 
Denne studien har bidratt til å underbygge og identifisere noen av de sentrale mekanismene som er 
knyttet til utviklingen av svangerskapsforgiftning, og vi forstår litt mer av sammenhengen til hjerte-
karsykdom. Målet på lang sikt vil være å identifisere kvinner med økt risiko for svangerskapsforgiftning 
og hjerte-karsykdom, samt å kunne utvikle nye diagnostiske tester og behandlingsmåter.  
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1. INTRODUCTION 
 
1.1 Prevalence, definition and diagnosis  
Preeclampsia 
Preeclampsia affects 2-8% of all pregnancies and is a substantial burden on maternal 
and fetal health worldwide [1-3]. The rate of preeclampsia differs among nations, and 
women in developing countries and some ethnic groups (e.g., African-American and 
Filipino women) are at increased risk [2]. The rate of preeclampsia in the USA has been 
increased slightly during the past 30 years [4, 5]. This increase might, at least partially, 
be related to an increased prevalence of disorders with a predisposure towards 
preeclampsia, such as chronic hypertension, diabetes mellitus and maternal obesity [5, 
6]. In Norway, the prevalence of preeclampsia increased from 2.1% in 1967 to 4.4% in 
1999. From 2002 onwards, there has been a consistent decline, with an overall 
prevalence of 3.0% [7], and a similar trend has been reported in other countries, such as 
Sweden, Australia and Canada [8]. These reduced rates of preeclampsia have been 
observed despite the steadily increasing rates of the above mentioned predisposing 
disorders [7]. It has been speculated that elective delivery prior to the due date for 
women with high risk of preeclampsia and the use of interventions that reduce the risk 
of progression to preeclampsia are responsible for this trend [8].  
 
The principal diagnostic clinical criteria for preeclampsia are new-onset hypertension 
and proteinuria after 20 weeks gestation [9]. The diagnostic criteria for preeclampsia in 
Norway are given by the Norwegian Association for Obstetrics and Gynecology [10] 
and primarily follow the recommendations of the (US) National High Blood Pressure 
Education Program Working Group on High Blood Pressure in Pregnancy [11]. 
According to these criteria, preeclampsia is defined as a pregnancy-specific syndrome 
that occurs after mid-gestation characterised by 1) de novo appearance of hypertension 
of ≥140/90 mmHg combined with 2) new-onset proteinuria of ≥0.3 g/L in a 24-hour 
urine sample. In addition, the Norwegian Association for Obstetrics and Gynecology 
requires two separate measurements of hypertension and proteinuria [10]. To provide 
accurate diagnosis, specific guidelines for blood pressure measurements and proteinuria 
are given. Two blood pressure measurements should be obtained at an interval of at 
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least four to six hours but not more than one week apart, and proteinuria should be 
measured on at least two occasions at an interval of four to six hours [12]. The gold 
standard for measuring proteinuria is a 24-hour urine sample, but when this is not 
feasible, a time measure corrected for creatinine excretion is recommended [13]. The 
dipstick test for urinary protein is simple and easy to perform. Excretion of ≥0.3 g 
protein/L in 24 hours usually corresponds to ≥30 mg/dl (≥1+) on a dipstick in a random 
urinary sample when there is no indication of urinary tract infection. On a clinical daily 
basis, this method is usually preferred for diagnostic purposes. 
  
The clinical manifestations of preeclampsia are heterogeneous, and the symptoms range 
from mild to severe. Mild cases, with onset near term and only a small increase in the 
risk of an adverse pregnancy outcome, are clearly most common [12]. The 
differentiation of mild and severe preeclampsia remains a topic of discussion [14]. 
Severe preeclampsia is not well defined with specific characteristics but includes 
assessment of both maternal (severe hypertension, end organ manifestation and preterm 
disease) and fetal (intrauterine growth restriction, fetal movement assessment and 
oligohydramnios) phenotypes [11]. One severe form of preeclampsia is characterised by 
microangiopathic haemolytic anaemia and is termed HELLP (Haemolysis, Elevated 
Liver enzymes and Low Platelets) syndrome. Early-onset (<34 weeks of gestation) 
preeclampsia is generally considered a severe form of preeclampsia, but this opinion is 
also controversial [14]. Early-onset preeclampsia occurs in approximately 10% of 
preeclamptic cases [8] and is often associated with more severe outcomes for the mother 
and child. It has been speculated that early-onset and late-onset preeclampsia are 
different phenotypes with different aetiologies [15]. Preeclampsia occurs mainly in first 
pregnancies (approximately 70% of preeclamptic cases), and the majority do not 
experience preeclampsia in later gestations [16, 17]. Recurrent preeclampsia tends to 
have an early onset and to show a more severe phenotype compared to non-recurrent 
preeclampsia [16, 18]. This includes a higher risk of preterm labour, increased rates of 
fetal growth restriction (FGR) and higher risk of cardiovascular disease (CVD) in later 
life.  
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Fetal growth restriction 
Inadequate fetal growth is a major concern in obstetric medicine, as fetal growth 
disorders are important causes of perinatal morbidity and mortality [19, 20]. In most 
pregnancies with inadequate fetal growth, the fetuses are physiologically normal and 
simply small for gestational age (SGA). This is in contrast to FGR, which is 
characterised by pathological small fetal size and failure to reach the genetically 
determined growth potential [21]. FGR affects 3-10% of all pregnancies [22] and is a 
substantial burden on perinatal morbidity and mortality [19, 20]. There is no universally 
accepted FGR definition, but international agreement has estimated that a fetal weight 
below the 10th percentile of expected birth weight adjusted for gestational age should 
alert clinicians to potential small fetal size. By reducing the cut-off to less than the 5th 
percentile or even lower, the specificity for true growth restricted infants might be 
increased, and help identify infants at increased risk of adverse outcome [21]. Clinical 
assessments during the pregnancy such as serial measurements of fundal height [23], 
serial ultrasound biometry [24], and Doppler ultrasound examination of umbilical 
arteries [25] are useful for diagnosis. However, as these methods are time consuming, 
measures of low birth weight (below a given percentile) as indicators of impaired fetal 
growth are often used for research purposes. 
 
1.2 Maternal and fetal outcome of preeclampsia 
In high-income countries, hypertensive disorders of pregnancy are responsible for 16% 
of maternal deaths [2]. Maternal mortality is even higher in low-income countries [2]. 
Furthermore, severe preeclampsia is a major cause of severe maternal morbidity (e.g., 
renal failure, hepatic infarction and rupture) and adverse perinatal outcomes such as 
poor growth and preterm delivery [3]. As preeclamptic symptoms resolve following 
delivery of the fetus and placenta, caesarean section (CS) performed due to a life-
threatening condition for the mother makes the syndrome a major contributor to 
premature deliveries. In Norway, 15% of premature deliveries may be ascribed to 
preeclampsia [26].  
 
Appropriate prenatal care is considered the most important factor in the management of 
preeclampsia [27] and reduces maternal and fetal mortality [28, 29]. In Norway, 
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antenatal care facilities and patient education are provided to pregnant women 
prenatally to ensure early detection of the clinical signs of preeclampsia. Special 
attention targeting new hypertension, new proteinuria, symptoms of headache, visual 
disturbance, epigastric pain, vomiting, reduced fetal movements and an infant that is 
SGA is emphasised [30]. Women with increased risk have frequent antenatal 
surveillance, including baseline and serial assessments of blood pressure, collection of 
urine samples, measurements of biochemical markers of renal function and liver 
function and of uric acid, and platelet counts. Unfortunately, these follow-ups are not 
performed in all parts of the world due to circumstances including lack of health care 
facilities, doctors, blood pressure measurement equipment and fetal monitoring, 
including Doppler ultrasounds and electrocardiograms. Consequently, the numbers of 
deaths from preeclampsia remains high globally [2]. The progression to generalised 
seizures of eclampsia is 10-30 times more common in developing countries than in 
high-income countries [3].  
 
1.3 Risk factors for preeclampsia 
Epidemiological studies have identified several risk factors for the development of 
preeclampsia. Some of these risk factors are listed in Table 1 (based on reviews by 
Dekker and Sibai [31] and Duckitt and Harrington [32]). The identification of women 
with an increased risk of preeclampsia is important to optimise the chances of 
prediction, prevention, and early diagnosis and to secure an appropriate management 
plan. The risk factors for preeclampsia may guide further research into its 
pathophysiological mechanisms. Genetic risk factors will be presented specifically in 
Section 1.6.  
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Table 1. Some known risk factors for preeclampsia. 
Partner-related       Risk*
Nulliparity/primipaternity 4: 1
Limited sperm exposure 12: 1
Fathered a preeclamptic pregnancy in another woman 2: 1
Maternal-specific
Age >40 years 2: 1
BMI >35 kg/m2 2: 1
Nulliparity/primiparity 3: 1
Preeclampsia in a previous pregnancy 7: 1
Family history of preeclampsia 3: 1
Pre-existing medical conditions
Insulin dependent diabetes 4: 1
Chronic hypertension 4: 1
Renal disease 20: 1
Chronic autoimmune disease 7: 1
Antiphospholipid syndrome 10: 1
Pregnancy associated
Multiple pregnancy 3: 1
Urinary tract infection 3: 2
 
* Published risk (odds ratio (OR) or relative risk), based on reviews by Dekker and Sibai [31] 
and Duckitt and Harrington [32].  
 
1.4 Preeclampsia – a window to future cardiovascular health 
CVD include disorders such as coronary heart disease, cerebrovascular disease, 
hypertension and peripheral artery disease. CVD is the leading cause of death in women 
in all major developed countries [33]. Female gender-specific factors and risk markers 
for CVD are well acknowledged, including menopause, hysterectomy and the use of 
exogenous hormones [34]. More recently, preeclampsia has been viewed as a separate 
risk factor for CVD in later life for both the women and offspring exposed to 
preeclampsia in utero [35-39]. A review and meta-analysis found that women with a 
history of preeclampsia have an approximately four-fold increased risk of chronic 
hypertension and a two-fold increased risk of coronary artery disease and stroke 10-15 
years after pregnancy compared to unaffected women [40]. The offspring of women 
with preeclampsia have an almost two-fold greater risk of stroke in adulthood [38]. A 
‘dose-response’ relationship between the severity of preeclampsia and future CVD has 
been proposed [35, 41]. This is supported by observations of a relative risk of 1.3-3.3 
for CVD in later life among women with a history of preeclampsia, with a higher risk 
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range of 2.7-8.1 when the preeclampsia was considered severe [42]. However, a recent 
large review and meta-analysis did not support this relationship, as the risk of CVD did 
not appear to increase if preeclampsia was further complicated by a pre-term delivery 
[39].  
 
The increased metabolic and vascular demands of a normal pregnancy may reveal a 
vulnerable maternal constitution, and pregnancy may represent a metabolic ‘stress test’ 
that unmasks an underlying risk of future CVD [43, 44]. Metabolic abnormalities might 
lead to preeclampsia and CVD at different times during a woman’s life [43, 45]. The 
relationship between preeclampsia and CVD risk is illustrated in a model by Sattar and 
Greer (Figure 1) [43].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Risk factors for CVD throughout life (reproduced with permission [43]). 
Early in life, the cardiovascular risk is low. The risk increases steadily with increasing 
age and ‘peaks’ during pregnancy. After delivery, the risk decreases again but never 
returns to pre-pregnancy levels [43].  
 
Preeclampsia and CVD share several risk factors for systemic inflammation (e.g., 
chronic hypertension, obesity, dyslipidaemia and insulin resistance) [46] as well as 
pathological features (endothelial dysfunction and inflammation) [45, 47] and tend to 
occur in the same families [48]. These common antecedents have drawn attention to the 
likelihood of a shared genetic susceptibility [49, 50]. This is supported by findings of 
Romundstad and co-workers [51]. They used the Medical Birth Registry of Norway 
(MBRN) to determine that the positive association between preeclampsia and CVD is 
  7 
more dependent on shared pre-pregnancy risk factors than the influence of the 
hypertensive disorder in the pregnancy itself [51]. These similarities and associations 
have encouraged the search for genetic determinants common to both disorders, but 
only a few shared genetic risk factors have been identified [52-56].  
   
1.5 Aetiology and pathogenesis of preeclampsia 
Preeclampsia has been named the ‘disease of theories’, which reflects the wide range of 
potential causes, clinical signs and complications [57]. Its precise aetiology and 
underlying pathogenic mechanisms remain unknown, but the placenta has been 
acknowledged as a lead actor for a century. The role of the placenta is supported by the 
observation that preeclampsia occurs solely in the presence of placental tissue (i.e., in 
pregnancy or hydatidiform mole) [58] and remits dramatically in the postpartum period 
after the placenta is delivered. Abnormal fetal trophoblast invasion and impaired 
remodelling of maternal spiral arteries at 8-18 weeks’ gestation are now widely 
accepted as primary causative factors [59]. In 1991, Redman described preeclampsia as 
a two-stage disorder, and this model has been a guiding framework for studies of the 
pathophysiology of preeclampsia (Figure 2) [60]. In the first stage, fetal trophoblasts 
fail to invade adequately into the decidua and the spiral arteries to achieve vessel 
remodelling, which is required for a proper increase in feto-placental blood flow. The 
second stage represents the maternal response to the first stage, in which systemic 
activation of the maternal endothelium is evoked by products released into the maternal 
circulation from the placenta [60].  
Stage 1:
Abnormal implantation 
and reduced placental 
perfusion
Stage 2: 
Maternal syndrome
Factor X
 
Figure 2. The two-stage model for the development of preeclampsia (modified 
from [60]). Stage 1 is reduced placental perfusion; stage 2 is the maternal syndrome. 
Several factors have been suggested as the ‘factor X’ that connects these stages. 
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However, not all cases of preeclampsia show abnormal placentation, and the complex 
interplay between the factors produced by the placenta and maternal adaptions to these 
factors is crucial for the development of disease. With increased knowledge of the 
complex aetiology and pathogenesis of preeclampsia, the two-stage model has been 
revised several times [61, 62]. Preeclampsia is now considered a multisystem disorder 
that is associated with pathological features including immune maladaptation, impaired 
placentation, angiogenic imbalance, placental stress, systemic inflammation and 
endothelial dysfunction [63]. These features will be presented in the following and 
further linked together in a step-wise model for the development of preeclampsia.  
 
Immune maladaptation  
Inadequate maternal tolerance of fetopaternal alloantigens has been suggested to be one 
of the primary dysfunctions in preeclampsia [64], leading to poor placentation and, 
consequently, reduced placental perfusion, increased oxidative stress and release of pro-
inflammatory factors [65]. Epidemiological studies indicate that immunological 
mechanisms are central to the initial pathogenesis of preeclampsia, with risk factors 
related to limited exposure to paternal sperm and/or seminal plasma [31, 66]. Further, 
pregnancies achieved after oocyte donation (no genetic contribution from the mother), 
have been reported to have an approximately 30% risk of preeclampsia and/or 
gestational hypertension [67, 68]. This may be the most compelling evidence that there 
is an immunological basis to preeclampsia.  
 
There are two main points of direct contact between the maternal immune system and 
the cells of the fetus: the local immune response in the decidua and the systemic 
immune response between maternal blood and syncytiotrophoblasts [69] (Figure 3). To 
ensure a successful pregnancy, an immunological truce must be made between the 
maternal and fetal cells at the local interface. In decidua, fetal trophoblasts are in direct 
contact with maternal immune cells in the decidua and in the intervillous space [70]. 
Syncytiotrophoblasts in the intervillous space do not express the classical human 
leukocyte antigen (HLA) class I or II molecules, and are relatively immunological inert. 
In contrast, extravillous trophoblasts (EVTs) in the decidua express polymorphic HLA-
C, and non-polymorphic HLA-E, and HLA-G. In early pregnancy, nearly 40% of the 
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cells in the decidua are maternal immune cells, including decidual natural killer (dNK) 
cells, T cells, macrophages and dendritic cells [71, 72]. The interaction between EVTs 
and these maternal immune cells is crucial for successful trophoblast invasion, spiral 
artery remodelling and immunotolerance of the allogenic placenta and fetus [73]. The 
interaction of trophoblast HLA-C with killer immunoglobulin-like receptors (KIR) on 
dNK cells has been shown to promote beneficial production of cytokines and 
angiogenic factors [72]. Specific combinations of HLA-C and KIR isoforms are 
associated with preeclampsia [74].  
 
 
Figure 3. The placenta is composed of fetal tissue (villi) that lie in maternal 
vascular spaces (intervillous spaces) (reproduced with permission from Merriam-
Webster Inc.) 
 
Animal and human studies suggest that regulatory T cells (Treg cells) are essential in 
immunoregulation at the maternal-fetal interface [75]. Pregnancy imprints the Treg cells 
that sustain protective regulatory memory of the fetal antigen, leading to the proposal of 
antigen-specific ‘memory’ Treg cells [76]. The presence of these memory cells could 
explain why rates of preeclampsia are reduced in secondary compared with primary 
pregnancy [16, 76].  
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Impaired placentation 
Development of the placenta in the first half of pregnancy is essential to maintain a 
successful pregnancy. The placental bed underlies the fetal placenta and includes the 
decidua basalis, the maternal part of the placenta, and the underlying myometrium and 
contains the uterine spiral arteries (Figure 3). During normal early pregnancy, extensive 
vascular alterations occur in the spiral arteries to supply maternal blood to the placenta. 
These alterations involve two populations of EVTs: the interstitial cytotrophoblasts, 
which invade the decidual stroma and superficial myometrium, and the endovascular 
cytotrophoblasts, which invade the lumen of the spiral arteries [77, 78]. The EVTs 
invade the vessels of the maternal spiral arteries in the decidua and parts of the 
myometrium and modify the spiral arteries from low-flow, high-resistance vessels to 
high-flow, low-resistance vessels in order to reach the demands of the developing fetus 
and placenta [79-81] (Figure 4). Histopathological studies of placental bed biopsies 
show defective vascular changes in preeclamptic and FGR pregnancies [79, 81, 82], and 
inadequate blood flow is considered a key element in the development of these 
disorders (Figure 4), as supported by observations of increased resistance in the uterine 
artery by Doppler velocimetry [83, 84]. In preeclampsia and FGR, impaired trophoblast 
differentiation, limited migration and invasion of trophoblasts, reduced remodelling of 
spiral arteries and excessive apoptosis during placentation have been observed [79, 82] 
(Figure 4).  
 
Figure 4. Spiral artery remodelling in normal and abnormal placentation (as 
occurs in some cases of preeclampsia and FGR) (reproduced with permission [85]).  
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Angiogenic imbalance 
Angiogenesis is essential for placental vascular development, but knowledge about the 
details of the genetic program required to pattern this development is limited [86]. The 
release of several angiogenic factors by the placenta has been proposed, including 
vascular endothelial growth factor (VEGF), placental growth factor (PlGF) and 
angiopoietins [87]. Increasing evidence suggests that an anti-angiogenic state plays an 
important role in the pathophysiology of preeclampsia [86]. Placental release of anti-
angiogenic factors has been suggested to result from syncytial knots induced by 
placental hypoxia and/or disturbed placental development [86]. It has been speculated 
that the association between preeclampsia and CVD in later life could be due to a 
chronic anti-angiogenic state resulting from genetic variants within genes encoding 
angiogenic factors [86]. 
 
Placental stress 
Impaired placentation leads to oxidative stress, endoplasmic reticulum (ER) stress and 
exaggerated local inflammation [63, 88]. There are close links between these three 
processes, with each being able to induce the others [88, 89]. Intermittent high 
uteroplacental velocity flow, with ischaemia-reperfusion insults, seems to explain why 
the oxidative stress arises better than chronic placental hypoxia [90]. Augmented 
oxidative stress and ischaemia-reperfusion insults have been well documented in 
placental tissue from pregnancies with preeclampsia and FGR compared to 
normotensive pregnancies [91-94]. This includes increased levels of reactive oxygen 
species (ROS), lipid peroxidation products and other oxidative stress markers [94-96]. 
The decidua basalis is probably one of the main sources of oxidative stress products in 
preeclampsia [92, 93]. Oxidative stress is an inflammatory stimulus and is highly 
related to chronic inflammation. Oxidative stress from other causes stimulates an 
inflammatory response, which generates oxidative stress; thus these phenomena are 
regarded as inseparable [97]. 
 
Hypoxia and ischaemia-reperfusion insults can induce ER stress [98], which may lead 
to a wide range of responses. This includes oxidative stress, inflammatory pathway 
activation, or, under severe or prolonged conditions of ER stress, apoptosis [98, 99]. 
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Correspondingly, ER stress has been implicated in a wide range of human disorders, 
including diabetes mellitus, obesity and atherosclerosis [100, 101]. ER stress results in 
activation of a coordinated adaptive program referred to as the unfolded protein 
response (UPR). The UPR consists of three signalling pathways, which are activated by 
the proximal ER transmembrane sensors inositol-requiring enzyme 1 (IRE-1), PKR-like 
ER kinase (PERK) and activating transcription factor 6 (ATF6) [99]. The aim of the 
UPR is to re-establish homeostasis in the ER by decreased protein synthesis, decreased 
cell proliferation and cell cycle arrest. If these attempts fail then the apoptotic 
machinery is activated [102]. Molecular evidence confirms high levels of ER stress and 
activation of the UPR in placentas from preeclamptic women [102-104]. Further, our 
Australian/New Zealand and Norwegian cohorts have revealed that variations in the 
selenoprotein S (SEPS1) and endoplasmic reticulum aminopeptidase 2 (ERAP2) genes, 
which are involved in ER stress, are associated with preeclampsia [105, 106]. 
 
Preeclampsia is characterized by an increased placental inflammation [69]. It has been 
proposed that the early and local inflammation is due to increased production of pro-
inflammatory factors. This production may result from several processes, including 
inadequate tolerance between maternal immune cells and fetal trophoblasts [69], and as 
earlier mentioned, placental oxidative and ER stress [63, 88]. It is hypothesised that 
inflammatory mechanisms generate the atherosclerotic-like lesions termed acute 
atherosis [62], which are observed in the decidual spiral arteries of 20-40% of 
preeclamptic women [107, 108]. Acute atherosis is characterised by the accumulation of 
lipid-filled foam cells, fibrinoid necrosis and leukocyte infiltration [109]. These lesions 
are similar to those occurring in the early atherosclerotic changes frequently observed in 
coronary and other large arteries in the middle aged and elderly. Acute atherosis may 
reduce the spiral artery calibre and likely impairs intervillous blood flow and 
contributes to placental dysfunction [110]. Decidual oxidative stress may arise by 
peroxidation of these lipid depositions. Correspondingly, increased contents of lipid 
peroxides in decidual tissue from preeclamptic pregnancies have been reported, and it is 
proposed that release of such oxidative lipid derivates could include endothelial 
dysfunction when reaching the maternal circulation [92].  
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Placental stress is likely to arise through interplay between oxidative stress, ER stress, 
and local inflammation. These processes generate the release of ‘danger signals’, 
subsequently affecting placental function and leading to endothelial dysfunction and 
systemic inflammation in the mother at later gestation [111].  
 
Systemic inflammation and endothelial dysfunction 
Pregnancy is a natural inflammatory state, which represents the body’s physiological 
adaption to pregnancy [112]. Inflammatory responses cause metabolic adaptions to 
ensure fetal growth and development [113], including induction of insulin resistance 
[114] and hyperlipidaemia [115]. In preeclampsia, all the inflammatory changes of 
normal pregnancy are exaggerated, and become a too large burden to the maternal 
system. In this manner, preeclampsia could be recognised as the extreme end of a 
continuum of maternal systemic inflammatory responses caused by pregnancy itself 
[116]. The elevated inflammation in preeclampsia might be triggered by placental 
debris shed into the maternal circulation (e.g., syncytiotrophoblast microparticles, 
soluble fms-related tyrosine kinase 1 (sFlt-1), soluble endoglin (sEng), activin-A, leptin, 
and PlGF), products of oxidative stress/ER stress, thrombin, pro-inflammatory 
cytokines, fetal haemoglobin and free fetal deoxyribonucleic acid (DNA). The levels of 
these activators are significantly increased in preeclampsia [63, 117-119]. 
 
Endothelial cells are a part of the inflammatory network and possess receptors that 
activate innate immune responders, present antigens to T cells after stimulation, produce 
pro-inflammatory cytokines and stimulate and are stimulated by inflammatory 
leukocytes [120]. Endothelial dysfunction or inappropriate endothelial activation is a 
hallmark of the development of preeclampsia and cardiovascular disorders. In 
preeclampsia, an excessive amount of activated neutrophils adhere to the endothelium 
and release proteases and ROS. Endothelial cell damage in preeclampsia leads to 
increased capillary permeability, platelet thrombosis and increased vascular resistance, 
preceding onset of symptomatic clinical disease [121].  
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A step-wise model for the development of preeclampsia  
Since the presentation of the two-stage model for the development of preeclampsia 
(Figure 2) [60], researchers have been looking for the ‘factor X’ that connects 
inadequate placental perfusion with overt preeclampsia, which remains an area of 
intense investigation. However, poor uteroplacental arterial remodelling is not a 
pathognomonic finding for preeclampsia, and clearly preeclampsia can be caused by 
factors other than inadequate placental perfusion. Thus, the concepts of ‘placental 
preeclampsia’ and ‘maternal preeclampsia’ have been proposed [122]. ‘Placental 
preeclampsia’ has been proposed to be the outcome of implantation problems and 
immunological issues at the maternal-fetal interface. ‘Maternal preeclampsia’, which 
mainly presents as a late-onset disease, does not necessarily feature abnormal 
placentation but occurs when the mother is predisposed to systemic inflammation (e.g., 
chronic hypertension, obesity and insulin resistance). In the maternal presentation, the 
maternal vessels react abnormally to the stress of even a normal pregnancy. However, 
many cases are a mix of both the maternal and placental presentations and are not easy 
to separate clinically. A step-wise model for the development of preeclampsia is shown 
in Figure 5.  
Stage 1
Stage 2
Stage 3
Stage 4
Maternal 
constitutional 
factors
Partial maternal tolerance 
of allogeneic trophoblasts
Poor placentation
Endoplasmic 
reticulum stressOxidative stress
Inflammatory stress
Placenta
Overt preeclampsia Acute atherosis (Stage 5?)
 
Figure 5. A step-wise model for the development of preeclampsia (modified from 
[60-63]). Stage 1 is poor immune regulation and/or vascular inflammation, while Stage 
2 is poor placentation. The three-way interaction between oxidative stress, ER stress 
and inflammatory responses in the placenta give rise to the inflammation that drives 
preeclampsia (stage 3). Stages 1, 2 and 3 lead to Stage 4, a systemic inflammatory 
disorder and overt preeclampsia. Most recently, Staff et al. included acute atherosis as a 
possible stage 5 in some pregnancies [62].  
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1.6 Genetics of preeclampsia 
Preeclampsia shows a strong familial aggregation, both within sibships and over 
generations, suggesting the importance of genetic factors [50, 123, 124]. Studies of 
families have indicated a 3- to 5-fold increased risk for a mother to develop 
preeclampsia if a first-degree relative (mother, sister or both) has experienced 
preeclampsia [125-127]. If the mother's partner was born after a preeclamptic 
pregnancy, the risk increases 1.5- to 2-fold [127, 128], suggesting that susceptibility can 
also be transmitted via paternal genes, presumably acting through the fetus. From 
studies of monozygotic and dizygotic twin pairs, the heritability of preeclampsia is 
estimated to be greater than 50% [129]. A large population-based Swedish cohort study 
including 244,564 sib pairs with a total of 701,488 pregnancies reported that 35% of the 
variance in the risk of preeclampsia was attributable to maternal genetic effects, 20% to 
fetal genetic effects (with an equal contribution from maternal and paternal genes), 13% 
to the liability of a specific couple, <1% to shared sib environment, and 32% to 
undetermined factors [130].  
 
Candidate gene studies 
A large number of candidate gene studies have been performed to elucidate the genetic 
background of preeclampsia. Candidate genes involved in the haemodynamic changes 
that occur during pregnancy (e.g., renin (REN), angiotensin (AGT) and nitrogen oxide 
(NO) synthetase), thrombophilia, oxidative stress and immune genetics [50, 123] have 
been proposed. However, most of these studies have yielded inconsistent and/or 
conflicting results. This lack of reproducibility may be due to inadequate sample sizes, 
population diversity, different environmental factors, false results in the original study 
and an unclear definition of the phenotype, among other factors [50, 131]. A recent 
review and meta-analysis of individual genetic variants associated with preeclampsia 
identified associations between preeclampsia and genetic variants in or near the genes 
angiotensin I converting enzyme (ACE), cytotoxic T-lymphocyte-associated protein 4 
(CTLA4), coagulation factor II (thrombin) (F2), coagulation factor V (FV), lipoprotein 
lipase (LPL) and serpin peptidase inhibitor (SERPINE1) [132]. On the basis of the 
identification of these individual genetic variants, the authors proposed that the 
following systems play a role in the pathogenesis of preeclampsia: the renin-angiotensin 
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system, coagulation and fibrinolysis, lipid metabolism and inflammation [132]. 
Notably, many of these variants are also risk factors for CVD, supporting a shared 
genetic susceptibility for preeclampsia and CVD [132]. 
 
Genome-wide studies 
Given the conflicting results of studies of candidate genes in preeclampsia, genome-
wide studies have been initiated to avoid focusing on a single gene. Genome-wide 
linkage studies in preeclampsia families have identified ‘hot spots’ on chromosomal 
regions 2p13 and 2q23 [133], 2p25, 4q32 and 9p13 [134], 2q22 [135], 4q34 [136], 5q 
and 13q [137], 10q, 12q and 22q [138] and 11q23–q24 [139]. Unfortunately, the 
findings of these studies have been inconsistent, illustrating the genetic complexity of 
preeclampsia and reflecting the possibility that different genetic factors might be 
involved in different populations.  
 
Advances in genotyping technology have allowed rapid genome-wide screening of 
common variants in large populations. To date, only a few genome-wide association 
studies (GWAS) of preeclampsia have been published [140-142]. Johnson et al. 
identified two significant single nucleotide polymorphisms (SNPs) both in the 
chromosome 2q14 region located downstream of the inhibin beta-B (INHBB) gene 
[142]. Neither SNP appeared to be causative, and thus the authors hypothesised that 
they were in linkage disequilibrium (LD) (the co-occurrence of an allele at two or more 
loci at a frequency greater than that expected by chance) with proximal causal variants. 
Six genes were identified in the region +/- 500 kB of the GWAS SNPs and their 
promoters, untranslated region of genes (UTRs) and exons are now targeted for 
sequencing with the aim of identifying any candidate causal variants in those regions 
(E. K. Moses, personal communication, July, 2013). In the other two published GWAS 
[140, 141], none of the detected SNPs reached genome-wide significance, most likely 
because these studies lacked power to detect effects of the size expected in 
preeclampsia. The InterPregGen research study is currently conducting a GWAS 
analysis of maternal and fetal genes in 13,000 preeclamptic pregnancies with the aim of 
examining maternal-fetal gene interactions and individual effects [143].  
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1.7 Gene expression studies of preeclampsia 
Placental and decidual tissues are central in the pathogenesis of preeclampsia and are 
both considered most relevant sites for studies of the pathogenesis of preeclampsia. 
Microarray-based transcriptional profiling can be a powerful strategy for the 
identification of disease-related genes and pathways [144], and placental/decidual 
ribonucleic acid (RNA) may serve as novel biomarkers for the prediction of 
preeclampsia. Several genome-wide expression studies have been performed in 
placental tissue from preeclamptic pregnancies [145]. Placental tissue is relatively easy 
to obtain from deliveries, and thus the placenta is a convenient source of gestational 
tissue for gene expression studies. A variety of differentially expressed genes have been 
reported, including genes associated with obesity [146], hypoxia [147], HLA-G 
genotype [148] and angiogenesis [149, 150]. A few micro-RNA (miRNA) expression 
studies have been performed in which gene expression in preeclamptic and non-
preeclamptic placental tissue was compared [151, 152]. miRNAs regulate gene 
expression and are considered a regulatory layer for silencing gene expression, 
predominantly by degradation of the target messenger RNAs (mRNAs) [153]. A recent 
review and meta-analysis of array-based gene-expression studies identified a placental 
meta-signature comprising 40 annotated gene transcripts and 17 miRNAs related to 
preeclampsia [154]. Among these transcripts, up-regulation of the well-known and 
validated transcripts fms-related tyrosine kinase 1 (Flt-1), endoglin (Eng), vascular 
endothelial growth factor A (VEGFA) and leptin was observed [154]. 
 
To our knowledge, only three decidual genome-wide studies have been published [135, 
155, 156]. Moses et al. focused on genes residing within a region previously shown to 
be in significant linkage with preeclampsia on chromosome 2q, and 17 transcripts 
within this region showed at least a 2.5-fold change in expression in association with 
preeclampsia [135]. Herse et al. observed dysregulation of the circulating and tissue-
based renin-angiotensin systems in decidual samples from preeclamptic pregnancies 
compared to controls [155]. Winn et al. identified 55 transcripts that were differentially 
expressed, which included transcripts previously associated with preeclampsia (e.g., Flt-
1 and leptin) and novel preeclampsia-associated genes (e.g., sialic acid binding Ig-like 
lectin 6) [156]. 
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2. AIMS  
 
Epidemiological research has led to an understanding of the genetic susceptibility and 
risk factors for preeclampsia. The understanding of preeclampsia pathophysiology has 
increased immensely in the last two decades. However, the association between genetic 
determinants of susceptibility and the complex causal pathways underlying the disease 
aetiology remain largely unknown and represent the current direction of preeclampsia 
research. The overarching objective of this thesis was to investigate genetic variations 
influencing preeclampsia susceptibility. To explore this theme, genetic association 
studies using population-based cohorts and transcriptional studies on decidua basalis 
tissue were performed. This thesis addresses the following specific aims: 
 
Paper I: To investigate how gene expression in the decidua basalis contributes to the 
pathogenesis of preeclampsia. This was assessed via genome-wide transcriptional 
profiling (measuring ≥48,000 transcripts from all known genes) of decidua basalis 
tissue from preeclamptic and normal pregnancies. We further aimed to identify the 
genetic pathways and gene-gene interaction networks represented by the differentially 
expressed genes using pathway analytical tools. 
 
Paper II: To evaluate the hypothesis that genetic variation in the storkhead box 1 
(STOX1) gene residing within the 10q22 preeclampsia susceptibility locus is a causal 
factor for developing severe preeclampsia. This was assessed by genetic studies of 
SNPs in STOX1 using a Norwegian preeclampsia population cohort. We further aimed 
to investigate the expression levels of the STOX1 gene and related transcripts in decidua 
basalis tissue from women with preeclampsia and/or FGR and those with 
uncomplicated pregnancies. 
 
Paper III: To investigate if the degree of ER stress and activation of the ER stress 
pathways differ in pregnancies complicated by preeclampsia and/or FGR. This was 
assessed by comparing the gene expression and protein levels of key mediators of each 
branch of the ER stress response in decidua basalis tissue from pregnancies complicated 
by preeclampsia and/or FGR and to that of uncomplicated pregnancies. 
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Paper IV: To replicate the association between our recently reported 2q22 
preeclampsia risk variants and cardiovascular-related traits in an independent Australian 
population-based cohort. This was assessed by genotyping four independent SNPs from 
four genes, lactase (LCT, rs2322659), low density lipoprotein receptor-related protein 
1B (LRP1B, rs35821928), rho family GTPase 3 (RND3, rs115015150) and grancalcin 
(GCA, rs17783344), and further association analysis of these genotypes, preeclampsia 
and cardiovascular risk factors for mothers and adolescents.  
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3. MATERIALS 
 
The papers included in this thesis are based on data from different sources. Papers I-III 
use data from the Biobank for pregnancy complications (the PE/FGR Biobank). In 
addition, Paper II also makes use of data from the second Nord-Trøndelag Health Study 
(HUNT2) and the MBRN. Paper IV uses data from The Western Australian Pregnancy 
Cohort (Raine) Study. These data sources are briefly summarised in the following 
sections.  
 
3.1 Biobank for pregnancy complications (the PE/FGR Biobank) 
Decidual tissue from women with pregnancies complicated by preeclampsia and/or 
FGR and those with non-preeclamptic pregnancies was collected at St. Olav’s 
University Hospital (Trondheim, Norway) and Haukeland University Hospital (Bergen, 
Norway) from 2002 to 2006. Preeclampsia was defined as persistent hypertension 
(blood pressure of ≥140/90 mmHg) plus proteinuria (≥0.3 g/L or ≥1+ on a dipstick) 
developing after 20 weeks of pregnancy [11]. FGR was defined by birth weight ≤2 
standard deviations (SD) below the expected birth weight according to gestational age 
and sex, corresponding to the 2.5th percentile in a Scandinavian normogram [157]. In 
addition, restricted fetal growth was confirmed by at least one of the following 
additional criteria; 1) reduced fundal height in serial measurements, 2) serial ultrasound 
biometry identifying a failure to grow along a consistent percentile, or 3) abnormal 
umbilical artery waveform. For the purpose of Paper III, cases with a debut of 
preeclamptic symptoms or FGR before gestational week 34 were classified as early-
onset. Preeclampsia was considered severe in accordance with the classification 
recommended by Sibai et al. [27], including severe hypertension (>160 mmHg systolic 
and/or 110 mmHg diastolic) associated with proteinuria or severe proteinuria (≥5g per 
day) associated with hypertension and/or multiorgan involvement (pulmonary oedema, 
seizures, oliguria, thrombocytopenia, abnormal liver enzymes, etc.). Severe FGR was 
defined as birth weight <1.7th percentile [19]. 
  
Due to tissue sampling procedures, only women with no labour activity who delivered 
by CS were included. Women with preeclamptic pregnancies underwent CS for medical 
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indications (indicating a severe manifestation of the disease), whereas women with 
normal pregnancies underwent CS for reasons considered irrelevant to the aims of the 
studies (e.g., breech presentation, cephalopelvic disproportion in previous delivery and 
fear of vaginal delivery). Only healthy women with no history of preeclampsia were 
accepted in the non-preeclamptic group. Multiple pregnancies and pregnancies with 
chromosomal aberrations, fetal and placental structural abnormalities or suspected 
perinatal infections were not included. 
 
Decidua basalis tissue was obtained by vacuum suction of the placental bed, a 
procedure which allows the collection of tissue from the entire placental bed [158]. The 
procedure is described in detail elsewhere [92, 158]. Briefly, the placenta was located 
by manual palpation after delivery and allowed to separate spontaneously. Collected 
samples were flushed with saline solution to remove excessive blood. The decidual 
tissue was immediately submerged into RNA-later (Ambion, Austin, Texas) (for 
microarray analyses), 10% neutral-buffered formalin and paraffin embedded (for 
immunohistochemical analyses), or snap-frozen in liquid nitrogen (for Western blot 
analyses) within 15 min of tissue collection. The quality of the decidual material was 
assessed by immunohistochemistry as previously described [159].  
 
3.2 The second Nord-Trøndelag Health Study (HUNT2) 
HUNT2 is a multipurpose population-based health survey conducted in Nord-Trøndelag 
County in Norway between 1995 and 1997 [160]. This population is ethnically 
homogeneous (>97% Caucasians) with low and stable immigration and emigration rates 
(net out migration of 0.3% per year). All residents of Nord-Trøndelag County aged 20 
years and older were invited to participate, and 75.5% of women (n = 35,280) accepted 
the invitation. They attended a standardised clinical examination including standardised 
measurements of height, weight, waist circumference, blood pressure, and non-fasting 
measurements of serum lipids and glucose, and they completed comprehensive 
questionnaires. A large biobank was established [160]. Further details about the study 
are described elsewhere [160].  
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To obtain extensive obstetrical data, all participating women in HUNT2 were linked to 
MBRN. Preeclampsia was defined in accordance with the National High Blood Pressure 
Education Program Working Group on High Blood Pressure in Pregnancy criteria [11], 
using diagnoses reported to MBRN (ICD-8 until 1998, ICD-10 after 1998). DNA 
samples were available for 1,139 women registered with preeclampsia and 2,269 non-
preeclamptic women. Of the available women registered with preeclampsia, 1003 
women were registered with one and 136 women were registered with more than one 
(recurrent) preeclamptic pregnancy. The mean follow-up time from diagnosis in the 
MBRN to inclusion in the study was 25 ± 10 years. Two controls per case were 
identified at random among parous women in the HUNT2 cohort with no registered 
preeclamptic pregnancy in the MBRN. 
 
3.3 The Medical Birth Registry of Norway (MBRN) 
Since 1967, all deliveries (2.6 million births) from the 16th week of gestation (12th week 
since 2002) in Norway have been recorded in MBRN [161]. For each birth, the unique 
national identification numbers of the child and parents are registered, and midwives or 
doctors at the delivery units complete a compulsory standardised form including 
information on maternal health before and during pregnancy, previous reproductive 
history, if there have been any complications during pregnancy and perinatal data of the 
newborn. Preeclampsia is entered as a specified diagnosis and is defined as an increase 
in blood pressure to at least 140 mmHg systolic or 90 mmHg diastolic (or an increase in 
diastolic blood pressure ≥15 mmHg from the level measured before 20th gestational 
week), combined with proteinuria (protein excretion of ≥0.3g/24 h or ≥1+ on a dipstick) 
[11]. Cross-linking of the HUNT2 and MBRN data was performed at MBRN, resulting 
in the identification of 1,179 women registered with preeclampsia [105]. A total of 
2,358 women with no preeclampsia were selected randomly on the basis of the next two 
normal pregnancies in the HUNT2 cohort (non pair-wise matching).  
 
3.4 The Western Australian Pregnancy Cohort (Raine) Study  
The Western Australian Pregnancy Cohort (Raine) Study is a pregnancy cohort that was 
recruited prior to 18 weeks’ gestation from the public antenatal clinic at King Edward 
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Memorial Hospital or surrounding private clinics in Perth, Western Australia (WA). The 
study has been described in detail previously [162]. Pregnant women (n = 2,979) were 
enrolled between August 1989 and April 1992. From the original cohort of women, 
2,868 of their children have been followed over the last two decades with detailed 
assessments performed every 2-3 years. At each follow-up, the participants attended a 
standardised clinical examination including standardised measurements of height, 
weight, waist circumference, blood pressure, and skinfolds. They also completed 
comprehensive questionnaires, and fasting venous blood samples were obtained for 
DNA and biochemical analyses [163, 164]. For this study, data from the pregnant 
women, the neonates, and the 8-, 14- and 17-year cohort follow-ups were assessed. 
 
The presence of preeclampsia and history of preeclampsia were collected from the 
mother at antenatal visits at the delivery units and later assessed from the medical 
records. The medical records were reviewed by obstetricians and research midwives to 
confirm a standardised diagnosis of preeclampsia as a pregnancy-induced increase in 
systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg in 
women who were normotensive before the 24th week of pregnancy, combined with 
significant new onset proteinuria (≥ 0.3 g/l in a 24-hours specimen) [165]. The maternal 
data for the present study were obtained from a simplified examination and blood 
sample collection at their children’s age 8 follow-up and included 1,685 mothers. The 
adolescent data were obtained from age 14 and 17 follow-ups with a cardiovascular risk 
assessment and included 1,094 [163] and 1,053 participants [164], respectively. Only 
subjects that had two Caucasian parents, were biologically unrelated, and who had no 
congenital deformities, were included in the study.  
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4. METHODS 
 
The papers included in this thesis used different methods to assess gene expression 
(Papers I-III) and genetic association (Papers II and IV) data. These methods will be 
briefly summarised in the following sections.  
 
4.1 Gene expression data 
Total RNA extraction and quality control 
Decidual tissue from the PE/FGR Biobank was used to obtain RNA (Papers I-III). Total 
RNA was isolated using a TRIzol (Invitrogen, Carlsbad, CA) extraction protocol with 
chloroform interphase separation, isopropanol precipitation, and ethanol wash steps. 
The isolated total RNA was purified with an RNeasy Mini Kit using spin technology 
(Qiagen, Valencia, CA, USA). The precipitated total RNA was resuspended in RNase-
free water and purified with an RNeasy Mini Kit using spin technology (Qiagen, 
Valencia, CA). A Nano-Drop ND-1000 (Thermo Scientific, Wilmington, DE) was used 
to evaluate the presence of impurities and low RNA concentrations after isolation. 
Samples with concentrations too low for accurate measurement or high levels of 
impurities (phenol, proteins, etc.), were excluded from further analysis. Total RNA 
quality was measured using an RNA 6000 Nano Series II Kit on a BioAnalyzer 2100 
(Agilent Technologies, Santa Clara, CA). This system reports an RNA integrity number 
(RIN) that is based on 10 parameters, all indicative of RNA integrity [166]. In the 
performed studies (Papers I-III), seven samples were excluded from the microarray 
analysis after assessment of the RIN value (<5) and visual evaluation of digital gel 
electrophoresis images.  
 
Microarray gene expression data 
Microarrays consist of small, solid surfaces onto which short oligonucleotide sequences 
(probes) are attached at fixed locations. Each probe represents an mRNA transcript. The 
Illumina technology used in the current studies (Papers I-III) is a 1-channel system that 
uses probe-covered beads to detect specific mRNA types. Each array contains up to 
48,000 probes covering RefSeq and UniGene annotated genes. For decidual gene 
expression (Papers I-III), purified antisense RNA (aRNA) was hybridised to Illumina’s 
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HumanWG-6 v2 Expression BeadChip (Illumina Inc. San Diego, CA). Washing, 
blocking and transcript signal detection (streptavidin-Cy3) was performed using 
Illumina’s 6x2 BeadChip protocol. Samples were scanned on the Illumina BeadArray 
500GX Reader using Illumina BeadScan image data acquisition software (version 
2.3.0.13). Illumina’s BeadStudio Gene Expression software module (version 3.2.7) was 
used to subtract background noise signals and generate an output file for statistical 
analysis.  
 
Quantitative RT-PCR 
Quantitative real-time polymerase chain reaction (qRT-PCR) is based on PCR, a 
primer-mediated enzymatic amplification of specific DNA sequences that can be used 
to quantify mRNA transcript abundance. To control for technical bias (Paper I), we 
verified the results of the microarray experiment using qRT-PCR of six of the most 
differentially expressed transcripts: phospholipase A2, group VII (PLA2G7), 
angiopoietin-like 2 (ANGPTL2), mannosidase α, class 1A, member 2 (MAN1A2), SLIT 
and NTRK-like family, member 4 (SLITRK4), frizzled family receptor 4 (FZD4) and 
ADP-ribosylation factor-like 5B (ARL5B). These transcripts were prioritised for qRT-
PCR based on beta values (a measure of distance between group means, expressed in 
SD units), false discovery rate (FDR) [167] p-values and manual literature searches. 
The same samples and RNA isolation methods were used as for the microarray 
experiment. A 7900HT Fast Real-Time PCR instrument (Applied Biosystems, Foster 
City, CA) was used. qRT-PCR was performed with 93 samples; two of the total 
collection of 95 samples were excluded due to a shortage of biological material. Pre-
optimised TaqMan Gene Expression Assays (Applied Biosystems) were performed in 
triplicate to measure mRNA expression levels relative to the reference genes, TATA 
box binding protein (TBP) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Reverse transcription and PCR amplification were performed in a two-step procedure 
according to the Applied Biosystems High-Capacity complementary DNA (cDNA) 
ReverseTranscription Kit Protocol and TaqMan Gene Expression Master Mix Protocol. 
Negative controls were performed in triplicate without RT enzyme or cDNA template. 
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4.2 Western blot analyses 
Western blotting is used to detect and quantify proteins in a given tissue or cell sample. 
Denatured proteins are separated based on polypeptide length on a gel by 
electrophoresis. The proteins are then transferred to a membrane for detection and 
visualisation using antibodies specific to the target protein [168, 169]. Western blotting 
was used to detect and quantify the protein levels of phosphorylated eukaryotic 
translation initiation factor 2α (pEIF2α), eukaryotic translation initiation factor 2-alpha 
(EIF2α), ATF6, x-box binding protein 1 unspliced XBP1(U), and x-box binding protein 
1 spliced XBP1(S) in decidua basalis tissue (Paper III) using the Odyssey Infrared 
Imaging System (Li-Cor Biosciences, Cambridge, UK). To ensure true positive staining 
and minimise background staining, this method is highly dependent on the sensitivity 
and specificity of the antibodies used. We selected antibodies by searching for previous 
studies that utilised the same antibodies. For the Western blot analysis, a subset of cases 
was chosen on the basis of clinical characteristics suggesting vascular malperfusion 
(i.e., abnormal uterine artery Doppler and/or early onset, severe preeclampsia and 
FGR). A total of 30 samples (preeclampsia, n=7; FGR, n = 7; preeclampsia and FGR, n 
= 8; and controls, n = 8) were included.  
 
4.3 Immunohistochemical analyses 
Immunohistochemistry is a method for localising proteins in tissue sections based on 
the principle of an antigen-antibody reaction. The reaction can be visualised by 
immunoenzymatic staining utilising antibodies conjugated to an enzyme than generates 
a coloured product [170]. Alternatively, in immunofluorescent techniques, the antibody 
can be labelled with a fluorophore, such as fluorescein, to indicate the occurrence of a 
specific antigen-antibody reaction [171]. Immunofluorescence analyses were used to 
assess cellular localisation and expression of ATF6 and x-box binding protein 1 (XBP1) 
in decidual tissue (Paper III). The same antibodies against XBP1 and ATF6 that were 
used in the Western blot experiments were used in the immunohistochemical analyses, 
along with antibodies against cytokeratin 7 (CK7) to detect EVTs, vimentin and 
prolactin to detect decidual cells, and CD68 to detect macrophages. Sixteen decidual 
samples that were randomly selected from the Western blot study population were 
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included in these analyses (preeclampsia, n = 4; FGR, n = 4; preeclampsia and FGR, n 
= 4; and controls, n = 4). 
 
4.4 Genetic association data 
DNA extraction  
For the HUNT2 subjects (Paper II), DNA for genotyping was extracted from blood 
samples obtained each time the participants attended HUNT2. DNA was extracted at the 
HUNT biobank as described elsewhere [105, 160]. In brief, DNA was extracted from 
peripheral blood leukocytes from blood clots or from ethylenediaminetetraacetic acid 
(EDTA)-treated blood using PUREGENE chemistry (Gentra Systems Inc., 
Minneapolis, MN) for large volumes (clots and EDTA-treated blood greater than 1 ml) 
or the MagAttract DNA Blood M48 kit (Qiagen, Hilden, Germany) for low volumes 
(<400 μl). For the Western Australian Pregnancy Cohort (Raine) Study subjects (Paper 
IV), DNA for genotyping was extracted from blood samples obtained from the mothers 
and adolescents during the 14- or 17-year cohort follow-ups as described elsewhere 
[172]. In brief, DNA was extracted from 4 ml EDTA-treated blood using Qiagen 
PureGene chemistry (Qiagen, Hilden, Germany).  
 
Genetic association studies 
Genetic association studies aim to identify associations between one or more genetic 
polymorphisms and a trait, which may be a quantitative characteristic or a discrete 
attribute or disease. Candidate-gene approaches were used to select six SNPs within 
STOX1 (Paper II) and four SNPs within four genes on chromosome 2q22: LCT- 
rs2322659, LRP1B- rs35821928, RND3-rs115015150 and GCA-rs17783344. In Paper 
II, the SNPs were genotyped using Applied Biosystems’ SNPlexTM Genotyping System, 
and sample genotypes were interrogated using Applied Biosystem’s GeneMapper 
(version 4.0) software. In Paper IV, the SNPs within LCT and GCA had already been 
genotyped in a previously performed GWAS of adolescents [173]. The genotyping and 
quality control performed in this GWAS have been described in detail elsewhere [173]. 
In brief, Raine adolescent samples were genotyped on the Illumina Human 660W-Quad 
SNP Chip at the Centre for Applied Genomics (Toronto, Ontario, Canada). For the 
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other two SNPs for mothers and adolescents, genotyping was commercially performed 
by KBioscience (now LGC Genomics), (Hertfordshire, UK) using their proprietary 
fluorescence-based competitive allele-specific PCR genotyping assay, KASPTM.  
 
4.5 Ethical approval 
Informed written consent was obtained from all participants included in the studies 
(Papers I-IV). The studies using the PE/FGR Biobank (Papers I-III) were all approved 
by the Regional Committee for Medical Research Ethics, REK Central Norway. Ethical 
approval for total RNA processing and decidual expression analysis was obtained from 
the institutional review board at the University of Texas Health Science Center in San 
Antonio (Papers I-III). The study using HUNT2 and MBRN (Paper II) was approved by 
the Regional Committee for Medical Research Ethics, REK Central Norway, the 
National Data Inspectorate and The Directorate of Health and Social Welfare, Norway. 
Ethical approval for genotyping (Paper II) was obtained from the institutional review 
board at the University of Texas Health Science Center in San Antonio. For the study 
using the Western Australian Pregnancy Cohort (Raine) Study (Paper IV), ethical 
approval was obtained for all protocols from the Human Ethics Committees of King 
Edward Memorial Hospital and Princess Margaret Hospital Ethics Committee, Perth, 
Western Australia. 
 
4.6 Statistical analyses 
Clinical characterisation 
For Papers I-III, SPSS (v16.0 for Papers I and II and v15.0 for Paper III) (SPSS, 
Chicago, IL) was used to compute descriptive statistics such as means and SDs. P 
values were computed based on t-test statistics for normally distributed variables. Non-
parametric methods (χ2) were used for categorical variables. For Papers II and III, 
subgroups of cases were analysed separately. In Paper II, multivariate logistic 
regression was used to model preeclampsia as the (dichotomous) dependent variable 
against maternal age. A threshold of α = 0.05 was set for statistical significance of all 
computed analyses. For Paper IV, the software package R (www.r-project.org) was used 
to compute descriptive statistics, means and 95% confidence intervals (CIs).  
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Microarray gene expression analyses 
Microarray expression analyses (Papers I-III) were performed in close collaboration 
with the AT&T Genomics Computing Center, Texas Biomedical Research Institute, San 
Antonio, Texas. The choices of methods were guided by their extensive experience with 
such analyses. The expression analyses were mainly performed using the Sequential 
Oliogenic Linkage Analysis Routines (SOLAR) statistical analysis software program 
[174], as previously described [175]. Briefly, transcript data for each sample were log 
transformed and quantile normalised prior to analyses. To evaluate the magnitude of 
differential gene expression the displacement of each detected transcript’s mean 
expression value was measured between the groups. A standard regression analysis was 
performed to determine if the mean transcript level differed between the groups. The 
microarray data were reported to Array Express (www.ebi.ac.uk/arrayexpress/) in 
accordance with the Minimum Information About a Microarray Experiment (MIAME) 
guidelines under accession number E-TABM-682. 
 
Quantitative RT-PCR analyses 
For qRT-PCR data (Paper I), the mRNA expression levels were calculated by the 
comparative threshold cycle (CT) method as described elsewhere [176]. For each target 
gene, the mean CT value for each sample was used for analysis, after exclusion of 
outliers. Outliers were determined as values >2 SDs from the mean. Delta CT (∆CT) 
values were computed as the difference between the given mean value for a target gene 
and the mean of the CT values for the two reference genes [177]. Fold-change values 
were calculated based on the differences in the ∆CT values between tissue from 
preeclamptic and non-preeclamptic pregnant women (2-∆∆CT) [176]. A t-test statistic 
using SPSS v16.0 (SPSS, Chicago, IL) was used to evaluate differences between the 
∆CT values of the preeclamptic pregnancies and those of the normal pregnancy group. 
Analysing the two reference genes separately did not change the results. 
 
Western blot analyses 
Band intensities were determined from two or three scans and quantified by 
densitometric analysis using Odyssey imaging software v3.0 (Li-Cor Biosciences) 
(Paper III). Band intensities were normalised relative to the loading control. Differences 
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in protein levels between study groups were tested using the Mann-Whitney U test in 
SPSS v15.0 (SPSS, Chicago, IL). 
 
Immunohistochemical analyses 
The proportions of XBP1- and ATF6-immunopositive EVTs, decidual cells and 
macrophages were counted in five randomly selected fields on each slide and calculated 
as the number of positive cells among the total number of CK7-, vimentin/prolactin- or 
CD68-positive cells, respectively (Paper III). Differences in the proportions of XBP1- 
and ATF6-immunopositive cells between study groups were tested using the Mann-
Whitney U test. Differences in the staining intensities of XBP1 and ATF6 in the 
different cells types between study groups were also tested using the Mann-Whitney U 
test. Both analyses were performed using SPSS v15.0 (SPSS, Chicago, IL).  
 
Genetic association analyses 
For Paper II, association analyses were performed for the total case/control cohort using 
Pearson’s χ2 statistics in SPSS v16.0 (SPSS, Chicago, IL). Multivariate logistic 
regression was used to model preeclampsia as the dependent variable against maternal 
age. ORs with 95% CIs were calculated. Concordance with Hardy-Weinberg 
proportions (p > 0.05) was tested using a χ2 goodness-of-fit statistic. A threshold of α = 
0.05 was set for statistical significance of all computed analyses. 
 
For Paper IV, measured genotype association analyses were conducted for all 
phenotypes by applying variance-component methods with implementation in SOLAR 
[174]. Because variance components are sensitive to kurtosis, all quantitative 
phenotypes were transformed using SOLAR’s inverse normalisation procedure. Genetic 
association was tested for each SNP under an additive genetic model allowing the mean 
phenotype value to vary by minor allele. This model was compared with the null model 
of no difference in mean phenotype value by SNP genotype using a likelihood ratio test. 
Twice the difference in the log-likelihoods of these models was distributed as a χ2 
random variable with 1 degree of freedom. Concordance with Hardy-Weinberg 
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proportions was tested using a χ2 goodness-of-fit statistic. A threshold of α = 0.05 was 
set for statistical significance of all computed analyses.  
 
4.7 Pathway analyses 
Differentially expressed transcripts in the preeclamptic group (p < 0.05, FDR p < 0.1) 
were imported into Ingenuity Pathways Analysis (IPA) v7.5 (Ingenuity Systems, 
Redwood City, CA) (Papers I and III). The transcripts gene identifiers were mapped to 
their corresponding gene object in the Ingenuity Pathways Knowledge Base. IPA was 
used to bioinformatically identify functional (i.e., cellular, physiological and disease 
processes) categories, pathways and gene-gene interaction networks (which 
diagrammatically represent molecular relationships between gene-gene products) 
potentially involved in preeclampsia within our data set. The significance of the 
association between the pathway and the dataset was calculated using Fisher’s exact 
test.  
 
To further explore the role of ER stress in the pathogenesis of both preeclampsia and 
FGR (Paper III), we performed pathway analyses on a group of 20 ER stress-related 
transcripts (as annotated by IPA) in cases and controls. Pathway analyses were 
performed using Rotation Gene Set Tests (ROAST) [178] and Rotation Gene Set 
Enrichment Analysis using rotation (ROMER) [179], implemented in the limma 
package [180]. ROAST was used to determine if any of the transcripts in the ER stress 
pathway were differentially expressed, and ROMER was used to determine if the subset 
of transcripts in the pathway was more differentially expressed than any other subset of 
transcripts in the total dataset. For both methods, transcripts were ranked by moderated 
t-statistics, and a rotation test [181], which is a smoothed version of permutation 
suitable for linear models, was used to assess significance. Both methods are available 
via the Bioconductor Project (Fred Hutchinson Cancer Research Center, Seattle, WA) 
[180]. 
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4.8 Correction for multiple testing 
Correction for multiple testing was required for both the microarray gene expression 
analyses (Papers I-III) and the genetic association analyses (Papers II and IV). Multiple 
testing is considered a major problem in whole genome analyses (Paper I), in which the 
number of statistical inferences far outnumbers the number of samples and the number 
of false positives using unmodified p-values will be unacceptable. The Illumina 
HumanWG-6 v2 whole genome expression bead chip used in Paper I allows us to 
explore the expression of 48,000 transcripts simultaneously, which will give 2,400 
expected false-positive transcripts with the use of a p-value of 0.05. To correct for this 
statistical source of error, Benjamini-Hochberg correction for multiple testing [167] was 
applied to the results. This model aims to control the FDR in the list of transcripts by 
modifying p-values to a level reflecting the acceptable number of false positives in the 
final list of transcripts. The factor used to modify the p-value is based on the rank of the 
original p-value, with a more stringent correction of low-ranking p-values. However, 
even with the use of an FDR p-value of 0.1, 10% of the 455 significantly differentially 
expressed transcripts are expected to be false positives. The Benjamini-Hochberg 
correction is less stringent than a traditional Bonferroni correction, and was used in 
Paper I because a strict correction for multiple testing would exclude true positive 
transcripts (increase the number of false negatives). These limitations are generally 
accepted and considered as weaknesses associated with microarray technology [182]. In 
Paper IV, correction for multiple hypothesis testing was performed according to a 
Bonferroni correction (α/(total number of SNPs x total number of phenotypic traits)). 
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5. MAIN RESULTS 
 
Paper I: A transcriptional profile of the decidua in preeclampsia 
Whole-genome microarray analysis revealed 455 differentially expressed transcripts 
when decidual basalis tissue from preeclamptic and normal pregnancies was compared. 
The technical replicate of the microarray experiment using qRT-PCR analysis of six of 
the most differentially expressed transcripts showed a high grade of correlation with the 
microarray data. Pathway analysis of the differentially expressed transcripts identified 
seven significant pathways, including tryptophan metabolism, notch signalling, 
endoplasmic reticulum stress, nuclear factor E2-related factor 2 (NRF2)-mediated 
oxidative stress response and pathways related to the metabolism of fatty acids (linoleic 
acid metabolism, fatty acid metabolism and arachidonic acid metabolism). Network 
analysis showed that 64 of the preeclampsia-associated transcripts could be connected 
into a single network of gene-gene product interactions, including a cluster of 15 up-
regulated genes associated with ER stress and oxidative stress.  
 
Paper II: STOX2 but not STOX1 is differentially expressed in decidua from pre-
eclamptic women: data from the Second Nord-Trøndelag Health Study  
Genetic association analysis of candidate SNPs in STOX1 could not confirm an 
association with preeclampsia. However, the recurrent group showed a tendency 
towards a higher frequency of the C genotypes for the previously reported STOX1A-
Y153H variation. Women experiencing recurrent preeclampsia showed an increased 
risk of complications and comorbidity (preterm birth, reduced birth weight and 
development of metabolic syndrome) compared to women experiencing preeclampsia 
once. Gene expression levels of the STOX1 paralogue storkhead box 2 (STOX2) were 
significantly lower in decidual tissue from pregnancies complicated with both 
preeclampsia and FGR compared to the other study groups. No differential gene 
expression of STOX1 was observed in any of the case groups. Furthermore, there was a 
strong correlation between transcriptional alterations reported previously in cultured 
trophoblast (JEG-3) cells overexpressing STOX1A and alterations observed in decidual 
tissue from pregnancies complicated with preeclampsia and FGR.  
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Paper III: Increased endoplasmic reticulum stress in decidual tissue from 
pregnancies complicated by fetal growth restriction with and without pre-
eclampsia 
Pathway analyses of decidual tissue transcriptional profiles revealed up-regulation of 
the ER stress pathway in pregnancies complicated by preeclampsia with FGR and by 
FGR. In pregnancies complicated by preeclampsia alone, only a trend towards up-
regulation was observed. Targeted transcriptional and protein analyses of the three ER 
stress signalling branches showed up-regulation of the PERK-pEIF2α and ATF6 
branches in preeclampsia with FGR and FGR. In preeclampsia alone, none of these 
branches were significantly altered; however, a marked increase in XBP1(U) was 
observed. Both nuclear and cytoplasmic immunoreactivity for XBP1 and ATF6 were 
observed in most (>80%) EVTs, decidual cells and macrophages. No differences in the 
proportion of XBP1- or ATF6-immunopositive cells or staining patterns were observed 
between any of the study groups. Correlation analyses demonstrated a negative 
correlation between pEIF2α/EIF2α and placental weight.  
 
Paper IV: Preeclampsia and cardiovascular disease share genetic risk factors on 
chromosome 2q22 
Genetic association analysis of four independent SNPs in four genes on chromosome 
2q22 (LCT-rs2322659, LRP1B-rs35821928, RND3-rs115015150 and GCA-rs17783344) 
previously associated with preeclampsia susceptibility and cardiovascular risk factors 
showed associations between all four SNPs and cardiovascular risk traits, for both 
mothers and adolescents in an Australian population cohort. Carrying the A allele of 
LCT rs2322659 was associated with decreased levels of the adolescent’s blood glucose 
in both mothers and adolescents and decreased maternal height in mothers. Carrying the 
T allele of LRP1B rs35821928 was associated with increased maternal height in both 
mothers and adolescents and decreased maternal weight in mothers. An association 
between the A allele of RND3 rs115015150 and decreased adolescent’s waist-hip ratio 
was observed in mothers, whereas this SNP was associated with decreased level of 
adolescent’s triglycerides in adolescents. In mothers, carrying the C allele of GCA 
rs17783344 was associated with increased adolescent’s height, whereas in adolescents, 
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carrying the C allele was associated with a lower risk of being born of a preeclamptic 
pregnancy and a lower risk of having a mother who had previously experienced a 
preeclamptic pregnancy. Our collective findings support the hypothesis that genetic 
mechanisms for preeclampsia and CVD are, at least in part, shared, but this conclusion 
requires some caution as a Bonferroni correction for multiple testing adjusted the 
statistical significance threshold.  
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6. DISCUSSION 
 
6.1 Discussion of materials and methods 
The accuracy of findings in a research study depends on the precision and validity of 
estimation in the study design. The estimation process is a combination of planning, 
conducting and analysing the data of the studies. The aim of this section is to summarise 
the methodological limitations and strengths of the studies included in this thesis, and to 
discuss the extent to which these limitations might have influenced the results.  
 
6.1.1 ‘Hypothesis-driven’ versus ‘hypothesis-generating’ 
There are two main categories of genetic studies: ‘hypothesis-driven’ (e.g., candidate-
gene approaches) and ‘hypothesis-generating’ (e.g., genome-wide approaches). 
Candidate SNPs (Papers II and IV) may be used in candidate gene analyses because 
they are hypothesised to be causal variants or because they are in LD with other SNPs 
in that genomic region and can therefore act as proxies for multiple variants. The latter 
are often referred to as marker SNPs, and their use allows a high degree of variation to 
be captured while typing a minimal number of SNPs. Therefore, identifying 
associations between SNPs and disease traits enables the ascertainment of potentially 
causative variants or variants in strong LD with potentially causative variants. By 
contrast, genome-wide hypothesis-generating approaches (Paper I) represent a 
(relatively) unbiased option that can be attempted even in the absence of convincing 
evidence regarding the function or location of the causal genes. With the use of 
genome-wide transcriptional profiling (Paper I), the expression of thousands of genes 
can be assayed simultaneously, reducing cost, time and biological material 
requirements. This method offers an opportunity to identify novel candidate genes and 
pathways for disease and could also facilitate the prioritisation of genes for further 
studies, e.g., sequencing after GWAS [135]. However, genome-wide studies are 
performed on commercial arrays, which are based on a number of assumptions. Further, 
assumptions about biology are necessary in order to narrow the question inquiry. The 
differentially expressed transcripts were translated into knowledge based on available 
information about biological pathways (Papers I and III). To prioritise findings for 
further examination (Paper III), we used previously obtained biological knowledge. 
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6.1.2 Diagnostic criteria and phenotypes  
Validity of the preeclampsia diagnosis 
The specificity and sensitivity of the preeclampsia diagnosis is of major importance for 
the power to detect true associations. Preeclampsia is a syndrome for which diagnostic 
criteria have arisen from consensus and not an understanding of the pathogenesis. The 
variation in clinical definitions of preeclampsia complicates comparisons between 
different studies. For research purposes, continuous measurements of blood pressure 
and proteinuria are forced into stringent definitions of preeclampsia by the use of cut-off 
values, which might mask the phenotypic diversity observed in clinical practice [50] 
and moreover, camouflage the underlying mechanisms of genetic susceptibility.  
 
A strength of the preeclampsia diagnosis in the PE/FGR Biobank (Papers I-III) and in 
the Western Australian Pregnancy Cohort (Raine) Study (Paper IV) is that preeclampsia 
was diagnosed by an obstetrician following the prevailing guidelines at a given period 
of time. These guidelines include thorough monitoring, including multiple blood 
pressure and proteinuria measurements, prenatal ultrasound measurements and fetal 
birth weight estimations. In addition, the women with preeclampsia in the PE/FGR 
Biobank were hospitalised and delivered by CS due to maternal and/or fetal medical 
indications, thereby decreasing the probability of a false-positive diagnosis. These 
women likely had more severe forms of preeclampsia. 
 
In the HUNT2 cohort (Paper II), preeclampsia diagnosis is based on cut-off values of 
hypertension and proteinuria from registrations in MBRN but is also a clinical diagnosis 
based on symptoms (e.g., epigastric pain, persistent headache or other cerebral or visual 
disturbances). The registration in MBRN is based on the information in the scheme 
completed by the midwives/obstetricians at the delivery ward. As diagnostic criteria for 
preeclampsia have changed over time, the diagnosis reported by midwives and 
obstetricians to MBRN may be based on individual interpretations of the total clinical 
presentation rather than the criteria set by MBRN. Moreover, with the use of large 
computerised systems such as MBRN, some registration errors are inevitable. An 
evaluation of the validity of the preeclampsia diagnoses reported by MBRN was 
recently published [183]. Medical doctors and/or study nurses at the obstetric 
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departments in which the women of the HUNT2 preeclampsia cohort gave birth 
compared the reported MBRN diagnoses to clinical findings documented in hospital 
records. The diagnosis was confirmed in 88.3% of the pregnancies [183]. Similar results 
have been reported for the Medical Birth Registries of Denmark [184] and Sweden 
[185]. The high positive predictive value (PPV) in the Norwegian validation study [183] 
indicates that MBRN is a reliable source of high-quality data for research purposes. 
Causes of exclusion from diagnosis were unfortunately not noted during the 
examination of the journals of the women in the HUNT2 preeclampsia cohort. To 
speculate, mild preeclampsia might have been misclassified as gestational hypertension 
(and vice versa) in MBRN.  
 
Validity of the FGR diagnosis 
In the PE/FGR Biobank (Papers I-III), the FGR diagnosis was assessed by stringent 
criteria by an obstetrician (as described in Section 3.1). Medical doctors and/or study 
nurses confirmed the FGR diagnosis at the obstetric departments in which the women of 
the PE/FGR Biobank gave birth. This confirmation was made by comparing the registry 
data of the biobank to clinical findings documented in hospital records (unpublished 
data). Validation of diagnosis was performed before the studies included in this thesis 
were undertaken, and only subjects with confirmed clinical diagnosis were included. 
Unfortunately, the PPV of these studies are not known.  
 
In the HUNT2 cohort (Paper II), we used a stringent SGA definition as a proxy for a 
definition of FGR. This method has proven to be more likely to identify true FGR cases 
within the SGA group [186, 187]. Growth estimations were based on ultrasonically 
estimated fetal weights appropriate for the population and considering the sex of the 
fetus [157]. Thus, we believe that SGA is a good approximation to FGR in this study. 
 
Validity of the control group  
In the studies included in this thesis, the preeclamptic cases were compared to non-
preeclamptic controls. The same women from the PE/FGR Biobank (Papers I-III) 
served as controls in the three studies. The control group was termed ‘normal 
pregnancies’ (Paper I) and ‘uncomplicated pregnancies’ (Papers II and III), both of 
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witch are rather unspecific terms. For the PE/FGR Biobank, it is specified that 
‘Exclusively healthy women with no prior pregnancy complications were included as 
controls.’ However, there was no scientific basis to the term ‘healthy’. A stringent 
definition of ‘healthy’ might have been beneficial, such as the one provided by the 
American Society of Anesthesiologists (ASA) Classification I or II, which includes 
women with no significant medical or surgical illness, non-smokers and unmedicated 
women.  
 
In the cohort studies (Papers II and IV), the controls were termed ‘non-preeclamptic’. 
We do not know if these women had other medical health problems and/or were 
medicated. For the HUNT2 cohort (Paper II), the controls were identified at random 
among parous women in the cohort. The only criterion was that they had no registered 
preeclamptic pregnancy in the MBRN, and women with a multiple pregnancy (e.g., 
twins) were excluded. For the Western Australian Pregnancy Cohort (Raine) Study, the 
controls were mothers included in the study who were registered without a history of 
preeclampsia.  
 
In conclusion, the uncertainties about the women serving as controls in these papers 
may add bias to the results. Due to incomplete registrations and misclassification, we 
cannot rule out the possibility that false-positives and false-negative controls were 
included in the studies and that their inclusion may have affected our results.  
 
Studies of phenotypic subgroups 
As presented in Section 1.1, preeclampsia is a heterogeneous disorder, and the 
pathogenic mechanisms underlying the different clinical manifestations may differ. 
Consequently, a logical assumption would be that preeclampsia is more than a single 
disorder. Thus, it has been suggested that studies of preeclampsia should divide 
preeclampsia into phenotypically homogenous subgroups, such as with or without FGR 
[188] and early- versus late-onset of disease [104]. We included the preeclamptic 
subgroups ‘preeclampsia with FGR’ (Papers II and III), ‘recurrent preeclampsia’ 
(Papers II and III) and ‘severe preeclampsia’ (Paper III). These subgroups may 
represent an extreme preeclampsia phenotype, which might help clarify disease 
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mechanisms and add power to genetic association studies [189]. In Papers I and IV, all 
women with preeclampsia, irrespective of the presence of FGR, recurrence of 
preeclampsia and/or gestational age at onset of disease, were included in the case group 
to increase sample size in order to increase the statistical power. Accordingly, these 
preeclamptic cases could be rather heterogeneous, which must be considered when 
interpreting the results and comparing our results with other studies. However, the 
preeclamptic women included in Paper I were all hospitalised and delivered by CS due 
to maternal and/or fetal medical indications, indicating severe/serious manifestation of 
the disease. Whole-genome profiling was performed using a large sample size (95 
samples) in Paper I, which may at least partially compensate for inter-individual 
variations. However, an increase in the number of samples would be beneficial and 
enable for subgroup analysis in future research. We are currently enrolling more women 
into the PE/FGR Biobank to enable such analyses.  
 
6.1.3 Confounding  
Confounding is a mixing or confusion of effects between the target effect and the 
effect(s) of a third factor(s). A confounder is a variable that is not the focus of the study 
and that is causative for the phenotype while at the same time being associated with the 
variable under investigation. Confounding raises the possibility of both false findings 
(positive confounding) and obscuring true associations (negative confounding), thus 
reducing the power to detect an effect.  
 
Population stratification 
If the confounder is ethnic affiliation of the individuals in the study, the effect is called 
population stratification, also termed confounding by ethnicity. This can occur if the 
cases and controls come from different ethnic populations and if the investigated marker 
alleles are unequally distributed in these populations. As an example (adapted from 
Hamer and Sirota [190]), if you are investigating the genetic basis for eating with 
chopsticks and collect your cases in Trondheim, Norway, it is most likely that the cases 
who eat with chopsticks are primarily of Asian origin, whereas the controls who do not 
eat with chopsticks will be mostly Caucasians. If you find a significant association of 
the case-control status to a marker locus, this could be nothing more than the HLA 
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locus, which is distributed differently in Asian and Caucasian individuals. This 
illustrates the importance of planning a case-control study to know the extent of 
population differentiation that can be expected in the area from which cases and 
controls are to be drawn. Genetically homogeneous populations are preferred to 
populations with high heterogeneity to avoid positive and negative confounding.  
 
In the PE/FGR Biobank (Papers I-III), we excluded mothers of non-Caucasian ethnicity 
(self-reported). However, we did not have any information about the ethnicity of the 
father. In the HUNT2 cohort (Paper II), we used a population considered ethnically 
homogeneous, with less than 3% non-Caucasians [160]. With the exception of selecting 
cases and controls from the same population, we did not perform any further approaches 
to correct for population stratification (such as genomic control or direct estimation of 
admixture with ancestry-informative markers). In the Western Australian Pregnancy 
Cohort (Raine) Study, only mothers and offspring of Caucasian ethnicity were included 
(self-reported). In the studies in which ethnicity was assessed, identification was based 
on self-reported ancestry, which has been determined to be a reasonable proxy for 
genetic ancestry [191]. However, this can be undermined by factors of cultural versus 
genetic specification and the occurrence of more hidden relatedness among the cases 
than among the controls simply because they share a genetically determined disorder. 
These factors may have biased our results.  
 
Covariates 
Measuring the known confounders and including them as covariates in multivariate 
analyses could control for confounding and was performed to a limited extent in all 
studies. In particular, differences in gestational age between the preeclamptic cases and 
non-preeclamptic controls could affect the results in Papers I-III. This is discussed in 
detail in Section 6.1.4. For the transcriptional data analyses, we did not match the case 
and control groups nor adjust for possible confounders, including age, body mass index 
(BMI), parity and medication. However, we reported some clinical data for the women 
included and were aware of these potential pitfalls when interpreting the results. In 
Paper IV, we only adjusted for maternal age and sex as confounding factors in the 
analyses. We did not adjust for other known confounding factors for CVD, including 
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socioeconomic status (e.g., education, receiving social security benefits) and smoking 
status, which may have affected our results.     
 
6.1.4 Gene expression studies 
Decidual samples 
Tissue was obtained by vacuum suction of the placental bed during CS [92, 158]. This 
procedure is considered safe, with no observed complications [158], and provides 
representative material for studies of feto-maternal interactions in the decidua basalis 
[92, 158]. A high success rate of obtaining spiral arteries has been demonstrated with 
the use of this method [158, 159]. This procedure ensures collection of decidual tissue 
from the entire placental bed, and the collected samples are more representative for the 
placental bed as a whole than are traditional placental bed biopsies [158]. However, the 
uncertain topographic localisation of tissue fragments is a disadvantage of this method. 
Moreover, with the use of the vacuum suction method, there is a risk of collecting 
decidua parietalis together with decidua basalis. To ensure that decidua basalis was 
collected, paraffin-embedded slides were stained for CK7 to demonstrate the presence 
of extravillous trophoblasts (which are not present in the decidua parietalis) [159]. Only 
samples with extravillous trophoblasts (96.4%) were included for further study. 
 
Microarray analysis of complex tissue 
We performed microarray expression analyses on whole sample (decidua) homogenates 
(Papers I-III). Compared to in vitro studies, analysing gene expression in natural tissues 
reflects processes occurring in the undisturbed in vivo situation at the time of collection. 
However, natural tissues consist of a number of cell types that likely have varying 
expression patterns [192]. Decidua basalis material consists of approximately 40% 
maternal leukocytes, 20% extravillous trophoblasts and 30% decidual stromal cells 
[193]. The various cell types constituting the decidua will naturally affect our results, 
which must be considered when analysing the data. In Paper III, we followed up the 
microarray results for the ER stress pathway using immunohistochemical analysis to 
identify the cells expressing the genes in question. It was not feasible to perform this 
follow-up analysis for all differentially expressed transcripts. However, our results were 
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interpreted in relation to and are consistent with earlier observations in decidual and 
placental tissue as well as in trophoblast cell lines [194-198].   
 
Gestational age - a possible confounding factor 
In the PE/FGR Biobank (Papers I-III), a lower gestational age was found in the 
preeclamptic group (average, 32 weeks; range, 28-36 weeks) as compared to the non-
preeclamptic group (average, 39 weeks; range, 38-40 weeks). This is not unexpected 
due to the need for early delivery in patients with severe preeclampsia. Because gene 
expression levels in utero-placental tissues may be influenced by gestational age [199-
201], it cannot be excluded that some of the differences observed between the 
preeclamptic and non-preeclamptic groups are, in fact, gestational age-related.  
 
Lian et al. evaluated the relative effect of gestational age and preeclampsia on gene 
expression [201]. The authors pooled our transcriptional data set (Paper I) with two 
other genome-wide transcription studies of tissue from the maternal-fetal interface 
[201]. A total of 22 transcripts were associated with preeclampsia, whereas 92 
transcripts were associated with gestational age [201]. This indicates that a large 
proportion of the variation in transcript levels can be attributed to gestational age. 
Pathway analysis of the transcripts associated with preeclampsia revealed an over-
representation of genes associated with metabolic disease [201]. However, their study 
was performed on samples collected with different sampling techniques and two 
profiling platforms (Illumina and Affymetrix). These differences restricted the number 
of possible comparisons, and the authors were only able to target 14,678 genes shared 
by both technological platforms.  
 
In our own comparison of possible gestational age related differentially expressed 
transcripts (Paper I), we compared our results to the data of Winn et al [199]. Of the 455 
transcripts found as differentially expressed (Paper I), 368 genes demonstrated no 
gestational age influenced changes [199]. This strengthens the assumption that the 
differential expression of these 368 genes may be related to disease mechanisms at play 
in preeclampsia. Fourteen of our differentially expressed genes (TEMEM97, KIAA1598, 
FHL1, PLA2G7, SHANK3, NOTCH4, UBASH3B, ROBO4, NRARP, GPR116, IL6ST, 
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LDLR, SRPRB, KREMEN1) were possibly related to differences in gestational age 
between preeclamptic cases and controls [199], and our conclusions might have been 
affected by this fact.  
 
Microarray technology - multiple testing and pathway analysis 
The possible pitfalls related to performing multiple tests when using whole genome 
analysis were presented in Section 4.8. In genome-wide transcriptional profiling (Paper 
I), the analysis of groups of genes is a strategy to increase power and reduce the 
dimensionality of the underlying statistical problem following multiple testing [202]. 
Furthermore, it may be advantageous to focus on functional categories, pathways and 
networks instead of single genes when the aim is to obtain insight into the 
pathophysiology of complex diseases such as preeclampsia. The high interconnectivity 
of focus genes with other correlated genes within a biological network may imply the 
functional and biological importance of these genes [203, 204]. To assess this 
interconnectivity in a comprehensive manner, we increased the FDR cut-off from 0.05 
to 0.1 and, consequently, the number of genes included in the analysis. An increased 
FDR p-value cut-off may be associated with the reporting of more false-positive, 
individual, and differentially expressed transcripts (genes). However, numerous genes, 
perhaps a family or network of genes, contribute to complex disease susceptibility. 
Although one gene alone may not depict significant differential expression patterns, this 
gene may be part of a greater network of genes or pathway(s) that are significantly 
associated with complex disease susceptibility. Hence, individual genes with small, 
non-significant, changes in gene expression may act in an additive or multiplicative 
manner with other networked genes displaying small changes in gene expression.  
 
Technical replication 
The key advantage of microarray technology versus qRT-PCR is the high throughput. 
However, microarrays tend to have a low dynamic range, leading to small but 
significant under-representation of fold changes in gene expression. qRT-PCR has a 
higher dynamic range and is used to validate observed trends rather than to duplicate the 
absolute values obtained by microarray chip experiments [146]. The described overall 
concordance of trends between the two techniques is 40-80% [205-207]. A technical 
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replication between these platforms was performed in Paper I. The trends towards up- 
and down-regulation for the six transcripts tested by microarray analysis were consistent 
with those detected by qRT-PCR, confirming a good correlation. 
 
Causality 
Women with a pregnancy complicated by preeclampsia are in a state of exaggerated 
oxidative stress and inflammation. This state itself is expected to result in changes in the 
expression of genes in the placenta in these women. Consequently, discriminating 
between causal factors and secondary responses is challenging. An alteration of the 
expression level of one gene may influence the transcription of others included in the 
network. Thus, it is difficult to precisely identify the genes with primary roles in 
perpetuating preeclampsia from our data set. Consequently, we focused on pathways 
and networks rather than single transcripts, with the aim of confirming the biological 
processes that are perturbed in preeclampsia.  
 
6.1.5 Genetic association studies 
A major source of frustration in genetic association studies has been the difficulty of 
obtaining robust replication of initial positive findings. Much of this inconsistency can 
be attributed to inadequacies in study design, implementation and interpretation, with 
the use of inadequately powered sample groups as a major concern. Some of these 
issues will be discussed in the following sections.   
 
Study sample size and effect sizes 
Study sample size is recognised as a key factor in the determination of quality in an 
association study. Meta-analyses have indicated that common causal variants of 
complex disorders may, when evaluated individually, have rather small effects, and thus 
large studies will be necessary to detect these effects [208]. This effectively means 
sample sizes in the thousands [209]. This phenomenon is most likely also relevant for 
preeclampsia due to its complex nature. Therefore, power and sample size calculations 
should be performed prior to conducting a genetic association study to determine if the 
study design is appropriate to answer the question of the study.  
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A priori power calculations ad modum Lalouel and Rohrwasser [210] were performed 
for the SNPs rs1341667 (STOX1A Y153H) (Paper II) and rs2322659 (LCT), rs35821928 
(LRP1B), rs115015150 (RND3) and rs17783344 (GCA) (Paper IV). The calculations 
included information on the number of subjects in the study groups and the minor allele 
frequencies (MAFs) of the individual SNPs. The MAFs were obtained from publically 
available databases. Effect sizes (OR) with according power were assessed. The SNP 
rs1341667 (STOX1A Y153H) demonstrated 90% power to detect an OR difference of 
1.3 for the total HUNT2 preeclampsia/non-preeclampsia cohort and 1.9 for the recurrent 
preeclampsia group (Paper I). The SNPs rs2322659 (LCT), rs35821928 (LRP1B), 
rs115015150 (RND3) and rs17783344 (GCA) demonstrated power to detect an OR 
difference of 1.5 for the total preeclampsia/non-preeclampsia cohort of 27%, 11%, 3% 
and 30% respectively, for both mothers and adolescents (Paper IV). The low power 
demonstrated by the latter calculations is typical of genetic variants with low MAF and 
the use of cohort studies. Unless the disease is very common, the study samples that 
cohort studies generate will be highly unbalanced, with far fewer individuals with the 
disease than without. Consequently, the nested case-control samples that emerge are 
often relatively modest in size.  
 
Accuracy of genotyping 
A genotyping error occurs if the observed marker genotype deviates from the true 
marker genotype. Genotype errors can have a marked effect on the outcome of an 
association study. They can increase the estimated recombination fraction between a 
marker and a disease locus and reduce the power to detect true case-control differences. 
Genotyping errors depend on many factors, including both human and technological 
factors. Most association studies are based on the assumption that the genotypes 
obtained are 100% correct, but this is seldom or never the case. Reduction of the impact 
of genotyping error on association studies require advances in genotyping platforms and 
the use of methods that establish and monitor the performance of each assay and reduce 
the possible sources of error and bias [211]. 
 
To avoid batch-related differences in genotyping performance, case and control samples 
were mixed on the well plates (Papers II and IV). Further, statistical calculations, 
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including accordance with Hardy Weinberg proportions among the controls and 
controls for gender inconsistencies, levels of heterozygosity and inter-sample 
relatedness, were used to predict genotype error.  
 
6.1.6 Preeclampsia – a complex disorder 
Preeclampsia is a complex disorder that does not involve simple Mendelian monogenic 
inheritance but rather is likely to involve interactions between variation in many genes 
and environmental factors [123]. As with other complex disorders, it is likely that each 
individual genetic locus contributes only modestly to preeclampsia, preeclampsia 
commonly occurs in the general population, does not follow a specific known pattern of 
inheritance and does not segregate within families with a clear pattern of inheritance. 
This makes genetic study design challenging, and international collaborations with large 
sample sizes to detect variants with small to modest effects are needed. This knowledge 
has encouraged collaborative approaches between research groups such as the 
InterPregGen research study (www.interpreggen.org). This is the largest international 
research project studying genetic susceptibility for preeclampsia, and includes 
participating centres from the UK, Norway, Finland, Iceland and two countries in 
Central Asia (Uzbekistan and Kazakhstan). Data from 10,400 maternal cases and 7,800 
affected babies will be assessed to identify preeclampsia susceptibility genes 
(www.interpreggen.org).  
 
Investigations into the aetiological effect of genetic variants continue to evolve with 
advances in technology and biological knowledge [212]. SNPs have usually been 
studied for common complex disorders, but the involvement of gene copy number 
variants (CNVs), deletions, insertions, miRNAs and the complex interplay between 
environmental exposure and polygenic susceptibility, are now gaining acceptance as 
possible major contributors to disease susceptibility. There is a growing body of 
evidence that non-coding genetic variation is involved in the heritability of many 
common complex disorders. SNPs account for approximately 90% of all known 
sequence variation, which is mostly located in non-coding regions of the genome [213]. 
Thus, many functional SNPs are likely located outside coding regions and affect the 
regulation of gene expression [214]. Recent estimates based on data from the 1000 
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Genomes Project indicate that the numbers of non-coding and coding functional 
variants are similar [213]. Thus, the genetic studies performed in this thesis have the 
potential to discover only some of the genetic causes of preeclampsia.  
 
The genome is apparently highly dynamic, and epigenetic mechanisms (changes in gene 
expression or cellular phenotype that are caused by mechanisms other than changes in 
the underlying DNA sequence) have been suggested to be involved in preeclampsia 
[215, 216]. Genomic imprinting is an epigenetic phenomenon in which certain genes are 
expressed in a parent-of-origin-specific manner. Imprinted alleles are silenced such that 
the genes are either expressed only from the non-imprinted allele inherited from the 
mother or from the non-imprinted allele inherited from the father. Up to now, about 80 
imprinted genes are known in humans (www.otago.ac.nz/IGC), but the actual number is 
expected to be much higher [217]. Evidence for a maternal effect in one of the 
preeclampsia susceptibility loci has been observed for a region of genes on chromosome 
10q22 [215]. However, our studies were not able to assess epigenetic effects, which 
likely decreased our power to detect true associations.  
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6.2 Discussion of biological observations 
 
Figure 6 places the most important results of this thesis in the context of a step-wise 
model for the development of preeclampsia (modified from [60-63]). These results will 
be discussed in detail in the following sections. 
 
Maternal 
constitutional 
factors
Partial maternal tolerance 
of allogeneic trophoblasts
Poor placentation
Endoplasmic 
reticulum stressOxidative stress
Inflammatory stress
Placenta
Overt preeclampsia Acute atherosis
• Tryptophan metabolism
• GCA
• Notch signalling
• STOX genes
• NRF-2 mediated oxidative 
stress response
• Endoplasmic reticulum stress
• Lipid metabolism
• Cardiovascular risk factors
 
Figure 6. Summary of the major findings of this thesis in the context of a step-wise 
model for the development of preeclampsia (modified from [60-63]). Tryptophan 
metabolism (Paper I) and GCA (Paper IV) are known factors involved in immune 
maladaptation. Notch signalling (Paper I), STOX genes (Papers I and II) may be 
implicated in impaired placentation. The oxidative stress, ER stress and inflammatory 
response pathways (Papers I and III) in the placenta give rise to the inflammatory drive 
of preeclampsia. Acute atherosis is recently suggested as possible last stage of 
development of preeclampsia in some cases [62], and is suggested as a link to later life 
CVD (Papers I and IV). Constitutional risk factors for preeclampsia are similar to 
cardiovascular risk factors (Paper IV), and could possibly affect all the above-
mentioned stages. 
 
Immune maladaptation 
Pathway analysis revealed that tryptophan metabolism was the most significant pathway 
among the differentially expressed transcripts (Paper I). Tryptophan metabolism, 
including the enzyme indoleamine 2,3-dioxygenase (IDO), is important for promoting 
immune tolerance at the maternal-fetal interface [218]. In preeclampsia, placental 
tryptophan degrading activity and placental IDO expression are reduced [219, 220]. In 
the absence of IDO, Treg cells are reprogrammed to resemble the phenotype of the more 
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pro-inflammatory T helper (Th) cells Th17 [221], which are increased in preeclampsia 
[222]. Other tryptophan catabolites can directly modulate the functions of the immune 
system [223-226] and might therefore also be important in the immunoregulation of 
pregnancy and the development of preeclampsia. Correspondingly, decreased levels of 
L-kynurenine have been observed in preeclampsia [219]. We observed an increased 
expression of the transcript encoding the enzyme kynureninase (KYNU). KYNU 
metabolises L-kynurenine, which suppress proliferation of T- and NK cells and 
influences immunotolerance to foreign antigens. We speculate that increased levels of 
KYNU could contribute to decreased levels of L-kynurenine, which may impair the 
necessary immune modulation during pregnancy in preeclamptic women. This could 
potentially lead to deficient placentation, as mentioned in Section 1.5. 
 
Previous findings from our collaborators’ Australian/New Zealand cohorts have 
demonstrated that variations in the genes tumour necrosis factor superfamily, member 
13b (TNFSF13B) and GCA, which both are involved in functions of the immune 
system, are associated with preeclampsia [227, 228]. GCA impacts the neutrophil 
adhesive properties to fibronectin [229], which promotes cytokines such as interleukin-8 
(IL-8) to exert their chemotactic effects. This could contribute to the pronounced 
abundance of neutrophils in the maternal systemic vasculature of both preeclamptic 
[230] and obese [231] women. In Paper IV, we showed nominal associations between 
GCA and lower risk in adolescents born of a preeclamptic pregnancy and those having a 
mother with a prior preeclamptic pregnancy. Together with the results of Johnson et al. 
[228], this finding supports the emerging evidence of an immune component to 
preeclampsia pathophysiology [232]. However, our results were not significant after 
correction for multiple testing, and must be interpreted with some caution.  
 
Impaired placentation 
Notch signalling was one of the top significant pathways among the differentially 
expressed transcripts (Paper I) and included the four transcripts deltex homolog 3 
(DTX3), hairy and enhancer of split 1 (HES1), notch homolog 3 (NOTCH3) and notch 
homolog 4 (NOTCH4). The involvement of Notch signalling has also been 
demonstrated in two global gene expression studies of placental tissue from 
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preeclamptic and non-preeclamptic women [233, 234]. The Notch signalling pathway is 
a conserved family of four transmembrane receptors (NOTCH1-4) and five ligands 
(DLL1/3/4 and JAG1/2). The pathway is important for embryonic development and 
normal development of the human placenta, and, as will be discussed in the next 
section, angiogenesis [196, 235, 236]. Both cytotrophoblasts and syncytiotrophoblasts 
have been shown to express NOTCH3 and NOTCH4, suggesting an involvement in the 
trophoblast differentiation program and invasion process of EVTs [196]. Moreover, 
protein analysis of placentas from preeclamptic women has indicated decreased levels 
of the Notch pathway members in all compartments of the placental villi [237]. We 
observed a down-regulation of both NOTCH3 and NOTCH4 in the preeclamptic cases 
compared to the controls, suggesting that both transcripts may be involved in the 
impaired trophoblast invasion observed in preeclampsia. However, NOTCH4 is 
reported to change expression with gestational age [199], and this might have affected 
our results.  
 
STOX1 is believed to play a role in trophoblast dysfunction underlying a familial form 
of early-onset preeclampsia with FGR [238]. The preeclampsia susceptibility linkage 
locus for STOX1 originally identified on chromosome 10q22 showed matrilineal 
inheritance [215]. Our genetic association analysis of candidate SNPs within STOX1  
(Paper II) could not confirm an association with preeclampsia, nor was differential gene 
expression of STOX1 observed in any of the case groups. We were not able to assess 
the proposed maternal imprinting effect on STOX1, which might have affected our 
results. In addition, the STOX1 genetic association was observed in Dutch families. The 
variants identified in preeclampsia families, which by definition have a higher 
penetrance, may not be replicated in population-based studies. However, we observed 
differential expression of STOX2 in preeclamptic pregnancies complicated with FGR. 
Information on the biological role of STOX2 is limited, and its plausibility as a 
candidate gene for preeclampsia rests largely on research done on STOX1, of which 
STOX2 is a paralogue (and is expected to be involved in some of the same biological 
processes) [239, 240], and that STOX2 resides close to or under a replicated 
preeclampsia susceptibility locus (4q31-q32) [134, 136, 139]. Thus, further molecular 
genetic studies are needed to evaluate the biological importance of our finding. 
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Angiogenic imbalance 
Immunostaining of endothelial cells of human placentas has revealed intense immune-
positivity of Notch family members [197], suggesting a role for the Notch signalling 
pathway in the placental angiogenesis process. In placentas from women with 
preeclampsia, the immunoreactivity of Notch proteins is decreased compared to that in 
placentas from non-preeclamptic women [237]. Consistently, all the four differentially 
expressed transcripts in the Notch signalling pathway were down-regulated in 
preeclamptic cases (Paper I). Hunkapiller et al. observed a correlation between absent 
jagged 1 (JAG1) expression in cytotrophoblasts and failed vascular remodelling in 
preeclampsia [241]. This is suggestive of an important functional role for Notch 
signalling in the remodelling of human spiral arterioles [241]. However, many questions 
remain to be answered concerning this possible relationship to determine the biological 
implications for preeclampsia. This includes an evaluation of possible causality, e.g., if 
decreased expression of Notch receptors and ligands in preeclampsia are prerequisites 
or by-products of failed endovascular invasion [241], as well as the clarification of up-
stream signalling pathways or factors controlling the expression of Notch family 
members in human placental trophoblasts and blood vessels, which are largely unknown 
[196].  
 
Cytochrome P450 (CYP)-dependent eicosanoids regulate vascular function, 
inflammation, and angiogenesis, all which are important factors in the pathogenesis of 
preeclampsia. We observed increased expression of CYP, family 2, subfamily J, 
polypeptide 2 (CYP2J2) in decidual tissue from preeclamptic cases compared to 
controls (Paper I). This is in accordance with findings in placental and decidual tissues 
from preeclamptic women published by Herse et al. [198]. These authors further 
localised CYP2J2 in trophoblastic villi and decidua at 12 weeks and term and observed 
that CYP2J2 metabolites were elevated in preeclamptic women compared to controls 
[198]. Furthermore, rat models have indicated reduced uterine perfusion related to 
increased levels of CYP2J2 protein expression [198]. Taken together, these results 
indicate that increased uteroplacental expression CYP2J2 could contribute to the 
disturbed spiral artery remodelling observed in preeclampsia.  
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Placental stress 
There is substantial evidence of decidual oxidative stress in preeclamptic women [91-
93, 107]. Pathway analysis demonstrated that the NRF2-mediated oxidative stress 
response was on the list of top pathways among the differentially expressed transcripts 
(Paper I). Our results suggest a possible role of NFR2 in preeclampsia, and this 
hypothesis is strengthened by similar findings of others [242, 243]. NRF2 plays an 
essential role in the defence against oxidative stress [244] by regulating the expression 
of antioxidant response elements (AREs) [89]. During excessive oxidative stress, ROS, 
NO and pro-inflammatory cytokines activate NRF2, which is translocated to the 
nucleus, where it binds to ARE sequences, leading to transcriptional activation of 
antioxidant genes, e.g., glutathione and heme oxygenase 1 (HMOX1) [245]. Several 
enzymes metabolise ROS to exportable compounds, and in our study, the antioxidant 
enzymes glutathione S-transferase (GST3), HMOX1 and ubiquitin-conjugating enzyme 
E2K (UBE2K) were up-regulated. HMOX1 has previously been suggested to have a 
role in the pathogenesis of preeclampsia [246, 247]. Using a subset of the decidua 
basalis samples in the PE/FGR Biobank (used in Papers I-III), Eide et al. demonstrated 
that HMOX1 protein expression was significantly increased in preeclamptic cases 
compared to controls [247]. In addition, these authors found elevated maternal serum 
HMOX1 levels in these preeclamptic women and a positive link between serum 
HMOX1 protein levels and the severity of maternal hypertension [247]. Taken together, 
the overall up-regulation (seven transcripts up-regulated, two transcripts down-
regulated) of the transcripts within the NRF2-mediated oxidative stress response 
pathway might indicate a defensive response to increased oxidative stress in the decidua 
basalis observed in preeclampsia.  
 
Our transcriptional data and pathway analyses suggest a central role of ER stress in the 
pathogenesis of preeclampsia (Paper I), preeclampsia with FGR and isolated FGR 
(Paper III). We observed up-regulation of key molecules in each of the signalling 
pathways of the UPR, including PERK (EIF2AK3), ATF6 and XBP1. Activation of the 
UPR has previously been associated with preeclampsia with FGR and isolated FGR in 
placental tissue [104], but our findings are novel because they were reported from 
decidua basalis tissue. Moreover, we identified increased activation of the UPR in 
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decidual tissue from preeclamptic women compared to controls at the protein level 
(Paper III). Yung et al. proposed ER stress as a mechanism responsible for the small 
placental phenotype observed in some cases of preeclampsia with FGR and FGR [102, 
104]. Our data support this hypothesis as we observed a negative correlation between 
placental weight and protein levels of ER stress markers (Paper III). Recently, the 
nuclear factor (NRF)-family proteins were suggested to play a central role in activating 
UPR transcription [248]. Additionally, the authors showed that URP and oxidative 
stress responses were integrated through NRF [248]. These findings support our 
observations of direct relationships between genes involved in the ER stress- and 
NRF2-mediated oxidative stress response pathways in the network of preeclampsia-
correlated genes (Paper I). 
 
Acute atherosis was observed more frequently in our decidual tissue from cases 
(preeclampsia and/or FGR) compared to controls [159]. The mechanisms underlying the 
development of acute atherosis are largely unknown. However, a similarity with early 
atherosclerotic changes has led to the suggestion that acute atherosis is the final 
manifestation of several inflammatory processes [62]. Our transcriptional analyses 
(Papers I and III) indicate an integrated role of decidual ER stress, oxidative stress, and 
altered lipid metabolism in the generation of inflammation and the development of 
acute atherosis, which are observed in both preeclampsia and CVD. ER stress appears to 
have negative effects on endothelial cell stability, and it has been speculated that this 
may in part account for plaque susceptibility to rupture through ER-stress mediated 
apoptosis, promoting loss of the endothelial layer covering the plaque [249]. Statins are 
anti-atherosclerotic and stabilises vulnerable plaques, and have been speculated to 
potentially ameliorate acute atherosis [62]. Research in this field might lead to 
preventive drugs for the development of preeclampsia and later CVD in subsets of 
women with preeclampsia. Currently, the StAmP (Trial of provaStatin to Ameliorate 
early onset Pre-eclampsia) trial is testing statins for the treatment of early-onset 
preeclampsia [250].  
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Preeclampsia and CVD 
The results of this thesis support the hypothesis that genetic mechanisms for 
preeclampsia and CVD are, at least in part, shared (Papers I, III and IV). In Paper I, the 
network of differentially expressed transcripts included 30 genes that were previously 
shown to be involved in CVD. Furthermore, the functional category ‘CVD’ included 21 
genes involved in, e.g., hypertension (HMOX1, NGF, REN), atherosclerosis (LDLR, 
PLA2G7) and invasion of endothelial cells (HPSE, THBS2, VEGFC), according to the 
Ingenuity Pathways Knowledge Base (Ingenuity Systems, Redwood City, CA). In Paper 
IV, we observed a shared genetic nominal association between the four SNPs rs2322659 
(LCT), rs35821928 (LRP1B), rs115015150 (RND3) and rs17783344 (GCA) and several 
cardiovascular risk factors. However, none of these association results satisfied our 
stringent correction for multiple testing, and consequently, the results must be 
interpreted with caution.  
 
Preeclampsia and CVD share several metabolic abnormalities, such as an increase in 
small, dense low density lipoprotein (LDL) and triglycerides [251-253]. Thus, 
dyslipidaemia serves as a link between maternal constitutional risk factors (insulin 
resistance, pre-pregnancy obesity) for preeclampsia and the development of CVD later 
in life. Three of the pathways identified in Paper I represent lipid metabolism: linoleic 
acid metabolism, fatty acid metabolism, and arachidonic acid metabolism. Johansson et 
al. combined our gene expression data (Paper I) with genome-wide SNP genotyping and 
cardiovascular-related lipid phenotypic data and identified the down-regulation of acyl-
Coenzyme A oxidase 2 (ACOX2) in our material as a common risk factor for 
preeclampsia and CVD [254]. ACOX2 is involved in the degradation of long branched 
fatty acids and the production of bile acids, and insufficient levels of ACOX2 may 
increase the fraction of bile acid intermediates relative to the fraction of mature bile 
acids [254]. Mature bile acids activate the farnesoid X receptor (FXR), leading to 
reduced levels of triglycerides [255], suggesting that FXR plays a critical role in lipid 
metabolism. The authors proposed that their observation of an inverse correlation 
between the transcript levels of ACOX2 and triglyceride levels implicates ACOX2 as a 
possible regulator of triglyceride levels through the FXR [254]. 
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Pregnancy is a unique opportunity to identify women and offspring at increased risk of 
premature CVD [43], and clinical risk assessments and preventive programmes are 
under development [256]. However, the optimal follow-up regimen of women after a 
preeclamptic pregnancy remains uncertain and was discussed without any clear answers 
at a panel debate of invited clinicians at the most recent European Congress of the 
International Society for the Study of Hypertension in Pregnancy (ISSHP) (12-14 June 
2013, Tromsø, Norway). In Norway, national guidelines for general practitioners 
recommend the evaluation of the risk for CVD 3-6 months post partum, with 
assessment of regular cardiovascular risk factors including measurements of blood 
pressure and weight and encouraging optimal weight range through diet, exercise and 
smoking cessation. A recent study indicated that lifestyle interventions after 
preeclampsia were likely to decrease future cardiovascular risk [257]. Nevertheless, the 
Norwegian national guideline for the primary prevention of CVD, NORRISK [258], 
does not address the association between preeclampsia and CVD in any form, which is 
similar to guidelines used in other European counties [259]. A few studies have 
investigated awareness and knowledge among physicians of future health risks 
(including CVD) after preeclampsia, long-term treatment after preeclampsia and the 
knowledge of current national guidelines [260-262]. The results of these studies are 
conflicting, ranging from good to limited knowledge among physicians, with a range of 
50-80% of responders aware of this association [260-262]. These results indicate the 
need for further academic education and increased flow of information between the 
different medical specialities, including obstetricians, cardiologists and general 
practitioners. Hopefully, research results in the near future will provide a basis for 
sound guidelines for the follow-up of women with a history of preeclampsia. In the long 
term, genetic studies will ideally increase the understanding of the pathophysiology of 
preeclampsia and CVD, thereby improving the prediction, prevention and management 
of both disorders.  
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7. CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
 
The results of this thesis suggest that perturbed gene expression at the maternal-fetal 
interface and genetic polymorphisms are likely to explain some of the mechanisms 
involved in the pathogenesis of preeclampsia. We have demonstrated that 
immunological perturbations in preeclampsia might be linked to disturbed tryptophan 
metabolism. We have also confirmed that decidua basalis tissue from pregnancies 
complicated with preeclampsia is characterised by the co-occurrence of increased 
oxidative, ER, and inflammatory stress. The investigations in this thesis generated 
evidence for the involvement of metabolic pathways in preeclampsia, particularly the 
involvement of cardiovascular risk factors. Our findings support the hypothesis that 
preeclampsia shares some underlying genetic risk factors with CVD.  
 
Some of these results are hypothesis generating, and further replication studies are 
required to elucidate the exact pathophysiological mechanisms involved in 
preeclampsia. Findings from gene expression studies must be verified, and protein 
analysis may confirm that the differences in mRNA expression between cases and 
controls are correlated with differences in protein levels. Genotype-level and functional 
studies (cell culture, animal models) may also be needed to confirm the involvement of 
the suspected genes/mechanisms in the pathogenesis of the disease [263]. Our results 
underpin preeclampsia as a complex disorder that involves different biological 
processes. We have identified possible preeclampsia susceptibility genes, each of which 
likely have a modest effect on the development of the disorder. Replication is needed to 
improve the statistical significance of the findings, decrease errors and biases, and 
affirm that the associations uncovered reflect processes that are biologically interesting, 
rather than methodological inadequacies [264]. 
 
The technological developments of the last decade have been striking, and new and 
powerful tools such as GWAS, exome sequencing and genome-wide sequencing are 
now being used to identify genetic variants, gene-gene and gene-environment 
interactions and underlying epigenetic mechanisms. A GWAS on a large (>5,000 
cases), population-based cohort may further elicit genetic variations associated with 
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preeclampsia. Such studies require huge national and international investment. 
Consequently, co-authors of the manuscripts comprising this thesis are currently 
collaborating through the InterPregGen research study, which plans to use genome-wide 
approaches including HUNT2 samples from preeclamptic and non-preeclamptic 
women. These sample sizes might also enable subgroup analysis of preeclampsia 
phenotypes. The InterPregGen research study further plans to analyse maternal-fetal 
interactions, as investigations of both maternal and fetal genotypes are essential to 
increase our understanding of the genetics of preeclampsia. We investigated both 
maternal and fetal genotypes in Paper IV; however, we did not assess mother-offspring 
pairs, which could be performed in further studies. Combinations of SNPs that may 
explain the variation in preeclampsia could also be investigated in larger samples that 
are powered to detect such associations. The recent technological advances and 
efficiencies in high-throughput next-generation DNA/RNA sequencing have enabled 
deep gene sequencing. We plan to investigate some of the genes investigated in this 
thesis by re-sequencing unrelated preeclampsia and control women from Australian, 
Finnish and Norwegian populations. The steady decrease in cost will soon enable 
increased use of genome-wide sequencing, which might become the state-of-the-science 
for genetic dissection of complex traits. The use of this technology will also require the 
development of analytical tools to interpret the results; the statistical methods and 
ability to process data continue to lag far behind the ability to produce huge amounts of 
genomic data.  
 
The understanding of preeclampsia pathophysiology has increased immensely in the last 
two decades, but only very modest changes to prevention, prediction and management 
have been presented [265]. To date, preeclampsia still lacks a reliable, early diagnostic 
marker and safe and effective treatment. Prediction of preeclampsia at an early stage 
would enable close surveillance and preventive strategies, which could have a great 
impact on maternal and fetal health. Biochemical markers have been tested throughout 
pregnancy for the prediction and diagnosis of preeclampsia, but no compelling evidence 
for the usefulness of these predictors has been reported [266, 267]. However, recent 
studies have yielded promising results [268, 269], and combinations of markers may 
help clinicians to identify women who should be followed more closely. Metabolomics 
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technology is a promising technique to characterise and identify biomarkers for 
preeclampsia [268]. Our research group is currently establishing metabolic profiles of 
body fluids (urine and serum) from women with and without preeclampsia by magnetic 
resonance (MR) metabolomics to identify potential clues to preeclampsia aetiology and 
pathogenesis, with promising results [270]. The identification of causal genetic factors 
underlying preeclampsia might enable fundamental insights into its pathophysiology 
and potentially lead to the development of better and more specific prediction and 
interventions to reduce the impact of preeclampsia on the community. A vital question 
is the cost-effective translation of genomic findings into improved health outcomes. 
This has proven difficult, and for most diseases, we are still far from personalised 
medicine informed by pharmacogenomics [271]. Current applications of genetic 
epidemiology have begun to lay the foundation for understanding the complex 
pathways that result in preeclampsia, but much work remains to obtain a complete 
picture. This thesis has presented novel investigations that have contributed to the 
current body of knowledge regarding preeclampsia and outlined potential directions for 
future research.  
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GENETICS
A transcriptional proﬁle of the decidua in preeclampsia
Mari Løset, MD; Siv B. Mundal, MD; Matthew P. Johnson, PhD; Mona H. Fenstad, MD;
Katherine A. Freed, PhD; Ingrid A. Lian, MD; Irina P. Eide, MD, PhD; Line Bjørge, MD, PhD;
John Blangero, PhD; Eric K. Moses, PhD; Rigmor Austgulen, MD, PhD
OBJECTIVE: We sought to obtain insight into possible mechanisms un-
derlying preeclampsia using genomewide transcriptional proﬁling in
decidua basalis.
STUDY DESIGN: Genomewide transcriptional proﬁling was performed
on decidua basalis tissue from preeclamptic (n 37) and normal (n
58) pregnancies. Differentially expressed genes were identiﬁed and
merged into canonical pathways and networks.
RESULTS: Of the 26,504 expressed transcripts detected, 455were dif-
ferentially expressed (P .05; false discovery rate, P .1). Both novel
(ARL5B, SLITRK4) and previously reported preeclampsia-associated
(PLA2G7, HMOX1) genes were identiﬁed. Pathway analysis revealed
that tryptophanmetabolism, endoplasmic reticulum stress, linoleic acid
metabolism, notch signaling, fatty acid metabolism, arachidonic acid
metabolism, and NRF2-mediated oxidative stress response were over-
represented canonical pathways.
CONCLUSION: In the present study single genes, canonical pathways,
and gene-gene networks that are likely to play an important role in the
pathogenesis of preeclampsia have been identiﬁed. Future functional
studies are needed to accomplish a greater understanding of themech-
anisms involved.
Key words: decidua, genomewide gene expression, microarray,
preeclampsia
Cite this article as: Løset M, Mundal SB, Johnson MP, et al. A transcriptional proﬁle of the decidua in preeclampsia. Am J Obstet Gynecol 2011;204:84.e1-27.
The etiology of preeclampsia is notfully understood, but a number of
observations suggest that divergent
abnormalities may be involved (immu-
nological, inﬂammatory, vascular/isch-
emic).1 In a normal pregnancy extravil-
lous trophoblasts (of fetal origin) invade
decidua basalis and modify the spiral ar-
teries. In preeclampsia, this pregnancy-
associated adaptionof spiral arteriesmay
fail, with a hypoperfused placenta as a
result. Oxidative stress is suggested to
play a central role in the pathogenesis of
preeclampsia,2 and may be generated
in the decidua basalis.3,4 Heritability of
the disease has been estimated to be
50%,5,6 with both maternal and fetal
(paternal) contributions.7
Microarray-based transcriptional pro-
ﬁling can be a powerful strategy for iden-
tiﬁcation of disease-related genes and
pathways,8 and this approach has been
used for analysis of placental9 as well as
decidual6,10,11 tissues from preeclamptic
pregnancies.However, the data obtained
have been inconsistent. In the case of the
3 decidual studies reported, the diverg-
ing results may be due to the relatively
small number of samples analyzed (12
preeclamptic samples included).6,10,11
In the current study, we have applied
genomewide transcriptional proﬁling
(measuring48,000 transcripts from all
known genes) on a large collection of de-
cidual samples (from 37 preeclamptic
and 58 normal pregnancies) to compre-
hensively investigate how gene expres-
sion at the maternal-fetal interface may
be contributing to the pathogenesis of pre-
eclampsia. We further aimed to identify
the genetic canonical pathways and gene-
gene interaction networks represented by
the differently expressed genes using con-
temporary bioinformatic approaches.
MATERIALS AND METHODS
Human subjects
Women with pregnancies complicated
by preeclampsia (n  43) and women
with normal pregnancies (n  59) were
recruited at St. Olav’s University Hospital
(Trondheim, Norway) and Haukeland
University Hospital (Bergen, Norway)
from 2002 through 2006. Preeclampsia
was deﬁned as persistent hypertension
(blood pressure of140/90 mm Hg) plus
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proteinuria (0.3g/Lor1bydipstick)
developing 20 weeks of pregnancy.12
Due to tissue sampling procedures, only
pregnancies delivered by cesarean section
were included. Women with preeclamptic
pregnancies had cesarean section per-
formed for medical indications, whereas
women with normal pregnancies under-
went cesarean section for reasons consid-
ered irrelevant to the aim of the study (eg,
breechpresentation, cephalopelvicdispro-
portion in previous delivery, and fear of
vaginal delivery). None of the included
mothers were in labor prior to cesarean
section. Exclusively healthy women with
no history of preeclampsia were accepted
in the normal pregnancy group. Multiple
pregnancies, pregnancies with chromo-
somal aberrations, fetal and placental
structural abnormalities, or suspected
perinatal infections were excluded from
both study groups. The study was ap-
proved by the Norwegian Regional Com-
mittee for Medical Research Ethics. In-
formed consent was obtained from all
participants prior to collection of decidual
samples.
Decidual tissue collection
Samples of decidua basalis tissue were
obtained by vacuum suction of the pla-
cental bed, a procedure that allows the
collection of tissue from the whole pla-
cental bed.13 Collected samples were
ﬂushed with saline solution to remove
excessive blood. The decidual tissue was
immediately submerged in RNA-later
(Ambion, Austin, TX).
Total RNA isolation
Total RNA was isolated using a TRIzol
(Invitrogen, Carlsbad, CA) extraction
protocol with chloroform interphase
separation, isopropanol precipitation,
and ethanol wash steps. Precipitated to-
tal RNA was resuspended in Rnase-free
water and puriﬁed with an RNeasy Mini
Kit using spin technology (Qiagen, Va-
lencia, CA). Spectrophotometric deter-
mination of puriﬁed total RNA yield
(g) was performed using the Nano-
Drop ND-1000 (Thermo Scientiﬁc, Wil-
mington, DE). Total RNA quality was
measured using RNA 6000 Nano Series
II Kit on a BioAnalyzer 2100 (Agilent
Technologies, Santa Clara, CA). Ethical
approval for total RNA processing and
decidua expression analysis was ob-
tained from the institutional review
board at the University of Texas Health
Science Center in San Antonio.
Synthesis, ampliﬁcation, and
puriﬁcation of antisense RNA
Antisense RNA (aRNA)was synthesized,
ampliﬁed, and puriﬁed using the Illu-
mina TotalPrep RNA Ampliﬁcation Kit
according to manufacturer’s instruc-
tions (Ambion, Austin, TX). Synthesis of
aRNA was performed using a T7 Oli-
go(dT) primer, and the ampliﬁcation
underwent in vitro transcription with a
T7 RNA polymerase to generate multiple
copies of biotinylated aRNA from a
double-stranded complementary DNA
(cDNA) template. Puriﬁed aRNA yield
was determined spectrophotometrically
using the NanoDrop ND-1000.
Microarray data
Puriﬁed aRNA was hybridized to Illumi-
na’s HumanWG-6 v2 Expression Bead-
Chip (Illumina Inc, San Diego, CA).
Washing, blocking, and transcript signal
detection (streptavidin-Cy3) was per-
formed using Illumina’s 6 2 BeadChip
protocol. Samples were scanned on the
Illumina BeadArray 500GX Reader us-
ing Illumina BeadScan image data acqui-
sition software (version 2.3.0.13). Illu-
mina’s BeadStudio Gene Expression
software module (version 3.2.7) was
used to subtract background noise sig-
nals and generate an output ﬁle for sta-
tistical analysis.
Real-time quantitative
polymerase chain reaction
We performed a veriﬁcation of the mi-
croarray experiment with quantitative
real-time (RT)-polymerase chain reac-
tion (PCR) on 6of themost differentially
expressed transcripts using a 7900HT
Fast RT-PCR instrument (Applied Bio-
systems, Foster City, CA). The 6 genes
were prioritized for RT-PCR based on
beta values, false discovery rate (FDR) P
values, and manual literature searches.
RT quantitative PCR was run with 93
samples. Two of the total collection of 95
samples were excluded due to shortage
of biological material. Preoptimized
TaqMan Gene Expression Assays (Ap-
plied Biosystems) were run, in triplicate,
to measure messenger RNA expression
levels relative to the reference genes,TATA
box binding protein and glyceraldehyde-
3-phosphatedehydrogenase.Reverse tran-
scription and PCR ampliﬁcation was per-
formed in a 2-step procedure, following
Applied Biosystems High-Capacity cDNA
ReverseTranscription Kit Protocol and
TaqMan Gene Expression Master Mix
Protocol. Negative controls were run, in
triplicate,withoutRTenzymeornocDNA
template.
Statistical analysis
Transcript data for each sample were pre-
processed and analyzed using our Sequen-
tial Oligogenic Linkage Analysis Routines
(SOLAR) statistical analysis software pro-
gram,14 as previously described.15 To
evaluate the magnitude of differential
gene expression the displacement of each
detected transcript’s mean expression
value was measured between the 2
groups. A standard regression analysis
was performed on the preeclamptic
group to test whether the mean tran-
scription level differed from that of the
normal pregnancy group.
The messenger RNA expression levels
were calculated by the Comparative
threshold cycle (CT) method, as described
elsewhere.16Foreachtargetgene, themean
CT value for each sample was used for
analysis, after exclusion of outliers. Outli-
ers were determined as values2SD from
the mean. Delta CT (CT) values were
computed as the difference between the
given mean value for a target gene and the
mean of the CT values for the 2 reference
genes.17 Fold change values were calcu-
lated, based on the differences inCT val-
ues between tissue from preeclamptic
women and women with normal preg-
nancy (2CT).16 A t test statistic (SPSS,
version 16; SPSS, Inc, Chicago, IL) evalu-
atedthedifferencebetweentheCTvalues
of the preeclamptic pregnancies, com-
pared with the normal pregnancy group.
Analyzing for the 2 reference genes sepa-
rately did not change the results.
Canonical pathway and
network identiﬁcation
Differentially expressed transcripts in
the preeclamptic group (P .05; FDR,18
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P  .1) were imported into Ingenuity
Pathways Analysis (IPA, v7.5; Ingenuity
Systems, Redwood City, CA). Tran-
scripts’ gene identiﬁers were mapped to
their corresponding gene object in the
Ingenuity Pathways Knowledge Base.
IPA was used to bioinformatically iden-
tify canonical (ie, cell signaling and met-
abolic) pathways and gene-gene interac-
tion networks potentially involved in
preeclampsia within our dataset. IPA
gene-gene networks were constructed
from the published literature, and they di-
agrammatically represent molecular rela-
tionships between gene-gene products.
Signiﬁcant IPA pathways were further
analyzed with Rotation Gene Set Enrich-
ment Analysis (ROMER; Fred Hutchin-
son Cancer Research Center, Seattle,
WA) pathway analysis, using the limma
package, available via the Bioconductor
Project (Fred Hutchinson Cancer Re-
search Center).19
RESULTS
Human subjects
The clinical information of women/
pregnancies enrolled is presented in Ta-
ble 1. Only those samples of sufﬁcient
RNA quality for gene expression analysis
have been included. In the preeclamptic
pregnancies, both mean gestational age
and birthweight were lower than in the
normal pregnancies (Table 1). As ex-
pected, the mean blood pressure was
higher among preeclamptic than normal
pregnancies (Table 1).
Decidual genomewide
transcriptional proﬁling
In total, 43 women with pregnancies
complicated by preeclampsia and 59
women with normal pregnancies were
included in the study. Six samples from
preeclamptic pregnancies and 1 sample
from a normal pregnancy were excluded
fromgene expression analyses due to low
RNA quality. The 95 samples with good
RNA quality were hybridized onto Illu-
mina’s HumanWG-6 v2 genomewide
Expression BeadChip.
The nonnormalized decidua basalis
transcriptional proﬁle data (n 48,095)
may be found at ArrayExpress (Euro-
pean Molecular Biology Laboratory-
European Bioinformatics Institute,
Hinxton,UK) (accession codeE-TABM-
682). We detected 26,504 signiﬁcantly
expressed transcripts (55.1%), of which
455 were differentially expressed after
FDR correction (P .05; FDR, P .1);
285 were down-regulated and 170 were
up-regulated. The signiﬁcant differen-
tially expressed transcripts are presented
inTable 2, togetherwith the correspond-
ing P values (raw and FDR adjusted) and
preeclampsia-correlated expression.
The RT quantitative PCR for the 6
genes (PLA2G7, ANGPTL2, MAN1A2,
SLITRK4, FZD4, and ARL5B) tested
showed a high grade of correlation with
the microarray data (Table 3).
Canonical pathways and network
The 455 differentially expressed tran-
scripts were analyzed using IPA. The sig-
niﬁcant canonical pathways (P  .01)
are shown in Table 4, along with the in-
cluded genes and P values. They in-
cluded tryptophan metabolism, endo-
plasmic reticulum (ER) stress, linoleic
acid metabolism, notch signaling, fatty
acid metabolism, arachidonic acid me-
tabolism, and NRF2-mediated oxidative
stress response. All the canonical path-
ways identiﬁed in IPA were also found to
be signiﬁcant (P  .01) using ROMER
(Table 4), with the exception of the
NRF2-mediated oxidative stress re-
sponse canonical pathway (IPA, P 
.009; ROMER, P .067).
Using network analysis in IPA, 59 of
the preeclampsia-associated genes could
be connected into a single network of
gene-gene product interactions (Figure).
The genes in this network were among
others involved in the function of ER,
oxidative stress, notch signaling, and cell
migration. The network included a clus-
ter of 15 up-regulated genes (ATP2A2,
TRAM1, FKBP2, HMOX1, SPCS2,
ATF6, DNAJC3, EIF2AK3, PIGA,
SEC23B, SEC24D, DNAJB9, SRPRB,
DNAJB11, and X-box binding protein 1
[XBP1]) associated with ER stress and
oxidative stress (Figure). All these genes
were in a direct relationship to XBP1.
Epidermal growth factor receptor
(EGFR)was another focusmoleculewith
a direct relationship to 7 other genes
(PLCG1, NGF, MET, LRIG1, SLN,
ATP2A2, and SHC2) in the network.
COMMENT
In this study, 455 differentially expressed
transcripts were found when decidua
basalis tissue from preeclamptic and
normal pregnancies was compared.
Some transcripts were novel ﬁndings (ie,
ARL5B and SLITRK4), whereas others,
such as PLA2G720 and HMOX1,21,22
have been reported to be associated with
preeclampsia previously. Pathway analy-
sis identiﬁed 7 signiﬁcant canonical
pathways.
Inourpatientcohort, a lowergestational
age was found in the preeclamptic group
(average, 32 weeks; range, 28–36) com-
pared with the normal pregnancy group
(39 weeks; range, 38–40). This is not un-
expected due to the need for early delivery
in patients with severe preeclampsia. Since
gene expression in uteroplacental tissues
TABLE 1
Clinical characteristics of study groups
Variable
Preeclamptic pregnanciesa
(n  37 )
Normal pregnanciesa
(n  58)
Gestational age, wk 32 	 4b 39 	 1
..............................................................................................................................................................................................................................................
Systolic blood pressure, mm Hg 152 	 16b 116 	 10
..............................................................................................................................................................................................................................................
Diastolic blood pressure, mm Hg 96 	 10b 70 	 9.0
..............................................................................................................................................................................................................................................
Birthweight, g 1555 	 769b 3619 	 469
..............................................................................................................................................................................................................................................
Body mass index, kg/m2c 27.7 	 6.2 25.3 	 5.7
..............................................................................................................................................................................................................................................
Values are means	 SD.
a In all, 43 women with pregnancies complicated by preeclampsia and 59 women with normal pregnancies were included in the
study. Six samples from preeclamptic pregnancies and 1 sample from normal pregnancy were excluded from gene expression
analysis due to low RNA quality; b P .001 obtained with t test statistics with software (SPSS, version 16; SPSS, Inc, Chicago,
IL); c Body mass index was measured at ﬁrst antenatal care visit.
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TABLE 2
Differentially expressed transcriptsa
Illumina ID GenBank ID Symbol Deﬁnition Ch
Beta
valueb P valuec
FDR P
valued
ILMN_1782259 NM_173078.2 SLITRK4 SLIT and NTRK-like family,
member 4
X 1.0363 4.6  108 .0012
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1680465 NM_178815.3 ARL5B ADP-ribosylation factor-like 5B 10 0.9122 4.5 107 .0039
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1743367 NM_012193.2 FZD4 Frizzled homolog 4 (Drosophila) 11 0.9122 4.1  107 .0054
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1726210 NM_178172.2 LOC338328 High density lipoprotein–binding
protein
8 0.8672 3.7  106 .0088
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1709222 NM_005692.3 ABCF2 ATP-binding cassette, subfamily
F (GCN20), member 2, nuclear
gene encoding mitochondrial
protein, transcript variant 2
7 0.8634 3.5  106 .0093
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1772612 NM_012098.2 ANGPTL2 Angiopoietin-like 2 9 0.8884 4.4  106 .0097
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1659792 NM_014213.2 HOXD9 Homeobox D9 2 0.8541 3.5  106 .0102
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1813295 NM_018640.3 LMO3 LIM domain only 3 (rhombotin-
like 2), transcript variant 1
12 0.8992 3.3  106 .0110
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1669023 NM_020482.3 FHL5 Four and a half LIM domains 5 6 0.8489 3.2  106 .0123
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1658677 NM_178502.2 DTX3 Deltex 3 homolog (Drosophila) 12 0.9038 2.9  106 .0130
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1812461 NM_003881.2 WISP2 WNT1 inducible signaling
pathway protein 2
20 0.8717 6.6  106 .0134
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1776157 NM_080415.1 SEPT4 Septin 4, transcript variant 2 17 0.8882 2.6  106 .0140
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1794370 NM_001031702.2 SEMA5B Sema domain, 7
thrombospondin repeats (type 1
and type 1-like),
transmembrane domain (TM)
and short cytoplasmic domain,
(semaphorin) 5B, transcript
variant 1
3 0.8695 8.0  106 .0141
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1719069 NM_213596.1 FOXN4 Forkhead box N4 12 0.8803 7.8  106 .0147
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1733667 NM_021931.2 DHX35 DEAH (Asp-Glu-Ala-His) box
polypeptide 35
20 0.8537 9.0  106 .0149
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1734276 NM_199169.1 TMEPAI Transmembrane, prostate
androgen-induced RNA,
transcript variant 2
20 0.8360 1.6  105 .0153
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1701195 NM_005084.2 PLA2G7 Phospholipase A2, group VII
(platelet-activating factor
acetylhydrolase, plasma)
6 0.8305 1.6  105 .0155
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1687821 NM_033201.1 C16orf45 Chromosome 16 open reading
frame 45
16 0.8218 1.4  105 .0156
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1736911 NM_003275.2 TMOD1 Tropomodulin 1 9 0.8178 1.5  105 .0157
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1744487 NM_015645.2 C1QTNF5 C1q and tumor necrosis factor-
related protein 5
11 0.8113 1.7  105 .0157
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1767556 NM_007021.2 C10orf10 Chromosome 10 open reading
frame 10
10 0.7966 1.3  105 .0158
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1668249 NM_022773.2 TMEM112 Transmembrane protein 112 16 0.8079 1.6  105 .0158
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1788462 NM_001033059.1 AMD1 Adenosylmethionine
decarboxylase 1, transcript
variant 2
6 0.8027 1.4  105 .0160
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1665945 NM_022735.3 ACBD3 acyl-Coenzyme A binding
domain containing 3
1 0.8297 1.3  105 .0164
................................................................................................................................................................................................................................................................................................................................................................................
Løset. A transcriptional proﬁle of the decidua in preeclampsia. Am J Obstet Gynecol 2011. (continued )
www.AJOG.org Genetics Research
JANUARY 2011 American Journal of Obstetrics& Gynecology 84.e4
TABLE 2
Differentially expressed transcriptsa (continued)
Illumina ID GenBank ID Symbol Deﬁnition Ch
Beta
valueb P valuec
FDR P
valued
ILMN_1657803 NM_001014975.1 CFH Complement factor H, transcript
variant 2
1 0.8780 2.5  106 .0164
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1880012 NM_003966.2 SEMA5A Sema domain, 7
thrombospondin repeats (type 1
and type 1-like),
transmembrane domain (TM)
and short cytoplasmic domain,
(semaphorin) 5A
5 0.8208 2.7  105 .0168
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1763036 NM_001286.2 CLCN6 Chloride channel 6, transcript
variant ClC-6a
1 0.8027 2.4  105 .0170
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1710962 NM_014573.2 TMEM97 Transmembrane protein 97 17 0.8236 2.6  105 .0171
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1801927 NM_001004311.2 FIGLA Folliculogenesis-speciﬁc basic
helix-loop-helix
2 0.8616 1.1  105 .0171
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1673773 NM_198516.1 GALNTL4 UDP-N-acetyl-alpha-D-galactosa-
mine:polypeptide N-acetyl-
galactosaminyltransferase-like 4
11 0.7998 2.3  105 .0172
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1711516 NM_001690.2 ATP6V1A ATPase, H transporting,
lysosomal 70 kDa, V1 subunit A
3 0.8101 1.2  105 .0172
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1715555 NM_001352.2 DBP D site of albumin promoter
(albumin D-box) binding protein
19 0.7916 1.3  105 .0172
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1779632 NM_001001723.1 TMEM1 Transmembrane protein 1,
transcript variant 2
21 0.8054 2.6  105 .0172
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1685703 NM_003500.2 ACOX2 acyl-Coenzyme A oxidase 2,
branched chain
3 0.8253 2.2  105 .0173
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1711157 NM_004557.3 NOTCH4 Notch homolog 4 (Drosophila) 6 0.7709 2.5  105 .0174
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1740160 NM_182811.1 PLCG1 Phospholipase C, gamma 1,
transcript variant 2
20 0.8077 2.1  105 .0176
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1834017 N25708 Hs.573236 yx79f04s1 Soares melanocyte
2NbHM cDNA clone IMAGE:
267967 3 sequence
0.8058 2.3  105 .0176
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1798076 NM_006898.4 HOXD3 Homeobox D3 2 0.8238 2.3  105 .0176
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1705985 NM_020473.2 PIGA Phosphatidylinositol glycan
anchor biosynthesis, class A
(paroxysmal nocturnal
hemoglobinuria), transcript
variant 3
X 0.7983 2.6  105 .0177
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1772302 NM_006441.1 MTHFS 5,10-Methenyltetrahydrofolate
synthetase (5-
formyltetrahydrofolate cyclo-
ligase)
15 0.7802 2.9  105 .0178
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1781791 NM_000950.1 PRRG1 Proline-rich Gla (G-
carboxyglutamic acid) 1
X 0.7681 3.2  105 .0179
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1748812 NM_152913.1 TMEM130 Transmembrane protein 130 7 0.7814 3.0  105 .0179
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1680774 XM_001132373.1 LOC730994 Similar to NACHT, leucine-rich
repeat and PYD (pyrin domain)
containing 1, transcript variant
1
17 0.8034 2.0  105 .0179
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1755120 NM_006699.3 MAN1A2 Mannosidase, alpha, class 1A,
member 2
1 0.8519 1.3  105 .0180
................................................................................................................................................................................................................................................................................................................................................................................
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TABLE 2
Differentially expressed transcriptsa (continued)
Illumina ID GenBank ID Symbol Deﬁnition Ch
Beta
valueb P valuec
FDR P
valued
ILMN_1788166 NM_003318.3 TTK TTK protein kinase 6 0.8169 2.1 105 .0181
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1685608 NM_002523.1 NPTX2 Neuronal pentraxin II 7 0.7865 3.1  105 .0181
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1678842 NM_003247.2 THBS2 Thrombospondin 2 6 0.8054 3.2  105 .0182
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1813430 NM_182985.3 TRIM69 Tripartite motif-containing 69,
transcript variant a
15 0.8120 3.5  105 .0192
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1675936 NM_016438.2 HIGD1B HIG1 domain family, member
1B
17 0.8060 3.9  105 .0202
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1877909 BX105647 Hs.125533 BX105647
Soares_NFL_T_GBC_S1 cDNA
clone IMAGp998F143713
sequence
0.7992 3.7  105 .0202
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1803279 NM_016040.3 TMED5 Transmembrane emp24 protein
transport domain containing 5
1 0.7904 3.8  105 .0202
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1700202 NM_022918.2 TMEM135 Transmembrane protein 135 11 0.7615 4.1  105 .0206
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1727589 NM_004605.2 SULT2B1 Sulfotransferase family,
cytosolic, 2B, member 1,
transcript variant 1
19 0.7826 4.2  105 .0209
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1811873 NM_002889.2 RARRES2 Retinoic acid receptor
responder (tazarotene induced)
2
7 0.7690 4.4  105 .0214
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1703955 NM_148177.1 FBXO32 F-box protein 32, transcript
variant 2
8 0.8049 4.8  105 .0225
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1731358 NM_018181.4 ZNF532 Zinc ﬁnger protein 532 18 0.7974 4.7  105 .0226
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1682937 NM_001038633.2 RSPO1 R-spondin homolog (Xenopus
laevis)
1 0.7973 5.0  105 .0230
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1695947 NM_174934.2 SCN4B Sodium channel, voltage-gated,
type IV, beta
11 0.7948 5.8  105 .0234
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1707342 NM_015541.2 LRIG1 Leucine-rich repeats and
immunoglobulin-like domains 1
3 0.7679 5.8  105 .0235
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1781626 NM_001734.2 C1S Complement component 1, s
subcomponent, transcript
variant 1
12 0.7833 5.7  105 .0236
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1676215 NM_001364.2 DLG2 Discs, large homolog 2,
chapsyn-110 (Drosophila)
11 0.7928 5.6  105 .0238
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1880210 BC038188 Hs.179213 Homo sapiens, clone IMAGE:
3451765
0.7666 5.7  105 .0239
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1767225 NM_006092.1 NOD1 Nucleotide-binding
oligomerization domain
containing 1
7 0.7808 5.3  105 .0239
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1793410 NM_021021.2 SNTB1 Syntrophin, beta 1 (dystrophin-
associated protein A1, 59 kDa,
basic component 1)
8 0.7636 5.5  105 .0239
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1752837 NM_018184.2 ARL8B ADP-ribosylation factor-like 8B 3 0.7644 5.3 105 .0241
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1791949 NM_032507.2 PGBD1 PiggyBac transposable
element-derived 1
6 0.7478 5.5  105 .0243
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1859863 BM458075 Hs.555181 AGENCOURT_6411402
NIH_MGC_71 cDNA clone
IMAGE:5530423 5 sequence
0.7667 6.4  105 .0248
................................................................................................................................................................................................................................................................................................................................................................................
Løset. A transcriptional proﬁle of the decidua in preeclampsia. Am J Obstet Gynecol 2011. (continued )
www.AJOG.org Genetics Research
JANUARY 2011 American Journal of Obstetrics& Gynecology 84.e6
TABLE 2
Differentially expressed transcriptsa (continued)
Illumina ID GenBank ID Symbol Deﬁnition Ch
Beta
valueb P valuec
FDR P
valued
ILMN_1782788 NM_003651.3 CSDA Cold shock domain protein A 12 0.7756 6.3  105 .0251
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1727740 NM_006372.3 SYNCRIP Synaptotagmin binding,
cytoplasmic RNA interacting
protein
6 0.6949 6.7  105 .0253
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1677396 NM_019080.1 NDFIP2 Nedd4 family interacting protein
2
13 0.7591 6.6  105 .0253
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1744191 NM_003042.2 SLC6A1 Solute carrier family
6 (neurotransmitter transporter,
GABA), member 1
3 0.7914 6.9  105 .0253
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1656129 NM_020342.1 SLC39A10 Solute carrier family 39 (zinc
transporter), member 10
2 0.7306 6.8  105 .0253
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1809639 NM_178505.5 TMEM26 Transmembrane protein 26 10 0.7732 7.9  105 .0287
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1786326 NM_024076.1 KCTD15 Potassium channel
tetramerization domain
containing 15
19 0.7853 8.2  105 .0291
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1651343 NM_001004439.1 ITGA11 Integrin, alpha 11 15 0.7812 8.2  105 .0292
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1739887 NM_031491.2 RBP5 Retinol-binding protein 5,
cellular
12 0.7607 8.7  105 .0304
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1716247 NM_203371.1 FIBIN Fin bud initiation factor 11 0.7760 8.9  105 .0307
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1752668 NM_015345.2 DAAM2 Disheveled-associated activator
of morphogenesis 2
6 0.7617 1.0  104 .0309
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1789243 NM_018668.3 VPS33B Vacuolar protein sorting 33
homolog B (yeast)
15 0.7368 1.0  104 .0312
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1763852 NM_001093.3 ACACB acetyl-Coenzyme A carboxylase
beta
12 0.7651 9.6  105 .0314
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1731561 NM_022370.2 ROBO3 Roundabout, axon guidance
receptor, homolog
3 (Drosophila)
11 0.7335 1.0  104 .0314
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1672635 NM_182947.2 GEFT RhoA/RAC/CDC42 exchange
factor, transcript variant 1
12 0.7711 9.3  105 .0315
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1691181 NM_030755.4 TXNDC1 Thioredoxin domain containing
1
14 0.7498 1.1  104 .0315
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1742034 NM_000261.1 MYOC Myocilin, trabecular meshwork-
inducible glucocorticoid
response
1 0.7416 1.0  104 .0315
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1761968 NM_033256.1 PPP1R14A Protein phosphatase 1,
regulatory (inhibitor) subunit
14A
19 0.7785 9.5  105 .0315
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1703142 NM_001005416.1 MARCH2 Membrane-associated ring
ﬁnger (C3HC4) 2, transcript
variant 3
19 0.7337 1.0  104 .0316
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1752225 NR_002330.1 ST7OT1 ST7 overlapping transcript 1
(antisense noncoding RNA)
7 0.7606 9.8  105 .0318
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1667692 NM_000961.3 PTGIS Prostaglandin I2 (prostacyclin)
synthase
20 0.7787 9.5  105 .0318
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1691457 NM_004900.3 APOBEC3B Apolipoprotein B mRNA editing
enzyme, catalytic polypeptide-
like 3B
22 0.7343 1.0  104 .0319
................................................................................................................................................................................................................................................................................................................................................................................
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TABLE 2
Differentially expressed transcriptsa (continued)
Illumina ID GenBank ID Symbol Deﬁnition Ch
Beta
valueb P valuec
FDR P
valued
ILMN_1728979 NM_207310.1 CCDC74B Coiled-coil domain containing
74B
2 0.7428 1.2  104 .0320
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1688346 NM_176814.3 ZNF800 Zinc ﬁnger protein 800 7 0.7259 1.2 104 .0323
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1682428 NM_144584.1 C1orf59 Chromosome 1 open reading
frame 59
1 0.7635 1.2  104 .0323
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1755173 NM_020904.1 PLEKHA4 Pleckstrin homology domain
containing, family A
(phosphoinositide binding
speciﬁc) member 4
19 0.7470 1.1  104 .0324
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1782954 NM_005339.3 UBE2K Ubiquitin-conjugating enzyme
E2-25K
4 0.7190 1.2  104 .0324
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1735996 NM_016931.2 NOX4 NADPH oxidase 4 11 0.7504 1.3  104 .0325
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1680110 NM_006829.2 C10orf116 Chromosome 10 open reading
frame 116
10 0.7497 1.2  104 .0325
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1755832 NM_000435.2 NOTCH3 Notch homolog 3 (Drosophila) 19 0.7589 1.1  104 .0325
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1800463 NM_017859.2 UCKL1 Uridine-cytidine kinase 1-like 1 20 0.7338 1.2  104 .0326
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1674337 NM_004470.2 FKBP2 FK506 binding protein 2, 13
kDa, transcript variant 1
11 0.7401 1.2  104 .0327
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1807171 NM_000929.2 PLA2G5 Phospholipase A2, group V 1 0.7349 1.3  104 .0327
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1724671 NM_207577.1 MAP6 Microtubule-associated protein
6, transcript variant 2
11 0.7623 1.2  104 .0328
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1655117 NM_025132.3 WDR19 WD repeat domain 19 4 0.7425 1.3  104 .0328
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1706511 NM_003216.2 TEF Thyrotrophic embryonic factor 22 0.7288 1.1  104 .0328
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1677018 NM_002141.4 HOXA4 Homeobox A4 7 0.7424 1.3  104 .0333
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1785646 NM_153321.1 PMP22 Peripheral myelin protein 22,
transcript variant 2
17 0.7487 1.3  104 .0334
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1709661 NM_145276.1 ZNF563 Zinc ﬁnger protein 563 19 0.7481 1.4  104 .0334
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1736863 NM_018295.2 TMEM140 Transmembrane protein 140 7 0.7336 1.3  104 .0337
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1807379 NM_023034.1 WHSC1L1 Wolf-Hirschhorn syndrome
candidate 1-like 1, transcript
variant long
8 0.7237 1.4  104 .0338
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1740842 NM_005407.1 SALL2 Sal-like 2 (Drosophila) 14 0.7458 1.4  104 .0340
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1734229 NM_032802.3 SPPL2A Signal peptide peptidase-like
2A
15 0.7168 1.4  104 .0343
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1696003 NM_006496.1 GNAI3 Guanine nucleotide binding
protein (G protein), alpha
inhibiting activity polypeptide 3
1 0.7101 1.5  104 .0343
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1793770 NM_058246.3 DNAJB6 DnaJ (Hsp40) homolog,
subfamily B, member 6,
transcript variant 1
7 0.7448 1.4  104 .0343
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1797861 NM_002184.2 IL6ST Interleukin 6 signal transducer
(gp130, oncostatin M receptor),
transcript variant 1
5 0.7406 1.6  104 .0353
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1720865 NM_145798.2 OSBPL7 Oxysterol binding protein-like 7,
transcript variant 1
17 0.7298 1.6  104 .0355
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1713978 NM_006923.2 SDF2 Stromal cell-derived factor 2 17 0.7243 1.6 104 .0356
................................................................................................................................................................................................................................................................................................................................................................................
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ILMN_1682231 NM_001003682.2 TTMB TTMB protein 1 0.7581 1.6  104 .0356
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1684554 NM_001856.3 COL16A1 Collagen, type XVI, alpha 1 1 0.7316 1.5  104 .0356
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1778595 NM_003063.2 SLN Sarcolipin 11 0.7375 1.6  104 .0356
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1811790 NM_004118.3 FKHL18 Forkhead-like 18 (Drosophila) 20 0.7197 1.6  104 .0357
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1712461 NM_004352.1 CBLN1 Cerebellin 1 precursor 16 0.7413 1.5  104 .0358
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1815874 NM_018946.2 NANS N-acetylneuraminic acid
synthase (sialic acid synthase)
9 0.7205 1.7  104 .0359
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1720819 XM_934796.2 LOC653566 Similar to signal peptidase
complex subunit 2 (microsomal
signal peptidase 25-kDa
subunit) (SPase 25-kDa
subunit), transcript variant 3
1 0.6515 1.7  104 .0359
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1669898 NM_201446.1 EGFL7 EGF-like-domain, multiple 7,
transcript variant 2
9 0.6935 1.5  104 .0359
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1740441 NM_000398.4 CYB5R3 Cytochrome b5 reductase 3,
transcript variant M
22 0.7263 1.7  104 .0360
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1700274 NM_031442.2 TMEM47 Transmembrane protein 47 X 0.7303 1.6  104 .0360
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1720889 NM_001017369.1 SC4MOL Sterol-C4-methyl oxidase-like,
transcript variant 2
4 0.6822 1.7  104 .0367
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1793543 NM_144697.2 C1orf51 Chromosome 1 open reading
frame 51
1 0.7115 1.8  104 .0376
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1734288 NM_152511.3 DUSP18 Dual speciﬁcity phosphatase 18 22 0.7243 1.9  104 .0383
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1678998 NM_014665.1 LRRC14 Leucine-rich repeat containing 14 8 0.7119 1.9  104 .0383
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1791508 NM_024302.3 MMP28 Matrix metallopeptidase 28,
transcript variant 1
17 0.7246 1.9  104 .0385
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1688295 NM_016423.1 ZNF219 Zinc ﬁnger protein 219 14 0.7437 1.9  104 .0388
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1770293 NM_001730.3 KLF5 Kruppel-like factor 5 (intestinal) 13 0.7122 1.9 104 .0388
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1886424 BG621061 Hs.559870 602616941F1 NIH_MGC_79
cDNA clone IMAGE:4730410 5
sequence
0.7236 1.9  104 .0388
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1697006 XM_930748.2 LOC642361 Hypothetical protein
LOC642361
10 0.6926 2.2  104 .0400
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1673543 NM_018290.2 PGM2 Phosphoglucomutase 2 4 0.6845 2.0 104 .0401
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1742230 NM_182648.1 BAZ1A Bromodomain adjacent to zinc
ﬁnger domain, 1A, transcript
variant 2
14 0.7376 2.1  104 .0401
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1659843 NM_006260.2 DNAJC3 DnaJ (Hsp40) homolog,
subfamily C, member 3
13 0.7094 2.1  104 .0401
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1696585 NM_017671.4 C20orf42 Chromosome 20 open reading
frame 42
20 0.7335 2.1  104 .0402
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1763641 NM_025040.2 ZNF614 Zinc ﬁnger protein 614 19 0.7013 2.1  104 .0402
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1726678 NM_014147.1 HSPC047 HSPC047 protein 7 0.7153 2.0  104 .0402
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1779034 NM_018161.4 NADSYN1 NAD synthetase 1 11 0.6854 2.1  104 .0402
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1705253 NM_130393.2 PTPRD Protein tyrosine phosphatase,
receptor type, D, transcript
variant 4
9 0.7342 2.1  104 .0403
................................................................................................................................................................................................................................................................................................................................................................................
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ILMN_1837017 CB269825 Hs.543359 1008732 Human Fat Cell 5-
Stretch Plus cDNA Library cDNA
5’ sequence
0.7281 2.1  104 .0405
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1829490 BX106357 Hs.445732 BX106357
Soares_NFL_T_GBC_S1 cDNA
clone IMAGp998B055155
sequence
0.6957 2.2  104 .0409
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1714691 NM_002148.3 HOXD10 Homeobox D10 2 0.7265 2.3  104 .0413
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1803213 NM_015419.2 MXRA5 Matrix-remodeling-associated 5 X 0.7061 2.3  104 .0416
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1732158 NM_001460.2 FMO2 Flavin containing
monooxygenase
2 (nonfunctional)
1 0.6950 2.4  104 .0424
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1681938 NM_022568.2 ALDH8A1 Sldehyde dehydrogenase 8
family, member A1, transcript
variant 1
6 0.6875 2.4  104 .0424
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1753243 NM_016306.4 DNAJB11 DnaJ (Hsp40) homolog,
subfamily B, member 11
3 0.7183 2.5  104 .0431
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1793846 NM_014670.2 BZW1 Basic leucine zipper and W2
domains 1
2 0.7033 2.7  104 .0431
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1852159 BF753039 Hs.557431 RC3-BN0425-011200-022-c08
BN0425 cDNA sequence
0.7234 2.4  104 .0432
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1805992 NM_018330.4 KIAA1598 KIAA1598 10 0.7077 2.4  104 .0433
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1740512 XM_936687.1 MGC39900 Hypothetical protein MGC39900 X 0.7227 2.6  104 .0433
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1708916 NM_032512.2 PDZD4 PDZ domain containing 4 X 0.7075 2.7  104 .0434
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1773563 NM_015927.3 TGFB1I1 Transforming growth factor
beta 1-induced transcript 1,
transcript variant 2
16 0.7335 2.6  104 .0435
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1674184 NM_153022.2 C12orf59 Chromosome 12 open reading
frame 59
12 0.7122 2.6  104 .0436
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1657483 NM_032985.4 SEC23B Sec23 homolog B (S
cerevisiae), transcript variant 2
20 0.6717 2.7  104 .0436
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1772540 NM_015251.2 ASCIZ ATM/ATR-Substrate Chk2-
Interacting Zn2-ﬁnger protein
16 0.6872 2.6  104 .0438
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1756862 NM_145641.1 APOL3 Apolipoprotein L, 3, transcript
variant beta/a
22 0.7021 2.8  104 .0438
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1685413 NM_024079.4 ALG8 Asparagine-linked glycosylation
8 homolog (S cerevisiae, alpha-
1,3-glucosyltransferase),
transcript variant 1
11 0.6986 2.8  104 .0439
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1686645 NM_021645.4 UTP14C UTP14, U3 small nucleolar
ribonucleoprotein, homolog C
(yeast)
13 0.6746 2.8  104 .0440
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1813746 NM_003389.2 CORO2A Coronin, actin-binding protein,
2A, transcript variant 1
9 0.7135 2.6  104 .0440
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1765557 NM_015441.1 OLFML2B Olfactomedin-like 2B 1 0.6714 2.7  104 .0441
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1740586 NM_000300.2 PLA2G2A Phospholipase A2, group IIA
(platelets, synovial ﬂuid)
1 0.7049 2.6  104 .0443
................................................................................................................................................................................................................................................................................................................................................................................
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ILMN_1758750 NR_003501.1 EARS2 Glutamyl-tRNA synthetase 2,
mitochondrial (putative),
transcript variant 2, transcribed
RNA
16 0.7199 2.6  104 .0444
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1703178 NM_003469.3 SCG2 Secretogranin II (chromogranin
C)
2 0.7239 2.6  104 .0444
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1710522 NM_175635.1 RUNX1T1 Runt-related transcription factor
1; translocated to, 1 (cyclin
D-related), transcript variant 3
8 0.6886 3.1  104 .0444
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1730048 NM_024067.2 C7orf26 Chromosome 7 open reading
frame 26
7 0.6943 2.9  104 .0444
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1722855 NM_003377.3 VEGFB Vascular endothelial growth
factor B
11 0.7039 3.0  104 .0445
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1752915 NM_004124.2 GMFB Glia maturation factor, beta 14 0.6872 2.6 104 .0445
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1702124 NM_153371.3 LNX2 Ligand of numb-protein X 2 13 0.7044 3.0  104 .0445
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1695299 NM_014476.1 PDLIM3 PDZ and LIM domain 3 4 0.7140 3.1  104 .0445
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1666364 NM_144576.3 COQ10A Coenzyme Q10 homolog A (S
cerevisiae), transcript variant 1
12 0.6949 2.6  104 .0445
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1756942 NM_001017371.3 SP3 Sp3 transcription factor,
transcript variant 2
2 0.6849 3.1  104 .0445
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1750386 NM_006172.2 NPPA Natriuretic peptide precursor A 1 0.6947 3.1  104 .0445
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1685433 NM_020351.2 COL8A1 Collagen, type VIII, alpha 1,
transcript variant 2
3 0.6900 2.9  104 .0445
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1665095 NM_015537.3 NELF Nasal embryonic LHRH factor 9 0.7203 2.9  104 .0445
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1695316 NM_022154.5 SLC39A8 Solute carrier family 39 (zinc
transporter), member 8
4 0.6843 2.9  104 .0446
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1749338 NM_173505.2 ANKRD29 Ankyrin repeat domain 29 18 0.6916 3.0  104 .0446
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1692340 NM_207404.2 ZNF662 Zinc ﬁnger protein 662 3 0.7117 2.9  104 .0447
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1730612 NM_001048223.1 DBNDD2 Dysbindin (dystrobrevin binding
protein 1) domain containing 2,
transcript variant 3
20 0.7208 3.1  104 .0447
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1778523 NM_001206.2 KLF9 Kruppel-like factor 9 9 0.6988 3.0  104 .0447
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1813175 NM_014921.3 LPHN1 Latrophilin 1, transcript variant
2
19 0.6905 3.0  104 .0447
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1800103 XM_001128785.1 LOC731196 Similar to proprotein convertase
subtilisin/kexin type 7 precursor
(proprotein convertase PC7)
(subtilisin/kexin-like protease
PC7) (prohormone convertase
PC7) (PC8) (hPC8) (lymphoma
proprotein convertase)
11 0.6977 2.9  104 .0447
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1801583 NM_017680.3 ASPN Asporin 9 0.7233 2.9  104 .0447
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1740024 NM_005467.2 NAALAD2 N-acetylated alpha-linked acidic
dipeptidase 2
11 0.6949 3.0  104 .0449
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1683133 NM_014079.2 KLF15 Kruppel-like factor 15 3 0.6842 3.2  104 .0451
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1801441 NM_144629.1 RFTN2 Raftlin family member 2 2 0.6948 3.2  104 .0452
................................................................................................................................................................................................................................................................................................................................................................................
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ILMN_1719097 NM_013326.3 C18orf8 Chromosome 18 open reading
frame 8
18 0.7098 3.2  104 .0452
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1723689 NM_003624.1 RANBP3 RAN binding protein 3,
transcript variant RANBP3-a
19 0.6899 3.2  104 .0452
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1790052 NM_004659.1 MMP23A Matrix metallopeptidase 23A 1 0.7011 3.3  104 .0456
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1679262 NM_001387.2 DPYSL3 Dihydropyrimidinase-like 3 5 0.7208 3.3  104 .0458
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1683487 NM_003444.1 ZNF154 Zinc ﬁnger protein 154 (pHZ-
92)
19 0.6905 3.3  104 .0460
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1710284 NM_005524.2 HES1 Hairy and enhancer of split 1,
(Drosophila)
3 0.7019 3.4  104 .0462
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1728710 NM_001031665.1 ZNF816A Zinc ﬁnger protein 816A 19 0.6975 3.5  104 .0462
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1685156 NM_020983.2 ADCY6 Adenylate cyclase 6, transcript
variant 2
12 0.6890 3.5  104 .0464
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1721087 NM_012435.1 SHC2 SHC (Src homology 2 domain
containing) transforming protein
2
19 0.6788 3.5  104 .0465
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1700811 NM_019116.2 UBFD1 Ubiquitin family domain
containing 1
16 0.6888 3.5  104 .0466
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1661066 XM_927710.1 LOC644596 Hypothetical protein
LOC644596
X 0.6663 3.5  104 .0466
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1733769 NM_001033047.1 NPNT Nephronectin 4 0.7029 3.5  104 .0466
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1784948 NM_144569.4 SPOCD1 SPOC domain containing 1 1 0.7223 3.6  104 .0467
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1727574 NM_178835.3 LOC152485 Hypothetical protein
LOC152485
0.6904 3.5  104 .0467
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1724984 NM_004836.4 EIF2AK3 Eukaryotic translation initiation
factor 2-alpha kinase 3
2 0.6981 3.7  104 .0467
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1660305 NM_177966.4 2’-PDE 2’-Phosphodiesterase 3 0.7031 3.5 104 .0468
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1782057 NM_020452.2 ATP8B2 ATPase, class I, type 8B,
member 2, transcript variant 1
1 0.7041 3.6  104 .0468
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1751072 NM_021203.2 SRPRB Signal recognition particle
receptor, B subunit
3 0.6672 3.7  104 .0468
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1740609 NM_032964.2 CCL15 Chemokine (C-C motif) ligand
15, transcript variant 1
17 0.6697 3.7  104 .0468
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1669982 NM_001080433.1 CCDC85A Coiled-coil domain containing
85A
2 0.6858 3.6  104 .0468
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1807515 NM_015235.2 CSTF2T Cleavage stimulation factor, 3’
pre-RNA, subunit 2, 64 kDa, tau
variant
10 0.6892 3.5  104 .0469
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1657361 NM_175709.2 CBX7 Chromobox homolog 7 22 0.6904 3.8  104 .0469
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1801043 NM_198252.2 GSN Gelsolin (amyloidosis, Finnish
type), transcript variant 2
9 0.7028 3.7  104 .0469
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1738116 NM_181724.1 TMEM119 Transmembrane protein 119 12 0.6425 3.7  104 .0470
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1760890 NM_206926.1 SEPN1 Selenoprotein N, 1, transcript
variant 2
1 0.6762 3.8  104 .0473
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1728785 NM_015234.4 GPR116 G protein-coupled receptor 116,
transcript variant 1
6 0.6903 3.8  104 .0475
................................................................................................................................................................................................................................................................................................................................................................................
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ILMN_1744647 NM_018448.2 CAND1 Cullin-associated and
neddylation-dissociated 1
12 0.6883 3.9 104 .0479
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1757440 XM_001130258.1 FAM69B Family with sequence similarity
69, member B
9 0.6706 3.9  104 .0480
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1783805 NM_013364.4 PNMA3 Paraneoplastic antigen MA3 X 0.7005 3.9  104 .0482
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1809098 NM_019599.2 TAS2R1 Taste receptor, type 2, member
1
5 0.7013 4.1 104 .0490
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1719759 NM_002160.2 TNC Tenascin C (hexabrachion) 9 0.7107 4.1  104 .0491
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1811313 NM_003062.1 SLIT3 Slit homolog 3 (Drosophila) 5 0.6810 4.0  104 .0491
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1700432 NM_002221.2 ITPKB Inositol 1,4,5-trisphosphate
3-kinase B
1 0.6983 4.1  104 .0495
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1809488 NM_014752.1 SPCS2 Signal peptidase complex
subunit 2 homolog (S
cerevisiae)
11 0.6204 4.2 104 .0498
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1795338 NM_013313.3 YPEL1 Yippee-like 1 (Drosophila) 22 0.6528 4.3  104 .0505
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1736242 NM_015432.2 PLEKHG4 Pleckstrin homology domain
containing, family G (with
RhoGef domain) member 4
16 0.6879 4.3  104 .0506
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1696568 NM_014382.2 ATP2C1 ATPase, Ca transporting,
type 2C, member 1, transcript
variant 1
3 0.6572 4.3  104 .0507
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1766925 NM_001257.3 CDH13 Cadherin 13, H-cadherin (heart) 16 0.7020 4.3  104 .0509
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1698252 NM_152633.2 FANCB Fanconi anemia,
complementation group B,
transcript variant 2
X 0.6928 4.5  104 .0526
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1781149 NM_006774.4 INMT Indolethylamine N-
methyltransferase
7 0.6688 4.6  104 .0530
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1665437 NM_000773.3 CYP2E1 Cytochrome P450, family 2,
subfamily E, polypeptide 1
10 0.6839 4.6  104 .0531
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1773395 NM_002905.2 RDH5 Retinol dehydrogenase 5 (11-
cis/9-cis)
12 0.6860 4.6  104 .0533
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1665483 NM_014878.4 KIAA0020 KIAA0020 9 0.6892 4.6  104 .0534
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1666545 NM_001097635.1 GCNT1 Glucosaminyl (N-acetyl)
transferase 1, core 2
(beta-1,6-N-
acetylglucosaminyltransferase),
transcript variant 4
9 0.6953 4.6  104 .0535
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1743864 NM_001453.2 FOXC1 Forkhead box C1 6 0.6694 4.8  104 .0542
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1709486 NM_006307.3 SRPX Sushi-repeat-containing
protein, X-linked
X 0.6834 4.8  104 .0543
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1676088 NM_198080.2 MSRB3 Methionine sulfoxide reductase
B3, transcript variant 1
12 0.6889 4.8  104 .0543
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1771238 NM_000390.2 CHM Choroideremia (Rab escort
protein 1), transcript variant 1
X 0.6744 4.9  104 .0544
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1656807 NM_000988.3 RPL27 Ribosomal protein L27 17 0.6987 4.9  104 .0545
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1711826 NM_020344.1 SLC24A2 Solute carrier family 24
(sodium/potassium/calcium
exchanger), member 2
9 0.6804 5.0  104 .0545
................................................................................................................................................................................................................................................................................................................................................................................
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ILMN_1660730 NM_032803.4 SLC7A3 Solute carrier family 7 (cationic
amino acid transporter, y
system), member 3, transcript
variant 1
X 0.6816 4.9  104 .0546
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1849218 BX451947 Hs.559564 BX451947 FETAL BRAIN cDNA
clone CS0DF008YL16 5-PRIME
sequence
0.6910 4.9  104 .0547
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1726752 NM_175071.1 APTX Aprataxin, transcript variant 5 9 0.6732 4.9 104 .0548
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1739640 NM_003737.2 DCHS1 Dachsous 1 (Drosophila) 11 0.6808 5.0  104 .0550
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1686968 NM_152493.2 FLJ25476 FLJ25476 protein 1 0.6856 5.1  104 .0557
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1718044 NM_018127.5 ELAC2 elaC Homolog 2 (E coli) 17 0.6695 5.3  104 .0562
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1799836 NM_006735.3 HOXA2 Homeobox A2 7 0.7036 5.3  104 .0563
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1658847 XM_939432.1 MGC61598 Similar to ankyrin-repeat
protein Nrarp
9 0.6363 5.3  104 .0565
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1764619 NM_207443.1 FLJ45244 FLJ45244 protein 14 0.6691 5.3  104 .0567
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1739521 NM_014932.2 NLGN1 Neuroligin 1 3 0.6893 5.4 104 .0568
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1710675 NM_005080.2 XBP1 X-box binding protein 1,
transcript variant 1
22 0.6814 5.3  104 .0568
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1772810 XM_946142.2 SHANK3 SH3 and multiple ankyrin repeat
domains 3, transcript variant 4
22 0.6733 5.4  104 .0570
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1693481 NM_021949.2 ATP2B3 ATPase, Ca transporting,
plasma membrane 3, transcript
variant 1
X 0.6669 5.3  104 .0570
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1671106 NM_002060.2 GJA4 Gap junction protein, alpha 4,
37 kDa
1 0.6706 5.3  104 .0572
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1773757 NM_138718.1 SLC26A8 Solute carrier family 26,
member 8, transcript variant 2
6 0.6936 5.5  104 .0573
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1680652 NM_003944.2 SELENBP1 Selenium binding protein 1 1 0.6566 5.6  104 .0585
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1813528 NM_133459.1 CCBE1 Collagen and calcium binding
EGF domains 1
18 0.6806 5.7  104 .0587
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1715175 NM_000245.2 MET Met protooncogene (hepatocyte
growth factor receptor)
7 0.6834 5.7  104 .0587
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1688160 NM_182552.3 WDR27 WD repeat domain 27 6 0.6906 5.7  104 .0587
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1805842 NM_001449.3 FHL1 Four and a half LIM domains 1 X 0.6833 5.6  104 .0587
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1806301 NM_002077.2 GOLGA1 Golgi autoantigen, golgin
subfamily a, 1
9 0.6603 5.8  104 .0595
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1734653 NM_032532.2 FNDC1 Fibronectin type III domain
containing 1
6 0.6810 5.9  104 .0596
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1706935 NM_022742.3 CCDC136 Coiled-coil domain containing
136
7 0.6766 5.9  104 .0597
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1727091 NM_138326.2 ACMSD Aminocarboxymuconate
semialdehyde decarboxylase
2 0.6688 5.9  104 .0597
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1740385 NM_014956.4 CEP164 Centrosomal protein 164 kDa 11 0.6244 5.9  104 .0598
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1746517 NM_003937.2 KYNU Kynureninase (L-kynurenine
hydrolase), transcript variant 1
2 0.6445 6.0  104 .0598
................................................................................................................................................................................................................................................................................................................................................................................
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ILMN_1801246 NM_003641.3 IFITM1 Interferon-induced
transmembrane protein 1 (9-27)
11 0.6716 6.0  104 .0599
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1756784 NM_014286.2 FREQ Frequenin homolog (Drosophila) 9 0.6824 6.1  104 .0599
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1652389 NM_001031733.2 CALML4 Calmodulin-like 4, transcript
variant 2
15 0.6783 6.1  104 .0600
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1794038 NM_030797.2 FAM49A Family with sequence similarity
49, member A
2 0.6333 6.1  104 .0601
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1758731 NM_000775.2 CYP2J2 Cytochrome P450, family 2,
subfamily J, polypeptide 2
1 0.6767 6.1  104 .0602
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1707380 NM_002725.3 PRELP Proline/arginine-rich end
leucine-rich repeat protein,
transcript variant 1
1 0.6844 6.1  104 .0603
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1801226 NM_020812.1 DOCK6 Dedicator of cytokinesis 6 19 0.6576 6.1  104 .0605
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1766386 XR_017805.1 LOC401433 Hypothetical gene supported by
AK127717, misc RNA
7 0.6178 6.2  104 .0607
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1763657 NM_025212.1 CXXC4 CXXC ﬁnger 4 4 0.6560 6.3  104 .0608
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1777221 NM_058182.2 C21orf51 Chromosome 21 open reading
frame 51
21 0.6266 6.3  104 .0612
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1712199 NM_024738.1 C12orf49 Chromosome 12 open reading
frame 49
12 0.6531 6.4  104 .0619
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1741801 NM_003503.2 CDC7 Cell division cycle 7 homolog (S
cerevisiae)
1 0.6725 6.6  104 .0631
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1891067 AK127526 Hs.553187 cDNA FLJ45619 ﬁs, clone
BRTHA3027318
0.6413 6.6  104 .0632
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1663843 NM_004161.3 RAB1A RAB1A, member RAS oncogene
family
2 0.6529 6.7  104 .0632
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1792571 NM_173728.2 ARHGEF15 Rho guanine nucleotide
exchange factor (GEF) 15
17 0.6508 6.7  104 .0632
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1790315 NM_001039706.1 FLJ21062 Hypothetical protein FLJ21062 7 0.6657 6.6  104 .0634
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1733756 NM_080645.2 COL12A1 Collagen, type XII, alpha 1,
transcript variant short
6 0.6799 6.8  104 .0638
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1812701 NM_001099783.1 C4orf33 Chromosome 4 open reading
frame 33, transcript variant 2
4 0.6666 6.8  104 .0640
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1782257 NM_022734.2 METT11D1 Methyltransferase 11 domain
containing 1, transcript variant
2
14 0.6653 6.9  104 .0643
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1691112 NM_176787.4 PIGN Phosphatidylinositol glycan
anchor biosynthesis, class N,
transcript variant 1
18 0.6741 6.9  104 .0646
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1756086 NM_023015.3 INTS3 Integrator complex subunit 3 1 0.6306 6.9  104 .0648
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1710303 NM_031421.2 TTC25 Tetratricopeptide repeat domain
25
17 0.6482 7.0  104 .0651
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1785765 NM_004800.1 TM9SF2 Transmembrane 9 superfamily
member 2
13 0.6617 7.1  104 .0656
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1684321 NM_030579.2 CYB5B Cytochrome b5 type B (outer
mitochondrial membrane)
16 0.6858 7.1  104 .0658
................................................................................................................................................................................................................................................................................................................................................................................
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ILMN_1722244 NM_001018011.1 ZBTB16 Zinc ﬁnger and BTB domain
containing 16, transcript variant
2
11 0.6734 7.2  104 .0660
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1787906 NM_014629.2 ARHGEF10 Rho guanine nucleotide
exchange factor (GEF) 10
8 0.6634 7.3  104 .0668
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1736974 NM_006943.2 SOX12 SRY (sex determining region
Y)-box 12
20 0.6435 7.4  104 .0668
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1808590 NM_000856.3 GUCY1A3 Guanylate cyclase 1, soluble,
alpha 3
4 0.6252 7.3  104 .0669
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1751559 NM_024600.2 C16orf30 Chromosome 16 open reading
frame 30
16 0.6442 7.4  104 .0671
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1774427 NM_020898.1 CALCOCO1 Calcium binding and coiled-coil
domain 1
12 0.6804 7.7  104 .0682
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1657502 NM_001098515.1 MRGPRF MAS-related GPR, member F,
transcript variant 1
11 0.6781 7.6  104 .0682
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1652128 NM_018368.2 LMBRD1 LMBR1 domain containing 1 6 0.6306 7.8  104 .0683
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1808417 NM_015102.2 NPHP4 Nephronophthisis 4 1 0.6615 7.7  104 .0684
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1657194 NM_018430.2 TSNAXIP1 Translin-associated factor X
interacting protein 1
16 0.6513 7.7  104 .0684
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1680948 NM_012134.2 LMOD1 Leiomodin 1 (smooth muscle) 1 0.6757 7.7  104 .0684
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1703471 NM_007348.2 ATF6 Activating transcription factor 6 1 0.6569 7.6 104 .0684
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1728742 NM_032385.3 C5orf4 Chromosome 5 open reading
frame 4, transcript variant 2
5 0.6564 7.8  104 .0686
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1702861 NM_172244.2 SGCD Sarcoglycan, delta (35 kDa
dystrophin-associated
glycoprotein), transcript variant
2
5 0.6460 7.6  104 .0686
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1868150 BX537697 Hs.98581 mRNA; cDNA DKFZp686D0853
(from clone DKFZp686D0853)
0.6645 7.9  104 .0686
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1694325 NM_002501.2 NFIX Nuclear factor I/X (CCAAT-
binding transcription factor)
19 0.6525 7.8  104 .0687
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1748432 XM_375646.3 ZNF525 Zinc ﬁnger protein 525 19 0.6710 8.0  104 .0691
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1743357 NM_003399.5 XPNPEP2 X-prolyl aminopeptidase
(aminopeptidase P) 2,
membrane-bound
X 0.6388 8.0  104 .0694
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1782125 NM_024422.2 DSC2 Desmocollin 2, transcript
variant Dsc2a
18 0.6142 8.0  104 .0695
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1687967 NM_001007156.1 NTRK3 Neurotrophic tyrosine kinase,
receptor, type 3, transcript
variant 3
15 0.6630 8.1  104 .0699
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1685286 NM_017607.2 PPP1R12C Protein phosphatase 1,
regulatory (inhibitor) subunit
12C
19 0.6754 8.3  104 .0710
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1756937 NM_005668.3 ST8SIA4 ST8 alpha-N-acetyl-
neuraminide alpha-2,8-
sialyltransferase 4, transcript
variant 1
5 0.6470 8.3  104 .0711
................................................................................................................................................................................................................................................................................................................................................................................
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ILMN_1794534 NM_021827.3 CCDC81 Coiled-coil domain containing
81
11 0.6588 8.4  104 .0712
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1793615 NM_001014811.1 ME3 Malic enzyme 3, NADP()-
dependent, mitochondrial,
nuclear gene encoding
mitochondrial protein, transcript
variant 2
11 0.6720 8.5  104 .0716
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1885397 BM311228 Hs.503590 ig62e09y1 HR85 islet cDNA 5
sequence
0.6606 8.5  104 .0717
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1759375 NM_001083330.1 ZNF133 Zinc ﬁnger protein 133,
transcript variant 2
20 0.6532 8.5  104 .0719
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1796851 XM_001131060.1 FOXL2 Forkhead box L2 3 0.6417 8.6  104 .0720
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1703105 NM_139178.2 ALKBH3 alkB, Alkylation repair homolog
3 (E coli)
11 0.6275 8.5  104 .0720
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1678710 NM_032439.1 PHYHIPL Phytanoyl-CoA 2-hydroxylase
interacting protein-like
10 0.6064 8.8  104 .0733
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1758398 NM_000858.4 GUK1 Guanylate kinase 1 1 0.6158 8.9  104 .0735
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1796734 NM_003118.2 SPARC Secreted protein, acidic,
cysteine-rich (osteonectin)
5 0.6468 8.8  104 .0737
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1653856 NM_032873.3 STS-1 Cbl-interacting protein Sts-1 11 0.6288 8.9 104 .0739
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1795251 NM_004684.3 SPARCL1 SPARC-like 1 (mast9, hevin) 4 0.6301 9.0  104 .0746
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1717206 NM_175060.1 CLEC14A C-type lectin domain family 14,
member A
14 0.6376 9.2  104 .0754
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1739496 NM_006902.3 PRRX1 Paired related homeobox 1,
transcript variant pmx-1a
1 0.6477 9.2  104 .0754
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1718552 NM_006419.1 CXCL13 Chemokine (C-X-C motif) ligand
13 (B-cell chemoattractant)
4 0.6037 9.2  104 .0755
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1797191 NM_014656.1 KIAA0040 KIAA0040 1 0.6227 9.2 104 .0757
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1737705 NM_015054.1 KIAA0701 KIAA0701 protein, transcript
variant 1
12 0.6459 9.5  104 .0770
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1682781 NM_003598.1 TEAD2 TEA domain family member 2 19 0.6440 9.5  104 .0771
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1673352 NM_006435.2 IFITM2 Interferon-induced
transmembrane protein 2 (1-
8D)
11 0.6409 9.6  104 .0772
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1750158 NM_007292.4 ACOX1 acyl-Coenzyme A oxidase 1,
palmitoyl, transcript variant 2
17 0.6554 9.7  104 .0772
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1657156 NM_207306.2 KIAA0495 KIAA0495 1 0.6716 9.7  104 .0773
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1787576 NM_004070.3 CLCNKA Chloride channel Ka, transcript
variant 1
1 0.6609 9.6  104 .0773
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1665449 NM_019055.4 ROBO4 Roundabout homolog 4, magic
roundabout (Drosophila)
11 0.6256 9.7  104 .0773
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1796018 NM_004554.3 NFATC4 Nuclear factor of activated T-
cells, cytoplasmic, calcineurin-
dependent 4
14 0.6726 9.6  104 .0774
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1765118 NM_003627.4 SLC43A1 Solute carrier family 43,
member 1
11 0.6174 9.9  104 .0784
................................................................................................................................................................................................................................................................................................................................................................................
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ILMN_1785424 NM_006720.3 ABLIM1 Actin-binding LIM protein 1,
transcript variant 4
10 0.6004 9.9  104 .0784
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1701204 NM_005429.2 VEGFC Vascular endothelial growth
factor C
4 0.6393 9.9  104 .0784
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1769186 NM_001755.2 CBFB Core-binding factor, beta
subunit, transcript variant 2
16 0.6454 1.0  103 .0785
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1651958 NM_000900.2 MGP Matrix Gla protein 12 0.6404 1.0  103 .0786
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1770803 NM_004330.1 BNIP2 BCL2/adenovirus E1B 19 kDa
interacting protein 2
15 0.6074 1.0  103 .0786
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1720452 NM_001031855.1 LONRF3 LON peptidase N-terminal
domain and ring ﬁnger 3,
transcript variant 1
X 0.6477 1.0  103 .0786
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1780349 NM_003292.2 TPR Translocated promoter region
(to activated MET oncogene)
1 0.6328 1.0  103 .0792
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1818018 DA321576 Hs.576997 DA321576 BRHIP3 cDNA clone
BRHIP3014850 5 sequence
0.6451 1.0  103 .0793
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1724424 NM_145239.1 PRRT2 Proline-rich transmembrane
protein 2
16 0.6496 1.0  103 .0794
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1760849 NM_018092.3 NETO2 Neuropilin (NRP) and tolloid
(TLL)-like 2
16 0.6201 1.0  103 .0794
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1773742 NM_012328.1 DNAJB9 DnaJ (Hsp40) homolog,
subfamily B, member 9
7 0.6452 1.0  103 .0794
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1792529 NM_004783.2 TAOK2 TAO kinase 2, transcript variant
1
16 0.6358 1.0  103 .0796
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1740772 NM_133172.2 APBB3 Amyloid beta (A4) precursor
protein-binding, family B,
member 3, transcript variant 3
5 0.6393 1.1  103 .0796
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1737604 NM_018291.2 FLJ10986 Hypothetical protein FLJ10986 1 0.6581 1.0 103 .0796
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1742272 NM_000537.2 REN Renin 1 0.6262 1.1  103 .0798
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1806403 NM_016563.2 RASL12 RAS-like, family 12 15 0.6338 1.1  103 .0798
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1715647 NM_020335.1 VANGL2 Vang-like 2 (van gogh,
Drosophila)
1 0.6544 1.1  103 .0800
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1655913 NM_005013.2 NUCB2 Nucleobindin 2 11 0.6408 1.1  103 .0801
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1736080 NM_012432.2 SETDB1 SET domain, bifurcated 1 1 0.6417 1.1  103 .0805
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1663033 NM_138385.2 TMEM129 Transmembrane protein 129 4 0.6319 1.1  103 .0809
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1697585 NM_022496.3 ACTR6 ARP6 actin-related protein 6
homolog (yeast)
12 0.6055 1.1  103 .0817
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1711124 NM_144724.1 MARVELD2 MARVEL domain containing 2,
transcript variant 2
5 0.6463 1.1  103 .0820
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1711919 NM_017988.4 SCYL2 SCY1-like 2 (S cerevisiae) 12 0.5937 1.1 103 .0821
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1669142 NM_057175.3 NARG1 NMDA receptor regulated 1 4 0.6007 1.1 103 .0822
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1678862 NM_173540.2 FUT11 Fucosyltransferase 11 (alpha
[1,3] fucosyltransferase)
10 0.6192 1.1  103 .0822
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1768393 NM_006938.2 SNRPD1 Small nuclear ribonucleoprotein
D1 polypeptide 16 kDa
18 0.5974 1.1  103 .0822
................................................................................................................................................................................................................................................................................................................................................................................
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ILMN_1782938 NM_018593.3 SLC16A10 Solute carrier family 16,
member 10 (aromatic amino
acid transporter)
6 0.5965 1.1  103 .0822
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1899428 AW173494 Hs.483540 xj07f12x1 NCI_CGAP_Ut2 cDNA
clone IMAGE:2656559 3
sequence
0.6320 1.1  103 .0825
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1748845 NM_002506.2 NGFB Nerve growth factor, beta
polypeptide
1 0.6390 1.1  103 .0832
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1767722 NM_203437.2 AFTPH Aftiphilin, transcript variant 1 2 0.6445 1.2 103 .0837
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1791545 NM_015515.3 KRT23 Keratin 23 (histone deacetylase
inducible)
17 0.6391 1.2  103 .0838
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1747183 NM_001099650.1 GLT8D3 Glycosyltransferase 8 domain
containing 3, transcript variant
2
12 0.6353 1.2  103 .0839
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1815666 NM_170665.2 ATP2A2 ATPase, Ca transporting,
cardiac muscle, slow twitch 2,
transcript variant 1
12 0.6340 1.2  103 .0840
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1761425 NM_182487.2 OLFML2A Olfactomedin-like 2A 9 0.6347 1.2  103 .0843
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1794825 NM_000382.2 ALDH3A2 Aldehyde dehydrogenase 3
family, member A2, transcript
variant 2
17 0.6101 1.2  103 .0845
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1767459 NM_018082.4 POLR3B Polymerase (RNA) III (DNA
directed) polypeptide B
12 0.6220 1.2  103 .0851
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1717905 NM_015726.2 WDR42A WD repeat domain 42A 1 0.6202 1.2  103 .0853
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1682404 NM_006515.1 SETMAR SET domain and mariner
transposase fusion gene
3 0.6306 1.2  103 .0861
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1725338 NM_194284.2 CLDN23 Claudin 23 8 0.6369 1.2 103 .0863
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1765371 NM_018032.3 LUC7L LUC7-like (S cerevisiae),
transcript variant 1
16 0.6428 1.2  103 .0863
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1756118 NM_014634.2 PPM1F Protein phosphatase 1F (PP2C
domain containing)
22 0.5914 1.2  103 .0864
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1793621 NM_001002262.1 ZFYVE27 Zinc ﬁnger, FYVE domain
containing 27, transcript variant
3
10 0.6345 1.2  103 .0865
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1654945 NM_153759.2 DNMT3A DNA (cytosine-5-)-
methyltransferase 3 alpha,
transcript variant 2
2 0.6434 1.2  103 .0866
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1754364 NM_001868.1 CPA1 Carboxypeptidase
A1 (pancreatic)
7 0.6196 1.2  103 .0866
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1663640 NM_000240.2 MAOA Monoamine oxidase A, nuclear
gene encoding mitochondrial
protein
X 0.6353 1.3  103 .0874
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1728581 NM_016210.2 C3orf18 Chromosome 3 open reading
frame 18
3 0.6159 1.3  103 .0876
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1736834 NM_005414.2 SKIL SKI-like oncogene 3 0.6206 1.3 103 .0883
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1800731 NM_018328.3 MBD5 Methyl-CpG binding domain
protein 5
2 0.6235 1.3  103 .0884
................................................................................................................................................................................................................................................................................................................................................................................
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TABLE 2
Differentially expressed transcriptsa (continued)
Illumina ID GenBank ID Symbol Deﬁnition Ch
Beta
valueb P valuec
FDR P
valued
ILMN_1805098 NM_000924.2 PDE1B Phosphodiesterase 1B,
calmodulin-dependent
12 0.6434 1.3  103 .0884
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1769764 NM_001039935.1 ANKRD55 Ankyrin repeat domain 55,
transcript variant 2
5 0.6090 1.3  103 .0885
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1814015 NM_004063.2 CDH17 Cadherin 17, LI cadherin (liver-
intestine)
8 0.6315 1.3  103 .0885
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1802669 NM_021132.1 PPP3CB Protein phosphatase 3 (formerly
2B), catalytic subunit, beta
isoform
10 0.6361 1.3  103 .0888
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1800512 NM_002133.1 HMOX1 Heme oxygenase (decycling) 1 22 0.5922 1.3 103 .0888
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1772731 NM_005326.4 HAGH Hydroxyacylglutathione
hydrolase, transcript variant 1
16 0.6280 1.3  103 .0890
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1756573 NM_020142.3 NDUFA4L2 NADH dehydrogenase
(ubiquinone) 1 alpha
subcomplex, 4-like 2
12 0.6186 1.3  103 .0891
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1686464 NM_180991.4 SLCO4C1 Solute carrier organic anion
transporter family, member 4C1
5 0.6381 1.3  103 .0903
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1769083 NM_000847.3 GSTA3 Glutathione S-transferase A3 6 0.6117 1.3 103 .0904
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1687410 NM_022776.3 OSBPL11 Oxysterol binding protein-like 11 3 0.6035 1.4  103 .0918
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1651611 NM_000527.2 LDLR Low-density lipoprotein
receptor (familial
hypercholesterolemia)
19 0.6122 1.4  103 .0937
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1665123 NM_178177.2 NMNAT3 Nicotinamide nucleotide
adenylyltransferase 3
3 0.6152 1.4  103 .0938
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1651370 NM_001014443.2 USP21 Ubiquitin-speciﬁc peptidase 21,
transcript variant 3
1 0.6228 1.4  103 .0939
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1774110 NM_004067.2 CHN2 Chimerin (chimaerin) 2,
transcript variant 2
7 0.6275 1.4  103 .0950
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1730662 NM_001008745.1 LOC401431 Hypothetical gene LOC401431 7 0.6048 1.4  103 .0950
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1753554 NM_022763.2 FNDC3B Fibronectin type III domain
containing 3B
3 0.6167 1.4  103 .0950
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1734254 NM_014106.2 ZNF770 Zinc ﬁnger protein 770 15 0.5801 1.4  103 .0951
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1801889 NM_015011.1 MYO16 Myosin XVI 13 0.6401 1.4  103 .0951
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1703074 NM_001304.3 CPD Carboxypeptidase D 17 0.6178 1.4  103 .0952
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1885728 XM_001130020.1 KIAA1147 KIAA1147 7 0.6203 1.5 103 .0952
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1652594 NM_024855.3 ACTR5 ARP5 actin-related protein 5
homolog (yeast)
20 0.6197 1.4  103 .0953
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1672287 NM_018657.3 MYNN Myoneurin 3 0.6237 1.5 103 .0954
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1680113 NM_004758.1 BZRAP1 Benzodiazepine receptor
(peripheral)-associated protein
1
17 0.6340 1.5  103 .0966
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1660282 NM_022135.2 POPDC2 Popeye domain containing 2 3 0.6316 1.5  103 .0967
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1683441 NM_015261.2 NCAPD3 Non-SMC condensin II complex,
subunit D3
11 0.6169 1.5  103 .0968
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1761486 NM_024808.2 C13orf34 Chromosome 13 open reading
frame 34
13 0.6187 1.5  103 .0970
................................................................................................................................................................................................................................................................................................................................................................................
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TABLE 2
Differentially expressed transcriptsa (continued)
Illumina ID GenBank ID Symbol Deﬁnition Ch
Beta
valueb P valuec
FDR P
valued
ILMN_1894569 BX093121 Hs.571048 BX093121 Soares_placenta_
8to9weeks_2NbHP8to9W cDNA
clone IMAGp998K13561;
IMAGE:257796 sequence
0.6106 1.5  103 .0970
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1751086 NM_015459.3 DKFZP564J0863 DKFZP564J0863 protein 11 0.5780 1.5  103 .0970
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1656386 NM_014822.1 SEC24D SEC24-related gene family,
member D (S cerevisiae)
4 0.6073 1.5  103 .0971
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1760271 NM_194314.2 ZBTB41 Zinc ﬁnger and BTB domain
containing 41
1 0.6038 1.5  103 .0972
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1702683 NM_004733.2 SLC33A1 Solute carrier family 33 (acetyl-
CoA transporter), member 1
3 0.6196 1.5  103 .0972
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1878019 AL512695 Hs.278285 mRNA; cDNA DKFZp547G133
(from clone DKFZp547G133)
0.6348 1.5  103 .0973
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1806487 NM_001002034.2 FAM109B Family with sequence similarity
109, member B
22 0.5735 1.5  103 .0973
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1779748 NM_004192.2 ASMTL Acetylserotonin O-
methyltransferase-like
X,Y 0.6146 1.5  103 .0974
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1770084 NM_006283.1 TACC1 Transforming, acidic coiled-coil
containing protein 1
8 0.6145 1.6  103 .0974
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1707534 NM_017544.2 NKRF NF-kappaB repressing factor X 0.6044 1.6 103 .0974
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1678086 NM_138770.1 CCDC74A Coiled-coil domain containing
74A
2 0.6070 1.6  103 .0975
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1669064 NM_001080493.2 HSZFP36 ZFP-36 for a zinc ﬁnger protein 19 0.6087 1.5  103 .0975
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1810093 NM_005725.3 TSPAN2 Tetraspanin 2 1 0.5941 1.5  103 .0976
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1673522 NM_017947.1 MOCOS Molybdenum cofactor sulfurase 18 0.6122 1.6  103 .0976
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1764309 NM_000667.2 ADH1A Alcohol dehydrogenase 1A
(class I), alpha polypeptide
4 0.6229 1.6  103 .0977
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1795325 NM_001615.3 ACTG2 Actin, gamma 2, smooth
muscle, enteric
2 0.6151 1.6  103 .0977
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1773814 NM_205853.2 MUSTN1 Musculoskeletal, embryonic
nuclear protein 1
3 0.6206 1.5  103 .0977
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1703576 NM_012334.2 MYO10 Myosin X 5 0.6086 1.6 103 .0977
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1780937 NM_025128.3 MUS81 MUS81 endonuclease homolog
(S cerevisiae)
11 0.6341 1.6  103 .0977
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1757162 XM_945736.2 LOC654085 Similar to Glycine cleavage
system H protein, mitochondrial
precursor, transcript variant 2
19 0.6181 1.5  103 .0977
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1832155 AK094744 Hs.167721 cDNA FLJ37425 ﬁs, clone
BRAWH2001530
0.6007 1.6  103 .0977
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1782688 NM_024838.4 THNSL1 Threonine synthase-like 1 (S
cerevisiae)
10 0.6374 1.6  103 .0977
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1757298 NM_018167.3 BTBD7 BTB (POZ) domain containing 7,
transcript variant 2
14 0.6056 1.6  103 .0978
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1798975 NM_005228.3 EGFR Epidermal growth factor
receptor (erythroblastic
leukemia viral [v-erb-b]
oncogene homolog, avian),
transcript variant 1
7 0.6186 1.6  103 .0978
................................................................................................................................................................................................................................................................................................................................................................................
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TABLE 2
Differentially expressed transcriptsa (continued)
Illumina ID GenBank ID Symbol Deﬁnition Ch
Beta
valueb P valuec
FDR P
valued
ILMN_1775974 NM_019012.2 PLEKHA5 Pleckstrin homology domain
containing, family A member 5
12 0.5995 1.6  103 .0979
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1872404 AK055652 Hs.478682 cDNA FLJ31090 ﬁs, clone
IMR321000102
0.6351 1.6  103 .0979
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1808999 NM_153213.3 ARHGEF19 Rho guanine nucleotide
exchange factor (GEF) 19
1 0.6104 1.6  103 .0979
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1733703 NM_018006.4 TRMU tRNA 5-methylaminomethyl-2-
thiouridylate methyltransferase,
nuclear gene encoding
mitochondrial protein, transcript
variant 1
22 0.6098 1.6  103 .0980
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1795574 XM_928045.1 LOC644968 Hypothetical protein
LOC644968
4 0.5916 1.6  103 .0980
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1700994 NM_001039571.1 KREMEN1 Kringle containing
transmembrane protein 1,
transcript variant 4
22 0.6255 1.6  103 .0980
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1737146 NM_014294.4 TRAM1 Translocation-associated
membrane protein 1
8 0.6212 1.6  103 .0980
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1809889 NM_173510.1 CCDC117 Coiled-coil domain containing
117
22 0.6109 1.6  103 .0981
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1735909 NM_001033678.2 TRPT1 tRNA phosphotransferase 1,
transcript variant 1
11 0.6155 1.6  103 .0982
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1670472 NM_014613.2 UBXD8 UBX domain containing 8 5 0.6387 1.7 103 .0986
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1700633 NM_022060.2 ABHD4 Abhydrolase domain containing
4
14 0.5964 1.7  103 .0988
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1914072 BQ718005 Hs.562762 AGENCOURT_8100698
Lupski_sympathetic_trunk
cDNA clone IMAGE:6190431 5
sequence
0.6098 1.7  103 .0989
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1651642 NM_152742.1 GPC2 Glypican 2 7 0.6187 1.7  103 .0990
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1671046 NM_001541.2 HSPB2 Heat shock 27-kDa protein 2 11 0.6162 1.7  103 .0990
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1662578 NM_020156.1 C1GALT1 Core 1 synthase, glycoprotein-
N-acetylgalactosamine 3-beta-
galactosyltransferase, 1
7 0.5897 1.7  103 .0990
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1693514 NM_001014795.1 ILK Integrin-linked kinase,
transcript variant 3
11 0.6264 1.7  103 .0992
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1800447 NM_001031835.1 PHKB Phosphorylase kinase, beta,
transcript variant 2
16 0.5895 1.7  103 .0992
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1701933 NM_007308.1 SNCA Synuclein, alpha (non-A4
component of amyloid
precursor), transcript variant
NACP112
4 0.5903 1.7  103 .0993
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1779547 NM_006665.2 HPSE Heparanase 4 0.6297 1.7 103 .0995
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1883624 DA589983 Hs.582952 DA589983 HLUNG2 cDNA clone
HLUNG2011800 5 sequence
0.5802 1.7  103 .0997
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1774717 NM_020182.3 TMEPAI Transmembrane, prostate
androgen-induced RNA,
transcript variant 1
20 0.5933 1.7  103 .0998
................................................................................................................................................................................................................................................................................................................................................................................
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maybe inﬂuencedbygestationalage,23,24 it
cannotbe excluded that someof thediffer-
ences observed between the preeclamptic
and normal pregnancy groups are, in fact,
gestational age related. Winn et al23 com-
pared global gene expression in basal plate
(decidual) biopsies fromnormal pregnan-
cies at mid-gestation (14-24 weeks) and at
term (37-40 weeks) and found that 418
genes (of 39,000 transcripts examined)
changed expression throughout gestation.
This provides a useful dataset for compar-
ison with the data obtained in this current
study, albeit different proﬁling platforms
were used. Winn et al23 used the Af-
fymetrix HG-U133 A&B chip for tran-
scriptional proﬁling, whereas we used the
Illumina HumanWG-6 v2 Expression
BeadChip. By this, the number of possible
comparisons was restricted to the 16,799
genes shared in both systems. Of the 455
transcripts found to be differentially ex-
pressed in this current study, 368 genes
demonstratenogestationalage-inﬂuenced
changes, according to the data of Winn et
al.23 It is therefore tempting to speculate
that thedifferential expressionof these 368
genes may be related to disease mecha-
nismsatplay inpreeclampsia.Seventeenof
our differentially expressed genes (TE-
MEM97, KIAA1598, SULT2B1, EGFR,
FHL1, PLA2G7, SHANK3, NOTCH4,
UBASH3B, ROBO4, NRARP, GPR116,
IL6ST, LDLR, ANGPTL2, SRPRB, and
KREMEN1) are reported to change ex-
pression with gestational age.23 For 2 of
thesegenes (SULT2B1andEGFR), expres-
sion increases toward term.23 Thus, iso-
lated gestational age-related inﬂuences in
the preeclampsia group would suggest a
lower expression of SULT2B1 and EGFR,
but both were up-regulated in our dataset.
Similarly, the ANGPTL2 gene is down-
regulated toward term,23 but in con-
trast to what might be expected from
gestational age–related changes, ex-
pression was lower in the preeclampsia
group than in the normal pregnancy
group. Based on this, we conclude that
the differential expression of these 3
genes may also be ascribed to disease-
related mechanisms. However, with
regard to the remaining 14 genes in our
dataset previously shown to exhibit
gestational age-dependent changes in
expression, conclusions are hampered
by the fact that gestational age may
have contributed to the differences ob-
served between preeclamptic and nor-
mal pregnancies. To illustrate: expres-
sion of FHL1, SHANK3, NOTCH4,
ROBO4, NRARP, and GPR116 in-
creases toward term23 and was down-
regulated in the preeclampsia group,
whereas TMEM97, KIAA1598, PLA2G7,
UBASH3B, IL6ST, LDLR, SRPRB, and
TABLE 2
Differentially expressed transcriptsa (continued)
Illumina ID GenBank ID Symbol Deﬁnition Ch
Beta
valueb P valuec
FDR P
valued
ILMN_1789463 NM_021902.2 FXYD1 FXYD domain containing ion
transport regulator
1 (phospholemman), transcript
variant b
19 0.6164 1.7  103 .0999
................................................................................................................................................................................................................................................................................................................................................................................
ILMN_1651900 NM_002233.2 KCNA4 Potassium voltage-gated
channel, shaker-related
subfamily, member 4
11 0.6164 1.7  103 .0999
................................................................................................................................................................................................................................................................................................................................................................................
FDR, false discovery rate; mRNA, messenger RNA.
a Gene expression in decidual tissue from preeclamptic and normal pregnancies has been compared; b Values are given in beta, measure of distance between group means, expressed in SD
units–positive beta implies up-regulation and negative beta implies down-regulation in preeclamptic group compared with normal pregnant group; c P .05, obtained with SOLAR; d FDR P .10.
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TABLE 3
Results for selected genes from microarray and real-time quantitative polymerase chain reaction expression
Microarray RT-qPCR
Gene symbol Up/down Beta value P valuea Fold change P valueb
SLITRK4 2 1.04 4.59  108 1.98  .0001 1.73 x 10-5
................................................................................................................................................................................................................................................................................................................................................................................
FZD4 2 0.91 4.05  107 1.35 .001 7.71 x 10-4
................................................................................................................................................................................................................................................................................................................................................................................
ANGPTL2 2 0.89 4.39  106 1.74  .0001 4.79 x 10-5
................................................................................................................................................................................................................................................................................................................................................................................
PLA2G7 1 0.83 1.58  105 1.26 .068 6.79 x 10-2
................................................................................................................................................................................................................................................................................................................................................................................
MAN1A 1 0.85 1.29  105 1.30 .025 2.49 x 10-2
................................................................................................................................................................................................................................................................................................................................................................................
ARL5B 1 0.91 4.46  107 1.22 .017 1.66 x 10-2
................................................................................................................................................................................................................................................................................................................................................................................
RT-qPCR, real-time quantitative polymerase chain reaction.
a P .05, obtained with SOLAR; b P .10, obtained with t test statistics with software (SPSS, version 16; SPSS, Inc, Chicago, IL).
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KREMEN1 expression decreases toward
term23 and was up-regulated in the pre-
eclampsia group.
In genomewide transcriptional proﬁl-
ing, analysis of groups of genes is a strat-
egy to increase power and reduce the di-
mensionality of the underlying statistical
problem following multiple testing.25
Further, it may be advantageous to put
focus on canonical pathways and net-
works instead of single genes when the
aim is to obtain insight in the pathophys-
iology of complex diseases, such as pre-
eclampsia. The high interconnectivity of
focus genes with other correlated genes
within a biological network may imply
functional and biological importance of
these genes.26,27 To be able to assess this
in a comprehensive manner, we in-
creased the FDR cutoff to 0.1 and conse-
quently the number of genes included in
the analysis. Using this approach, 7 sig-
niﬁcant canonical pathways were found
to be represented by the differentially ex-
pressed genes identiﬁed in this current
study (Table 4).
The most signiﬁcant canonical path-
way detected was tryptophan metabo-
lism. The metabolism of tryptophan,
through the kynurenine pathway, has
previously been suggested to be involved
in preeclampsia pathogenesis,28,29 and,
in accordance with this, the activity of
the ﬁrst enzyme of the kynurenine path-
way, indoleamine 2,3 dioxygenase, has
been reported to be reduced in placenta
from preeclamptic pregnancies.28 We
found no disease-associated changes in
indoleamine 2,3 dioxygenase expression,
but the transcript encoding the enzyme
kynureninase (KYNU) was up-regu-
lated. KYNU metabolizes L-kynurenine,
which suppresses T-cell proliferation
and natural killer cells and inﬂuences
immunotolerance to foreign antigens.30
This implies that a consequence of
KYNU up-regulation may be an in-
creased inﬂammatory response (due to
lack of L-kynurenine). An additional 7
genes were assigned to this canonical
pathway (Table 4).
The second most signiﬁcant canonical
pathway identiﬁed was the ER stress
pathway. Three genes (EIF2AK3, ATF6,
andXBP1) included in the unfoldedpro-
tein response, a coordinated adaptive re-
sponse to ER stress, were up-regulated.
ER stress has previously been suggested
as one of themain sources for generation
of placental oxidative stress.31 Yung et
al32 have reported similar associations of
the unfolded protein response signaling
pathways to preeclampsia in placental
tissue, but these ﬁndings are reported for
the ﬁrst time in decidual tissue. There is a
close connection between oxidative
stress andER stress,31,33 also indicated by
the many direct relationships of the ER
and oxidative stress–related genes in the
generated network (Figure). The canon-
ical pathway NRF2-mediated oxidative
stress response was also among the sig-
niﬁcant pathways identiﬁed (Table 4).
The nuclear factor NFR2 plays an essen-
tial role in the defense of oxidative stress
by regulating the expression of antioxi-
dant response elements.34 In case of ex-
cessive oxidative stress, activation by re-
active oxygen species, nitrogen oxide,
and proinﬂammatory cytokines results
in translocation of NRF2 to the nucleus.
NRF2 binds to antioxidant response ele-
ment sequences, leading to transcrip-
tional activation of antioxidant genes
(eg, glutathione and HMOX1). NRF2-
mediated oxidative stress response in-
cluded 9 genes, of which 3 genes have pre-
TABLE 4
Canonical pathway analysis
Canonical pathwaya Genes
P valueb Ingenuity
Pathway Analysis
P valuec Rotation Gene
Set Enrichment Analysis
Tryptophan metabolism ACMSD, ALDH3A2,
ASMTL, CYP2E1, CYP2J2,
INMT, KYNU, MAOA
5.51  104 2.0  104
................................................................................................................................................................................................................................................................................................................................................................................
Endoplasmic reticulum stress pathway ATF6, DNAJC3, EIF2AK3,
XBP1
5.81  104 5.3  103
................................................................................................................................................................................................................................................................................................................................................................................
Linoleic acid metabolism CYP2E1, CYP2J2, PLA2G5,
PLA2G2A, WISP2
3.91  103 1.5  103
................................................................................................................................................................................................................................................................................................................................................................................
Notch signaling DTX3, HES1, NOTCH3,
NOTCH4
6.72  103 7.9  103
................................................................................................................................................................................................................................................................................................................................................................................
Fatty acid metabolism ACOX1, ACOX2, ADH1A,
ALDH3A2, CYP2E1,
CYP2J2
7.90  103 10.0  105
................................................................................................................................................................................................................................................................................................................................................................................
Arachidonic acid metabolism CYP2E1, CYP2J2, PLA2G5,
PLA2G2A, PTGIS, WISP2
8.66  103 10.0  105
................................................................................................................................................................................................................................................................................................................................................................................
NRF2-mediated oxidative stress response ACTG2, DNAJB6, DNAJB9,
DNAJB11, DNAJC3,
EIF2AK3, GSTA3, HMOX1,
UBE2K
9.99  103 6.7  102
................................................................................................................................................................................................................................................................................................................................................................................
a Ingenuity Pathway Analysis (www.ingenuity.com; Ingenuity Systems, Redwood City, CA) was used to bioinformatically identify canonical (ie, cell signaling and metabolic) pathways potentially
involved in preeclampsia within our dataset; b P value obtained with Fisher’s exact test; c P value obtained with use of limma package.
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viously been associated with preeclampsia
(EIF2AK3,32GSTA3,10 andHMOX121,22).
Several enzymes metabolize reactive oxy-
gen species to exportable compounds, and
in this study the transcripts encoding the
antioxidant enzymes GSTA3, HMOX1,
and UBE2K were up-regulated.
Three of the remaining signiﬁcant ca-
nonical pathways generated by IPA
represented metabolism of fatty acids:
linoleic acidmetabolism, fatty acidmetab-
olism, and arachidonic acid metabolism.
The genes included in thesepathwayswere
partly overlapping, as shown in Table
4. Decidual arterioles of preeclamptic
women show atherosclerotic-like le-
sions,35 suggesting an underlying athero-
genic process of low-density lipoprotein
lipid peroxidation.36 Lipid peroxidation
contributes to the development of pre-
eclampsia,37 and decidua basalis tissue
from preeclamptic women has an in-
creased content of lipid peroxides.4 The
ﬁrst enzyme of the fatty acid -oxida-
tion pathway, acyl-coenzyme A oxidase
(ACOX)1/palmitoyl-coAoxidase, donates
electrons directly to molecular oxygen,
thereby producing hydrogen peroxides.
ACOX1 was found to be up-regulated,
whereas ACOX2/branched chain ACOX,
which is involved in the degradation of
long branched fatty acids and bile acid in-
termediates in peroxisomes, was found to
be down-regulated. Two genes involved in
elimination of lipid peroxidation products
were also down-regulated in the material:
alcohol dehydrogenase 1a, which metabo-
lizes a wide variety of substrates including
lipid peroxidation products, and aldehyd-
edehydrogenase 3 family member A2
isozymes, thought to play a major role in
the detoxiﬁcation of aldehydes generated
by alcoholmetabolismand lipid peroxida-
tion. Increased generation or decreased
elimination of lipid peroxidation products
may be among the factors activating the
maternal endothelium38 and triggering
systemic inﬂammation in preeclampsia.
Finally, the pathway analysis suggested
a role of notch signaling, with inclusion
of 4 down-regulated genes: DTX3,
HES1,NOTCH3, andNOTCH4.Notch
signaling is known to be involved in cell
differentiation, proliferation, apopto-
FIGURE
Network of preeclampsia-correlated genes
Ingenuity Pathway Analysis (www.ingenuity.com; Ingenuity Systems, Redwood City, CA) generated gene-gene product interaction network of preeclamp-
sia-correlated genes. Genes or gene products are represented as nodes, and biological relationship between 2 nodes is represented as edge (line). All
edges are supported by at least 1 published reference. Solid edges represent direct relationship, and dashed edges represent indirect relationship. Node
color represents correlation of expression level with preeclampsia, and color intensity indicates degree of correlation (red is positive and green negative).
Shape of each node represents functional class of gene product, as shown in key.
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sis,39 and blood vessel formation,40 pro-
cesses neatly regulated in the placenta to
maintain a normal pregnancy. Notch re-
ceptors are expressed on extravillous tro-
phoblasts and are hypothesized to be
involved in the differentiation and pro-
liferation of both extravillous tropho-
blasts and endothelial cells.41 Placental
villi from preeclamptic pregnancies
show down-regulation of notch pathway
members.42 Notch signaling in placenta
has been suggested to play a role in the
development of preeclampsia,42,43 and
the altered expression of DTX and HES1
in tissue from preeclamptic pregnancies
compared with normal pregnancies is
presented for the ﬁrst time.
In summary, we have provided a com-
prehensive transcriptional proﬁle of the
decidua in preeclampsia. Our network
analysis has demonstrated extensive
connectivity between the differently ex-
pressed genes. Alteration of the expres-
sion level of 1 gene may inﬂuence the
transcription of others included in the
network. Due to this, it is difﬁcult to pin-
point the genes having primary roles in
perpetuating preeclampsia from our
dataset. Some of our ﬁndings conﬁrm
and elaborate the current knowledge on
the pathophysiology of preeclampsia,
while others are novel. Further studies
are warranted to replicate ﬁndings and
conﬁrm involvement of speciﬁc genes
that have been identiﬁed. f
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abstract: Variation in the Storkhead box-1 (STOX1) gene has previously been associated with pre-eclampsia. In this study, we
assess candidate single nucleotide polymorphisms (SNPs) in STOX1 in an independent population cohort of pre-eclamptic (n ¼
1.139) and non-pre-eclamptic (n ¼ 2.269) women (the HUNT2 study). We also compare gene expression levels of STOX1 and
its paralogue, Storkhead box-2 (STOX2) in decidual tissue from pregnancies complicated by pre-eclampsia and/or fetal growth
restriction (FGR) (n ¼ 40) to expression levels in decidual tissue from uncomplicated pregnancies (n ¼ 59). We cannot conﬁrm
association of the candidate SNPs to pre-eclampsia (P . 0.05). For STOX1, no differential gene expression was observed in any
of the case groups, whereas STOX2 showed signiﬁcantly lower expression in deciduas from pregnancies complicated by both
pre-eclampsia and FGR as compared with controls (P ¼ 0.01). We further report a strong correlation between transcriptional
alterations reported previously in choriocarcinoma cells over expressing STOX1A and alterations observed in decidual tissue of
pre-eclamptic women with FGR.
Key words: intrauterine growth restriction (IUGR) / decidua basalis / pre-eclampsia / HUNT2 / STOX genes
Introduction
Pre-eclampsia is a serious complication of pregnancy and a major
cause of preterm intervention by Caesarean section, as delivery
relieves symptoms. The condition presents with de novo elevated
blood pressure and proteinuria after 20 weeks of pregnancy. Severe
pre-eclampsia is not well deﬁned, but assessment for severity includes
both the mother (severe hypertension, end organ manifestations and
preterm disease), and the fetus (intrauterine growth restriction, fetal
movement assessment and oligohydramnios) (Gifford et al., 2000).
As deﬁned in clinical practice, 20% of pre-eclamptic cases are
severe. Early identiﬁcation, as well as more reﬁned treatment
options, is particularly important for these women, and this remains
a major challenge in obstetric medicine. Thus, there is a rationale
for concentrating research efforts on severe cases (Gifford et al.,
2000).
Pre-eclampsia is a complex disorder, including both placental and
maternal components. Disease heritability is as high as 54% (Salonen
et al., 2000), but a distinct pattern of inheritance is not known.
Whole genome linkage studies of families with an increased preva-
lence of pre-eclampsia have identiﬁed several genetic susceptibility
loci for pre-eclampsia (Harrison et al., 1997; Arngrimsson et al.,
1999; Moses et al., 2000, 2006; Lachmeijer et al., 2001; Laivuori
et al., 2003; Johnson et al., 2007). Several studies have suggested
the involvement of epigenetic mechanisms for the disease (Graves,
1998), and evidence for a maternal effect in one of the pre-
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eclampsia susceptibility loci has been observed for a region of genes
on chromosome 10q22 (Oudejans et al., 2004). The exons of 17
positional candidate genes in this region were sequenced in a
Dutch cohort of families with two or more sibling pairs
affected by pre-eclampsia (van Dijk et al., 2005). All families with
increased prevalence of pre-eclampsia showed missense mutations
within the Storkhead box-1 (STOX1, AK057891) gene on chromo-
some 10q22, identical between affected sisters (van Dijk et al.,
2005).
The STOX1 gene encodes a winged-helix domain-containing tran-
scription factor, and is believed to play a role in the differentiation
of trophoblast cells (van Dijk et al., 2005). The longest isoform of
the STOX1 protein, STOX1A (NM_152709) exerts regulatory
effects in several tissues (van Dijk et al., 2010a). Over expression
of STOX1A in choriocarcinoma cells (JEG-3 cell line) was shown
to be associated with transcriptional alterations similar to those
observed in third-trimester pre-eclamptic placentas (Rigourd
et al., 2008). The predominant variation co-segregating with pre-
eclampsia disease status in the Dutch families (van Dijk et al.,
2005), STOX1A-Y153H (rs1341667) is located in the DNA
binding domain. Recently published data suggest that this variant
may negatively regulate trophoblast invasion by up-regulation of
the cell–cell adhesion protein a-T-catenin (CTNNA3) (van Dijk
et al., 2010b).
Storkhead box 2 (STOX2, AB037813) has been identiﬁed as the
only known human paralogue to STOX1 (van Dijk et al., 2005;
Kivinen et al., 2007), but to our knowledge little is known of its func-
tion. In humans, there is evidence that STOX2 is a component of a
molecular proﬁle unique and globally characteristic of uncommitted
stem cells (Thomas et al., 2008). The STOX2 transcript is also included
in a transcriptional proﬁle observed with increased inﬂammatory
response to air pollutants, differing between pregnant and non-
pregnant mice (Fedulov et al., 2008). The gene is situated at chromo-
some 4q35, near a replicated region of known, suggestive linkage to
pre-eclampsia on chromosome 4q31-q32 (Harrison et al., 1997;
Moses et al., 2000; Laivuori et al., 2003).
The involvement of STOX1 in pre-eclampsia observed in the Dutch
families (Oudejans et al., 2004; van Dijk et al., 2005) has not been con-
ﬁrmed in independent studies (Berends et al., 2007; Kivinen et al.,
2007; Iglesias-Platas et al., 2007). It has therefore been hypothesized
that STOX1 is relevant to a clinically severe subgroup of women
with early onset of the disease, and fetal growth restriction (FGR)
(Oudejans et al., 2007; Oudejans and van Dijk, 2008; van Dijk et al.,
2007).
In the present study, we investigated candidate functional single
nucleotide polymorphisms (SNPs) within STOX1 in an independent
large population-based pre-eclampsia cohort. The proposed
disease-causing STOX1A-Y153H (rs1341667) variant was tested
for association with deﬁned clinical subgroups of pre-eclamptic
women. We also compared decidual gene expression of STOX1
and STOX2 in uncomplicated pregnancies and pregnancies compli-
cated by pre-eclampsia, FGR or both. Furthermore, we compared
transcriptional alterations in Rigourd’s cultured trophoblast cells
with increased expression of STOX1A (Rigourd et al., 2008),
with transcriptional alterations seen in our clinically deﬁned
subgroups.
Materials and Methods
Candidate gene expression study
Human subjects
Women with pregnancies complicated by pre-eclampsia, FGR, pre-
eclampsia with FGR and women with uncomplicated pregnancies were
recruited at St Olavs Hospital, Trondheim, Norway and Haukeland Uni-
versity Hospital, Bergen, Norway from 2002 to 2006. Pre-eclampsia was
deﬁned as hypertension (blood pressure ≥140/90 mmHg) plus protei-
nuria (≥0.3 g/24 h or ≥1 + according to a dipstick test) on at least
two occasions, developing after 20 weeks of pregnancy (Gifford et al.,
2000). FGR was deﬁned by a stringent small for gestational age (SGA) deﬁ-
nition (birthweight ≤2 SD below the expected weight for gestational age
and sex, corresponding to the 2.5 percentile) (Marsal et al., 1996), con-
ﬁrmed by at least one of the following: reduced fundal height in serial
measurements, serial ultrasound biometry identifying failure to grow
along a consistent centile or abnormal umbilical artery wave form. Multiple
pregnancies and pregnancies with chromosomal aberrations, fetal and pla-
cental structural abnormalities or suspected perinatal infections were
excluded.
Decidual tissue collection
Decidua basalis tissue samples were collected by vacuum aspiration of the
placental bed during Caesarean section as previously described (Staff et al.,
1999; Harsem et al., 2004). Caesarean section in the control group was
done for reasons considered irrelevant to the study hypotheses (breech
presentation, cephalopelvic disproportion or maternal request). Samples
were ﬂushed with 500 ml sterile saline solution at room temperature to
remove excess blood. The decidual tissue was immediately submerged
in RNA-later (Ambion, Huntington, UK), incubated at 48C and stored
at 2808C for later RNA extraction. The quality of the decidual material
was assessed by immune histochemistry, as described in Eide et al.
(2006). Only specimens containing extravillous trophoblast (decidua
basalis) were included in the study.
Total RNA processing
Decidua basalis tissue was disrupted in a 2:1 (w/v) trizol:sample tissue mix
using a Polytronw PT 1300 D digital, handheld homogenizer with a PT-DA
1307/2EC generator (Kinematica Inc., Lucerne, Switzerland). Total RNA
was isolated using a trizol extraction protocol with chloroform interphase
separation; isopropanol precipitation and ethanol wash steps. Isolated
total RNA was puriﬁed with an RNeasy Mini Kit using spin technology
(Qiagen, Valencia, CA, USA). Spectrophotometric determination of puri-
ﬁed total RNA yield (mg) was performed using the NanoDrop ND-1000
(Wilmington, DE, USA). Total RNA quality was measured using the total
RNA Nano Series II kit on the Agilent BioAnalyzer 2100 using the 2100
Expert software (Agilent Technologies, Germany). Synthesis, ampliﬁcation,
puriﬁcation and biotin labelled complementary RNA (cRNA) was pro-
duced from a total RNA template using the Illumina TotalPrep RNA
Ampliﬁcation Kit (Ambion, TX, USA), according to manufacturer’s instruc-
tions. Puriﬁed cRNA yield was determined spectrophotometrically using
the NanoDrop ND-1000.
A total of 1.5 mg puriﬁed cRNA per sample was hybridized onto Illumi-
na’s HumanWG-6 v2 Expression BeadChipw following Illumina’s 6 × 2
BeadChip protocol (Illumina, San Diego, CA, USA). After hybridization,
the 6 × 2 expression arrays were washed, blocked, stained with
streptavidin-Cy3 (GE Healthcare, Buckinghamshire, UK) and dried prior
to them being scanned on the Illumina BeadArrayer 500GX reader
using Illumina BeadScan image data acquisition software (version
2.3.0.13). Illumina’s BeadStudio Gene Expression software module
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(version 3.2.7) was used to subtract background noise signals for each indi-
vidual sample and generate an output ﬁle for statistical analysis. The
control summary report generated by the Gene Expression software
module was used to evaluate the performance of the built-in controls
for each BeadChip. The control summary report summarizes signal inten-
sity, hybridization signal, background signal and the background to noise
level for all samples scanned in a particular batch.
Candidate gene association study
HUNT2 case/control subjects
The samples used for our candidate gene association study were retrospec-
tively identiﬁed from the second Nord-Trøndelag Health Study in Norway
(HUNT2). The HUNT2 study was conducted from 1995 to 1997. All resi-
dents above 19 years were invited and 75.5% of the invited women (n ¼
35.280) participated. This population is considered well suited for genetic
studies as it is homogeneous (,3% non-Caucasians) and stable (net out
migration of 0.3% each year). The HUNT2 survey included a questionnaire,
a clinical examination and collection of biological samples as previously
described (Holmen et al., 2003). Obstetrical data from these women were
obtained by linking the HUNT2 data with the The Medical Birth Registry of
Norway (MBRN). Physicians and midwives have been registering obstetrical
data fromall deliveries inNorway after 16weeksof gestation in standard ques-
tionnaires since 1967. More than 1.8 million births are included. Each resident
in Norway is registered with an 11-digit personal identiﬁcation number, also
used for all national registries such as the MBRN and HUNT. The women
having experienced pre-eclampsia in one or more pregnancies, deﬁned as
newonset of hypertension (bloodpressure≥140/90 mmHg) andproteinuria
(≥0.3 g/d or≥1 + according to a dipstick test), developing after 20weeks of
pregnancy (Gifford et al., 2000) were identiﬁed using diagnosis codes ICD-8
(before 1998) and ICD-10 (after 1998). Pre-eclamptic women with multiple
pregnancies were excluded. Two controls per case were identiﬁed at
random among parous women in the HUNT2 cohort with no registered pre-
eclamptic pregnancy in the MBRN. All personal identiﬁcation numbers in the
total data set were randomly replaced by a serial number in order to ensure
patient anonymity.
Clinical characterization of the HUNT2 pre-eclampsia-cohort
Preterm delivery was deﬁned as delivery before 37.0 weeks (Gifford et al.,
2000), and FGR as delivery of a SGA infant (birthweight ≤2 SD below the
expected weight for gestational age and sex, corresponding to the 2.5 per-
centile) (Marsal et al., 1996). As fasting blood glucose was not available for
all the individuals in the study cohort, an International Diabetes Federation
(IDF)-proxy deﬁnition [waist circumference ≥80 cm plus any two of the
following: high-density lipoprotein (HDL) cholesterol ,1.29 mmol/l,
treatment for hypertension or blood pressure ≥130/85 mmHg, diabetes
diagnosed after the age of 30] (Hildrum et al., 2007) was used for assess-
ment of metabolic syndrome. This method has been evaluated in a cross-
sectional analysis of 10.206 participants in HUNT2 and no differences in
the prevalence of metabolic syndrome between fasting and non-fasting
groups were shown using the IDF-proxy deﬁnition (Hildrum et al., 2007).
Genotyping
DNA from pre-eclamptic (case) and non-pre-eclamptic (control) pregnan-
cies was extracted from peripheral blood leukocytes from blood clots or
from EDTA blood stored in the HUNT biobank, using the PURGENE
chemistry (Gentra Systems Inc, Minneapolis, MN, USA) for large
volumes or the MagAttract DNA Blood M48 kit (Qiagen, Hilden,
Germany) for low volumes (,400 ml) as previously described (Holmen
et al., 2003; Moses et al., 2007).
The four STOX1 missense SNPs described by van Dijk et al. (2005) plus
two additional known STOX1 missense SNPs were selected for genotyping
in the HUNT2 case/control cohort. The additional STOX1 SNP was
selected from the NCBI SNP database (Homo sapiens NCBI Build 35;
dbSNP build 124). The six STOX1 SNPs were genotyped using Applied
Biosystems’ SNPlexTM Genotyping System and sample genotypes were
interrogated using Applied Biosystems’ GeneMapper (version 4.0) soft-
ware as previously described (Moses et al., 2007; Roten et al., 2008).
Statistical analysis
Gene expression analysis
Decidual gene expression proﬁles were analysed using SOLAR (Almasy
and Blangero, 1998) as previously described (Goring et al., 2007). All
raw gene expression signals were initially log-transformed. To identify sig-
niﬁcantly expressed genes in decidua, the distribution of expression values
for a given gene across all samples was compared with the distribution of
the expression values of the control targets implemented in each
expression array. For each gene, we performed a x2 tail test using a
false discovery rate (Hochberg and Benjamini, 1990) of 0.01 to determine
whether there was a signiﬁcant excess of samples with expression values
above the 95th percentile of the control null distribution (Goring et al.,
2007). The pre-processing of gene expression signals produces a sub-set
of signiﬁcantly expressed (detected) genes from the total number of
targets synthesized onto each expression array. Within each sample, the
mean log expression signal for each detected gene was ranked and
grouped into bin sets of 2.000 genes. Each bin set was then z-scored inde-
pendently. We applied a direct normalization procedure using an inverse
Gaussian transformation for each detected same gene across all
samples. This conservative procedure results in normalized expression
phenotypes that are comparable between individuals and across all
genes (Goring et al., 2007). To evaluate the magnitude of differential
gene expression between case (pre-eclampsia and/or FGR) and control
women, we measured the displacement of each detected gene’s mean
expression value between the two groups. We performed a standard
regression analysis on the case group to test whether the mean gene
expression level is signiﬁcantly different (up- or down-regulated) in the
case group compared with the control group.
When evaluating the correlation between transcriptional alterations
in Rigourd’s data set (Rigourd et al., 2008) and our data set
(E-TABM-682), we performed a Spearman rank test, as the beta-values
and the fold change values generated from these two studies are not
directly comparable.
The microarray data have been reported to ArrayExpress according to
MIAME standards with accession number E-TABM-682.
SNP association analysis
SNP association analyses of all selected SNPs were performed for the total
case/control cohort using Pearson’s x2 statistic in the software package
SPSS 16.0 for Windows. The Y153H variation was analyzed separately
for subgroups of pre-eclamptic women and control women (FGR, recur-
rence) for both a dominant (CC + CT genotype frequency versus TT gen-
otype frequency) and additive (C allele frequency versus T allele
frequency) genetic model. Multivariate logistic regression was used to
model pre-eclampsia as the (dichotomous) dependent variable against
maternal age. Odds ratios (OR) with 95% conﬁdence intervals were calcu-
lated. Concordance with Hardy–Weinberg proportions was tested using a
x2 goodness-of-ﬁt statistic. A threshold of a ¼ 0.05 was set for statistical
signiﬁcance of all computed analyses.
Clinical characterization
Descriptive statistics means and standard deviations were computed in the
software package SPSS 16.0 for Windows. P-values were computed based
on t-test statistics. Recurrent and non-recurrent pre-eclamptic cases were
962 Fenstad et al.
analyzed separately. Each pre-eclamptic group (recurrent and non-
recurrent) was compared with the non-pre-eclamptic group. Multivariate
logistic regression was used to model pre-eclampsia as the (dichotomous)
dependent variable against maternal age. A threshold of a ¼ 0.05 was set
for statistical signiﬁcance of all computed analyses.
Ethical approval
Informed written consent was obtained from all participants in this study.
The study was approved by the Regional Committees for Medical
Research Ethics, the National Data Inspectorate and The Directorate of
Health and Social Welfare, Norway. Ethical approval for genotyping the
Norwegian case/control cohort (HUNT2), decidual RNA processing
and statistical analysis of decidual RNA was obtained from The University
of Texas Health Science Center at San Antonio, Institutional Review
Board.
Results
Decidual tissue candidate gene expression
analysis
Decidua basalis tissue was vacuum aspirated from the placental bed of
14 women with pre-eclampsia, 9 non-pre-eclamptic women with FGR
neonates, 29 women with both pre-clampsia and FGR
(pre-eclampsia + FGR) and 59 normal pregnancies. Seven samples
of low RNA quality were excluded (assessed by the RIN value and
visual evaluation of digital electrophoretic gel pictures). We therefore
processed a total of 104 samples. Clinical characteristics of the study
groups are presented in Table I.
Both the STOX1 (NM_152709.3) and STOX2 (NM_020225.1)
targets were represented on each expression array as a single
known transcript, respectively and were annotated from NCBI’s
Human Genome Build 36.2, RefSeq content release 17. The
expression of both the STOX1 and STOX2 targets were signiﬁcantly
detected in decidual tissue using a conservative false detection rate
of 1%. To evaluate the magnitude of differential gene expression,
we measured the displacement of the mean STOX1 or STOX2
expression signals in the case group from the control group. We per-
formed this measurement on the three different sample groups and
found no signiﬁcant difference in STOX1 gene expression levels (P .
0.05) (Table II). The expression of STOX2 however, was signiﬁcantly
lower in the group of pre-eclamptic women delivering FGR neonates
compared with the control group (P ¼ 0.01) (Table II).
In the study by Rigourd et al. (2008), 259 of the 500 most up/
down-regulated genes in pre-eclamptic placentas had detectable tran-
script levels in the microarray experiment comparing JEG-3 cells over
.............................................................................................................................................................................................
Table I Clinical characteristics of the cohort used in the gene expression analysis.
Pre-eclampsia (n5 13) FGRa (n 5 9) Pre-eclampsia with FGR (n5 24) Controls (n 5 58)
Maternal age (years) 30+5* 34+4 31+5 31+5
Gestational age (weeks) 35+3** 32+5** 30+4** 39+1
Systolic blood pressure (mmHg) 153+18** 128+15 151+16** 116+11
Diastolic blood pressure (mmHg) 95+9** 74+8 97+12* 70+9
Birthweight (g) 2364+510** 1225+21** 1118+470** 3619+469
Data are presented as mean+ SD. All case groups were compared with controls and P-values were computed based on t-test statistics.
a≤2 SD of expected weight, conﬁrmed by at least one of the following: reduced fundal height in serial measurements, serial ultrasound biometry identifying failure to grow along a
consistent centile or abnormal umbilical artery wave form.
*P, 0.05; **P, 0.001.
...............................................
.................... .......................
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Table II Decidua basalis differential STOX1 and STOX2
expression analysis.
Sample group comparison Gene
STOX1 STOX2
b* P-value b* P-value
Pre-eclampsia versus control 0.39 0.19 0.07 0.81
FGR versus control 0.49 0.18 20.17 0.61
Pre-eclampsia with FGR
versus control
0.04 0.86 20.59 0.01
*The b (beta) value is the measure of displacement between the case and control group
mean expression signals and is expressed in standard deviation units. A positive b
implies a higher mean transcript expression signal in the case group compared with the
control group and is analogous to a gene/transcript being up-regulated. A negative b
implies a lower mean transcript expression signal in the case group compared with the
control group and is analogous to a gene/transcript being down-regulated. Values
signiﬁcant at the 1% level are outlined in bold.
........................................................................................
Table III Correlation between transcriptional
alterations seen in JEG-3 cells over expressing STOX1A
and alterations observed in decidua basalis tissue from
pre-eclamptic and/or FGR pregnancies.
Correlation coefﬁcient2
(Spearman r)
P-value
Pre-eclampsia 0.16 0.004*
Pre-eclampsia with FGR1 0.23 0.00008*
FGR 0.09 0.17
1≤2 SD of expected weight, conﬁrmed by at least one of the following: reduced fundal
height in serial measurements, serial ultrasound biometry identifying failure to grow
along a consistent centile or abnormal umbilical artery wave form.
2correlation between the degrees of up/down-regulation of 259 pre-eclampsia related
genes from the study of Rigourd et al. (comparing JEG-3 cells over expressing STOX1
with mock-transfected JEG-3 cells) with the present study (comparing decidua basalis
samples from patients with pre-eclampsia and/or FGR with control decidua basalis
samples).
*P, 0.01.
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expressing STOX1A with mock-transfected JEG-3 cells. Of these 259
genes, 242 were found to have transcripts expressed above the back-
ground in the transcriptomic data from our material (E-TABM-682).
We observed a strong correlation (Spearman r ¼ 0.23, P ¼
0.00008) between the beta-values (ratio of up/down-regulation com-
pared with controls) for these genes in our subgroup of women
experiencing pre-eclampsia with FGR and the ratio of up/down-
regulation in the study by Rigourd et al. (2008). The beta-values for
the women with pre-eclampsia only, showed a weaker correlation
(Spearman r ¼ 0.16, P ¼ 0.004), and there was no correlation to
the beta-values for the non-pre-eclamptic women delivering FGR neo-
nates (Spearman r ¼ 0.09, P ¼ 0.17) (Table III).
The HUNT2 case/control cohort
DNA samples were available for 1139 women registered with pre-
eclamptic pregnancies (cases) and 2269 non-pre-eclamptic women
(controls) (Moses et al., 2007). Of the available cases, 1003 women
were registered with one and 136 women with more than one pre-
eclamptic pregnancy. Mean follow-up time from diagnosis in the
MBRN to inclusion in the present study was 25+ 10 years. As
expected, gestational age and birthweight differed between the
neonates in pre-eclamptic and non-pre-eclamptic pregnancies; the
pre-eclamptic women had a higher risk of delivering preterm, and of
delivering a FGR neonate (Table IV, P, 0.001). The metabolic syn-
drome, evaluated by data from the HUNT2 study, was also higher
in the case groups as compared with controls (Table IV, P, 0.001).
After adjusting for maternal age, the differences in clinical phenotype
between case and control groups remained signiﬁcant at a, 0.001
level (Table IV).
We also observed clinical differences between the recurrent and
non-recurrent pre-eclamptic groups (Table IV). The women in the
recurrent group delivered earlier (P ¼ 0.018) and the neonates had
a lower birthweight (adjusted for gestational age, P ¼ 0.055). The
prevalence of preterm birth was higher in the recurrent group
(22%) compared with the non-recurrent group (14%) (P, 0.01),
but the seemingly different prevalence of FGR (20 versus 15%) was
not statistically signiﬁcant (P ¼ 0.2). The P-values are adjusted for
maternal age. Metabolic syndrome at inclusion in the HUNT2 study
was more prevalent in the recurrent group compared with the non-
recurrent when adjusting for age at inclusion (P ¼ 0.019).
Statistical power analysis for the HUNT2 case/control cohort
A priori power calculations ad modum Lalouel and Rohrwasser (2002)
for the STOX1A Y153H (rs1341667) variant demonstrated 90% power
to detect an effect size (OR) difference of 1.3 for the total case/
control (HUNT2) cohort and 1.9 for the recurrent pre-eclampsia
subgroup (n ¼ 136).
STOX1 genotyping and association analysis
The R18P STOX1 SNP failed the SNPlex assay design due to high hom-
ology and another two STOX1 SNPs were non-polymorphic. There
were no signiﬁcant differences in allele frequencies between the case
and control groups for the genotyped SNPs (Table V). There was a
high average sample genotype success rate of 87% (range 84–88%)
and all SNPs conformed to Hardy–Weinberg proportions (P. 0.05).
Assuming a dominant genetic model for the Y153H variant, it is
proposed that this variant becomes mutagenic through mechanisms
of imprinting either of STOX1 itself, or of downstream proteins (van
Dijk et al., 2005). Under this analysis model, the pre-eclampsia +
FGR subgroup did not show any association with the STOX1A-
Y153H variant when compared with the control group (Table VI).
However, the recurrent pre-eclampsia subgroup showed a tendency
towards higher incidence of the C-genotype (P ¼ 0.09) (Table VI).
Discussion
In this study, we demonstrate reduced decidual gene expression of
STOX2 in pre-eclamptic women delivering FGR neonates. To our
.............................................................................................................................................................................................
Table IV Clinical characteristics of the HUNT2 case/control cohort.
Pre-eclampsia
(recurrent1, n 5 136)
Pre-eclampsia
(non-recurrent, n5 1.003)
Control (n 5 2.269)
Maternal age at index pregnancy (years) 25+5 27+6* 25+5
Gestational age (days) 271+20* 275+22* 282+18
Birthweight (g) 3.040+846* 3.238+837* 3.483+592
FGR2 26 (20)* 147 (15)* 87 (4)
Preterm birth3 29 (22)* 132 (14)* 114 (5)
Maternal age at inclusion in HUNT2 37+9* 40+11 40+11
Metabolic syndrome4 30 (22)* 163 (16)* 212 (9)
Data presented as mean+ SD or number (percentage). P-values are computed based on t-test statistics, each pre-eclamptic group is compared with the non-pre-eclamptic group. IDF,
the International Diabetes Federation; HDL, high-density lipoprotein; CI, conﬁdence interval.
1More than one pre-eclamptic pregnancy.
2≤2 SD of expected weight.
3Delivery before week 37.
4IDF-proxy deﬁnition; waist circumference ≥80 cm plus any two of the following: (HDL cholesterol ,1.29 mmol/l, treatment for hypertension or blood pressure ≥130/85 mmHg,
diabetes diagnosed after age of 30 or fasting plasma glucose ≥5.6 mmol/l) [43].
*P, 0.001.
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knowledge, this is a novel ﬁnding. We also elaborate the results of
Rigourd et al. showing correlation between transcriptional alterations
of pre-eclamptic placentas (relative to controls) and JEG-3 cells over
expressing STOX1A (relative to mock-transfected JEG-3 cells)
(Rigourd et al., 2008). Transcriptional alterations in our decidua
basalis tissue (E-TABM-682) show the strongest correlation to
Rigourd’s data set in pre-eclamptic pregnancies complicated by FGR,
but not in non-pre-eclamptic pregnancies with FGR. Furthermore, in
a population- and registry-based cohort, we ﬁnd that women experi-
encing pre-eclampsia more than once are at a higher risk of compli-
cations and co-morbidity (preterm birth, lower birthweight and
development of metabolic syndrome) compared with those experien-
cing pre-eclampsia once. There is also a tendency towards higher
frequency of the C genotypes for the previously reported
STOX1A-Y153H variation (van Dijk et al., 2005) in this group of
women.
Reduced placental perfusion due to impairment of trophoblast inva-
sion and failed spiral artery remodelling are proposed to be pathogenic
features of both fetal growth restriction and pre-eclampsia (Brosens
et al., 1972, 1977). We believe the present study of decidua basalis
tissue, where these disease processes are taking place, to be an
important supplement to previous reports of STOX1 gene expression
in placental tissues (van Dijk et al., 2005; Iglesias-Platas et al., 2007;
Kivinen et al., 2007) and cultured trophoblast cells (van Dijk et al.,
2005, 2010; Rigourd et al., 2009). We show novel evidence that the
STOX2 gene is down-regulated in term decidua basalis from pre-
eclamptic women delivering FGR neonates. STOX2 resides on
chromosome 4q35, near a replicated region of suggestive linkage to
pre-eclampsia on chromosome 4q31-q32 (Harrison et al., 1997;
Moses et al., 2000; Laivuori et al., 2003). To our knowledge, the
role of STOX2 in the maternal– fetal interface is not known. Gene
duplication is an important evolutionary mechanism, and is a continu-
ous matter of research in evolutionary systems biology (Hughes, 2005;
Hittinger and Carroll, 2007). Studies of paralogous genes show that
duplication does not create genes with novel functions, but rather
daughter genes performing specialized sub functions of the ancestral
gene (Jensen, 1976; Conant and Wolfe, 2008). STOX2 has a high
sequence similarity to STOX1 (van Dijk et al., 2005; Kivinen et al.,
2007), and it is reasonable to hypothesize that it is involved in some
of the same biological processes. Therefore, the role of STOX2 in
.............................................................................................................................................................................................
Table V Genotyped SNPs within STOX1.
SNP Genotype (NN), Allele (N) Pre-eclampsia (proportion of total) Control (proportion of total) P-value
R18P Failed assay design
rs1341667 (Y153H) CC 412 (0.418) 840 (0.416) 0.9
CT 450 (0.456) 931 (0.462)
TT 124 (0.126) 245 (0.122)
C 1274 (0.646) 2611 (0.648)
T 698 (0.354) 1421 (0.352)
rs41278530 (L582F) Non-polymorphic
rs10509305 (E608D) AA 583 (0.591) 1206 (0.597) 0.5
AC 346 (0.351) 716 (0.355)
CC 57 (0.058) 97 (0.048)
A 1512 (0.767) 3128 (0.775)
C 460 (0.233) 910 (0.225)
rs41278532 (N825I) AA 953 (0.968) 1827 (0.972) 0.4
AT 28 (0.028) 50 (0.027)
TT 3 (0.004) 2 (0.001)
A 1934 (0.983) 3704 (0.986)
T 34 (0.017) 54 (0.014)
rs7904300 (A865T) Non-polymorphic
P-values were computed using Pearson’s x2 statistic.
.............................................................................................................................................................................................
Table VI The STOX1A-Y153H variation in severe subgroups of pre-eclamptic women.
Y153H variation Pre-eclampsia1 FGRa Recurrentb pre-eclampsia Control
Number of individuals genotyped 151 115 2010
Dominant model frequency CC + TC 0.881 0.930 0.878
OR* (CI) 1.0 (0.6–1.7) 1.9 (0.9–3.9)
P-value 0.92 0.09
aFGR, fetal growth restriction measured by birthweight below 2 SD for gestational age.
bMore than one pre-eclamptic pregnancy.
*OR for each of the subgroups of pre-eclamptic women compared with controls with 95% conﬁdence intervals (CIS) using x2 statistics.
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normal placental development as well as in the pathogenesis of pre-
eclampsia with FGR warrants further investigation. A comprehensive
assessment of genetic regulatory variation as well as a molecular func-
tional evaluation is required to conﬁrm the biological importance of
our observation.
Rigourd et al. recently showed a strong correlation between tran-
scriptional alterations in trophoblast cell-lines over expressing
STOX1A and transcriptional alterations shown in term pre-eclamptic
placentas (Rigourd et al., 2008). This supports the observation
made by others, that the possible disease-causing effects of STOX1
dysregulation are mediated through aberrant transcriptional regulation
of trophoblasts (van Dijk et al., 2005, 2010). The dysregulation of
STOX1 can potentially have deleterious effects as it affects the tran-
scription level of many other genes shown to be important in the
development of pre-eclampsia (such as Endoglidin, human Chorionic
Gonadotrophin, and Glial Cell Missing Homolog (Rigourd et al.,
2009). Furthermore, a direct effect of STOX1 on CTNNA3 expression
was recently conﬁrmed, affecting trophoblast differentiation and
growth (van Dijk et al., 2010b). When comparing the transcriptional
alterations of our deﬁned subgroups of women with the transcrip-
tional alterations in Rigourd’s trophoblast cell line over expressing
STOX1A, we conﬁrm their results from placental tissue in decidua
basalis. Furthermore, the observed correlation is strongest in the
group of women with both pre-eclampsia and FGR. Our ﬁndings
suggest that the STOX genes are associated with a severe fetal pheno-
type (FGR), interestingly though, only in pre-eclamptic patients, and
not in non-pre-eclamptic women delivering FGR neonates. This sup-
ports the opinion that FGR in pre-eclampsia and FGR alone represent
different pathogenic conditions, as discussed by others (Ness and
Sibai, 2006; Huppertz, 2008; Srinivas et al., 2009).
The analysis of gene expression in whole tissue harvested from
patients with manifest disease beneﬁts from describing the in vivo situ-
ation. However, interesting differences will potentially be masked due
to the heterogeneity of the material. Approximately 40% of cells in
decidua basalis are maternal leukocytes, 20% are extravillous tropho-
blast and 30% are decidual stromal cells (Benirschke et al., 2006). This
is a possible confounding factor; however, our results were inter-
preted in relation to, and are consistent with, earlier observations
(Rigourd et al., 2009; van Dijk et al., 2010b). Our ﬁndings are
limited to describing gene expression in decidua basalis samples col-
lected at birth; we do not report expression throughout the preg-
nancy. The strength of this study, however, is a thorough monitoring
by an obstetrician; multiple blood pressure and proteinuria measure-
ments, prenatal ultrasound measures and birthweight conﬁrmation,
providing a sound diagnostic basis (Eide et al., 2006).
There were no signiﬁcant differences in allele frequencies between
the case and control groups in the population-based cohort for the
genotyped candidate SNPs within STOX1. This is in agreement with
smaller population samples included in other studies (Berends et al.,
2007; Kivinen et al., 2007).
Severe pre-eclampsia is diagnosed by assessment of both maternal
and fetal phenotypes (Gifford et al., 2000). It has been shown that
mothers developing early onset pre-eclampsia have a higher preva-
lence of fetal growth restriction, as well as increased maternal morbid-
ity and cardiovascular risk later in life (Ness and Roberts, 1996;
Mostello et al., 2002; Brown et al., 2007). The MBRN did not
include information about onset of disease until 1998, and we are
therefore not able to include this parameter in our analyses. It has
been shown, however, that women developing severe pre-eclampsia
in the second trimester are at high risk of recurrent pre-eclampsia
as well as later life chronic hypertension and increased maternal mor-
bidity and mortality (Sibai et al., 1986, 1991; Odegard et al., 2000).
Therefore, research on multiparous pre-eclamptic women is encour-
aged as a tool of better understanding of disposition to, and develop-
ment of strategies for treatment and prevention of pre-eclampsia
(Gifford et al., 2000). Findings in our cohort are consistent with
earlier studies, as the recurrent group shows the highest risk of
preterm labour, of low fetal birthweight and the highest later life car-
diovascular risk, assessed as metabolic syndrome. We do ﬁnd a ten-
dency towards higher incidence of the C genotypes of the Y153H
mutation in the recurrent group under a dominant genetic model.
This ﬁnding is however, not signiﬁcant at the 5% level. Assessment
of the Y153H mutation in pre-eclamptic women delivering FGR neo-
nates did not show association. Thus, we cannot conﬁrm the hypoth-
esis that this variant is linked to severe pre-eclampsia, or
pre-eclampsia with FGR in the Norwegian population.
In the population-based part of the study, we are using registry data,
and some misclassiﬁcation can be expected. This will limit the power
to detect a true association. The prevalence and recurrence rates of
pre-eclampsia in MBRN are, however comparable to those reported
in other Nordic countries (Trogstad et al., 2001). Being born SGA
does not necessarily imply FGR, but can also reﬂect e.g. different eth-
nicity, constitutional smallness and chromosomal aberrations.
However, the growth curves used in this study are based on ultrasoni-
cally estimated fetal weights, appropriate for the population (which is
homogeneous) and considers the sex of the fetus (Marsal et al., 1996).
Furthermore, a stringent SGA deﬁnition of +2 SD is used, which is
more likely to identify the true FGR cases within the SGA group
(ACOG, 2002; Sheridan, 2005).This leads us to believe that SGA is
a good approximation to FGR in our study. Also, the possible maternal
imprinting effect on STOX1 is a matter of debate (Berends et al., 2007;
Iglesias-Platas et al., 2007; van Dijk et al., 2007). We are not able to
evaluate this in a case–control cohort, and epigenetic effects will
lessen our power to detect a true association. However, the strength
of this study is a large sample size, and the extensive clinical infor-
mation available.
In conclusion, we present novel observations suggesting involve-
ment of STOX2 in the pathogenesis of pre-eclampsia with FGR. We
conﬁrm Rigourd’s ﬁndings in decidual tissue, and link the transcrip-
tional alterations observed with STOX1A over expression to altera-
tions seen in deciduas of pre-eclamptic women delivering FGR
neonates. Conceivably, these ﬁndings might reﬂect a role for the
STOX genes in the pathophysiology of pre-eclampsia with FGR.
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Objectives: Endoplasmic reticulum (ER) stress has been implicated in both pre-eclampsia (PE) and fetal
growth restriction (FGR), and is characterised by activation of three signalling branches: 1) PERK-pEIF2a,
2) ATF6 and 3) splicing of XBP1(U) into XBP1(S). To evaluate the contribution of ER stress in the path-
ogenesis of PE relative to FGR, we compared levels of ER stress markers in decidual tissue from preg-
nancies complicated by PE and/or FGR.
Study design: Whole-genome transcriptional proﬁling was performed on decidual tissue from women
with PE (n ¼ 13), FGR (n ¼ 9), PEþFGR (n ¼ 24) and controls (n ¼ 58), and used for pathway and targeted
transcriptional analyses of ER stress markers. The expression and cellular localisation of ER stress
markers was assesses by Western blot and immunoﬂuorescence analyses.
Results: Increased ER stress was observed in FGR and PEþFGR, including both the PERK-pEIF2a and ATF6
signalling branches, whereas ER stress was less evident in isolated PE. However, these cases demon-
strated elevated levels of XBP1(U) protein. ATF6 and XBP1 immunoreactivity was detected in most
(>80%) extravillous trophoblasts, decidual cells and macrophages. No difference in the proportion of
immunopositive cells or staining pattern was observed between study groups.
Conclusions: Increased PERK-pEIF2a and ATF6 signalling have been associated with decreased cellular
proliferation and may contribute to the impaired placental growth characterising pregnancies with FGR
and PEþFGR. XBP1(U) has been proposed as a negative regulator of ER stress, and increased levels in PE
may reﬂect a protective mechanism against the detrimental effects of ER stress.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Impaired spiral artery remodelling is a prominent feature of the
decidua basalis in pregnancies complicated by pre-eclampsia (PE)
and/or fetal growth restriction (FGR) [1]. The incompletely
remodelled spiral arteries retain their musculo-elastic structure,
which renders the vessels more responsive to vasoactive stimuli.
Subsequent ﬂuctuation in uteroplacental blood supply is proposed
to cause ischaemia-reperfusion insults and oxidative stress [2].
Several studies have shown that decidual tissue is an important
source of oxidative stress [3,4], and increased levels of oxidative
stress have been reported in pregnancies complicated by PE and
FGR [3,5,6]. Furthermore, ischaemia-reperfusion insults can induce
endoplasmic reticulum (ER) stress in trophoblast-like cell lines [7].
The ER is an eukaryotic organelle involved in protein folding and
maturation, lipid synthesis and calcium homeostasis [8], as well as
sensing, coordinating and mediating stress responses [9,10].
Conditions that interfere with ER functions are collectively called
ER stress. Stimuli such as accumulation of unfolded proteins,
nutrient deprivation and oxidative stress can induce ER stress and
activate the unfolded protein response (UPR) [8,9]. The UPR is
a cellular self-defence mechanism, aiming to alleviate ER stress and
re-establish homeostasis [8]. Three ER transmembrane sensors,
Abbrevations: ER, endoplasmic reticulum; UPR, unfolded protein response;
PERK, PKR-like ER kinase; IRE1, inositol-requiring enzyme 1; ATF6, activating
transcription factor 6; EIF2a, eukaryotic translation initiation factor 2a; XBP1, X-box
binding protein 1.
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PKR-like ER kinase (PERK), inositol-requiring enzyme 1 (IRE1) and
activating transcription factor 6 (ATF6), regulate the UPR through
their respective signalling cascades [9]. Activated PERK phosphor-
ylates the eukaryotic translation initiation factor 2a (EIF2a), which
leads to attenuation of mRNA translation and a reduced ER work-
load [8]. IRE1 splices the constitutively expressed (unspliced)
mRNA of the X-box binding protein 1, XBP1(U), into a spliced iso-
form, XBP1(S) [11]. Both XBP1(U) and XBP1(S) mRNA are translated
into transcription factors, but XBP1(S) has higher transcriptional
activator activity [11]. The transcription factor ATF6 is activated by
proteolytic cleavage in the Golgi compartment [12]. With partly
overlapping functions, XBP1 and ATF6 initiate transcription of
genes that aim to increase protein folding capacity and degradation
of misfolded proteins in ER [8]. These multiple signalling pathways
allow for diversity in responses to ER stress, from minor homeo-
static adjustments to oxidative stress [13] and activation of
inﬂammatory pathways [10]. Additionally, if the cell fails to combat
ER stress, the UPR can trigger apoptosis to eliminate damaged cells
[9], but the manner in which the UPR switches from a protective to
an apoptotic role is complex and not fully understood [14].
Increased levels of ER stress have been detected in FGR and
PEþFGR placentas, where ER stress was associated with decreased
cellular proliferation and apoptosis, and proposed as an important
cause for the reduced placental growth characterising these
phenotypes [15,16]. We recently performed whole-genome tran-
scriptional proﬁling of decidual tissue from pre-eclamptic and
normal pregnancies, identifying upregulation of several transcripts
involved in ER stress in PE [17]. Thus, current data indicate that ER
stress is involved in the pathogenesis of both PE and FGR, but
whether the degree of ER stress differs between these pregnancy
complications is unknown. Emerging observations indicate that PE
and/or FGR may represent more or less severe stages on a contin-
uous spectrum of responses to impaired placentation, where
ischaemia-reperfusion insults and oxidative stress following
impaired spiral artery remodelling appear to be common patho-
physiological events [16,18]. However, as the clinical outcomes
differ, disparate phenomena must take place at some point during
the pathogenesis. Given the multiple responses ER stress may elicit,
differential activation of UPR signalling branches might explain
some of the differences in clinical outcome. The present study
aimed to compare the degree of ER stress in pregnancies compli-
cated by PE and/or FGR by analysing transcriptional- and protein
expression of key mediators in each branch of the ER stress
response.
2. Materials and methods
2.1. Study subjects
Women with pregnancies complicated by PE and/or FGR (cases) and women
with uncomplicated pregnancies (controls) were recruited at Trondheim University
Hospital (Norway) and Haukeland University Hospital (Bergen, Norway) from 2002
to 2006. PE was deﬁned as persistent hypertension (blood pressure of 140 mmHg
systolic or 90 mmHg diastolic), plus proteinuria (0.3 g in a 24 h urine collection
or  1þ according to a dipstick test), developing after 20 weeks of gestation [19]. PE
was sub-classiﬁed as severe in accordance with criteria recommended by Sibai et al.
[20]. FGR was deﬁned as birthweight <2.5 percentile adjusted for gestational age
and sex according to a Scandinavian normogram [21], in addition to at least one of
the following criteria: 1) reduced fundal height in serial measurements; 2) serial
ultrasound biometry identifying failure to grow along a consistent percentile; or 3)
abnormal umbilical artery waveform. Severe FGR was deﬁned as birthweigh <1.7
percentile [22]. Cases diagnosed with PE or FGR before gestational week 34 were
classiﬁed as early onset. Exclusively healthy women with no prior pregnancy
complications were included as controls. Pregnancies with chromosomal aberra-
tions, fetal and placental structural abnormalities or suspected perinatal infections
were excluded from both study groups. Cases had caesarean section (CS) performed
due to medical indications, whereas controls were undergoing CS for reasons
considered irrelevant to the aim of this study (i.e. breech presentation, previous CS
or maternal request). Only singleton pregnancies delivered by CS without labour
activity were included. The study was approved by the Norwegian Regional
Committee for Medical Research Ethics (REK no. 054-02) and informed consent was
obtained from all participants.
2.2. Decidual tissue
Decidua basalis tissue was collected by vacuum suction immediately after
separation of the placenta from the placental bed during CS [3,23]. The vacuum
suction procedure was performed in less than 1 min. Collected tissue was ﬂushed
with saline to remove excessive blood. Decidual tissue was placed in RNAlater (for
microarray analyses), 10% neutral-buffered formalin and parafﬁn embedded (for
immunohistochemical analyses) and snap frozen in liquid nitrogen (forWestern blot
analyses) within 15 min of tissue collection.
2.3. Illumina microarray analysis
Total RNA extracted from decidual tissue was used for synthesis of biotin
labelled anti-sense RNA (aRNA) which was hybridised to Illumina HumanWG-6 v2
Expression BeadChips (Illumina Inc., San Diego, CA) as previously described [17].
Microarray expression data were preprocessed and analysed using Sequential Oli-
gogenic Linkage Analysis Routines (SOLAR) [24] as previously described [25].
Microarray were performed in accordance with the Minimum Information About
a Microarray Experiment (MIAME) guidelines [26]. Experimental data have been
submitted to ArrayExpress (www.ebi.ac.uk/arrayexpress/) under accession no. E-
TABM-682. The microarray dataset was validated by quantitative real-time poly-
merase chain reaction (qRT-PCR) analyses for six of themost differentially expressed
transcripts as previously described [17].
Table 1
Primary and secondary antibodies used for Western blot and immunohistochemical analyses.
Species Manufacturer Catalogue no. Dilution Western blot Dilution immunoﬂuorescence
Primary antibodies
XBP1 Rabbit anti-human Santa Cruz Biotechnology, CA sc-7160 1:500 1:5
ATF6 Mouse anti-human Imgenex, San Diego, CA IMG-273 1:200 1:300
pEIF2a Rabbit anti-human Cell Signalling Technology, Danvers, MA #9721 1:1500
EIF2a Rabbit anti-human Cell Signalling Technology, Danvers, MA #9722 1:3000
b-actin Mouse anti-human Abcam, Cambridge, UK ab6276-100 1:30,000
CK7 Mouse anti-human Dako, Glostrup, Denmark M7018 1:750
CK7 Rabbit anti-human Abcam, Cambridge, UK ab52870 1:50
Vimentin Mouse anti-human Dako, Glostrup, Denmark M0725 1:200
Prolactin Rabbit anti-human Dako, Glostrup, Denmark A0569 1:60
CD68 Mouse anti-human Dako, Glostrup, Denmark M0814 1:1000
CD68 Rabbit anti-human Santa Cruz Biotechnology, CA sc-9139 1:5
Secondary antibodies
IRDye 680 Goat anti-rabbit Li-Cor Biosciences, Cambridge, UK #926-32221 1:5000
IRDye 800CW Donkey anti-mouse Li-Cor Biosciences, Cambridge, UK #926-32212 1:5000
FITCa Goat anti-mouse Dako, Glostrup, Denmark F0479 1:10
TRITCb Swine anti-rabbit Dako, Glostrup, Denmark R0156 1:10
a Fluorescein iso-thiocyanate.
b Tetramethyl rhodamine iso-thiocyanate.
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2.4. Pathway and targeted transcriptional analyses of ER stress markers
We recently performed whole-genome transcriptional proﬁling of decidual
tissue from pre-eclamptic and normal pregnancies, identifying upregulation of
several transcripts involved in ER stress in PE. In the previous study, we solely
focused on PE associated transcriptional changes, i.e. using only a subset of the total
microarray dataset used in this work [17]. To further explore the role of ER stress in
the pathogenesis of both PE and FGR, we performed pathway analyses on a group of
20 ER stress related transcripts (as annotated by Ingenuity Pathway Analysis)
(Supplementary Table 1) in cases and controls. Pathway analyses were performed
using Rotation Gene Set Tests (ROAST) and Rotation Gene Set Enrichment Analysis
(ROMER), implemented in the limma package [27] available via the Bioconductor
Project (www.bioconductor.org). ROAST was used to test whether any of the tran-
scripts in the pathway were differentially expressed [28] and ROMER was used to
test whether the subset of transcripts in the pathway was more differentially
expressed than any other subset of transcripts in the total dataset [29]. As a second
step in our approach, three central ER stress marker from each branch of the UPR
(ATF6, XBP1 and PERK), known to be upregulated by ER stress [30,31], were selected
for a targeted transcriptional comparison to test if there was any differential UPR
activation between cases with PE, FGR, PEþFGR and controls.
2.5. Western blotting
Decidual tissue was homogenised in lysis buffer (Active Motif, Rixensart,
Belgium) using a rotor-stator homogeniser (Ultra-Turrax T25, Janke & Kunkel IKA
Labortechnik, Staufen, Germany). Total protein extracts were prepared using
a Nuclear extract kit (#40010, Active Motif), following manufacturer’s instructions.
Homogenised decidual tissue was lysed on ice for 30 min and cell debris pelleted at
14,000 g at 4 C for 20 min. The supernatant was recovered and equal amounts
(100 mg) of protein were separated on precast 10% denaturing NuPAGE gels (Invi-
trogen Life Technologies, Carlsbad, CA) and transferred to polyvinylidene diﬂuoride
(PVDF) membranes (Millipore, Billerica, MA). Membranes were blocked in Odyssey
blocking buffer (Li-Cor Biosciences, Cambridge, UK) for 1 h at room temperature (RT)
before incubating with primary antibodies against pEIF2a, EIF2a, XBP1 and ATF6.
The antibody against XBP1 detected both spliced and unspliced variants of XBP1
[32,33], and the antibody against ATF6 detected both cleaved and uncleaved ATF6
[33,34]. Blots were reprobed with b-actin as a loading control. Primary antibodies
were diluted in Odyssey blocking buffer (Li-Cor Biosciences) and hybridised to the
membranes overnight at 4 C. Membranes were washed 3  10 min in tris-buffered
saline (TBS) and incubated with ﬂuorescently labelled secondary antibodies diluted
in Odyssey blocking buffer (Li-Cor Biosciences) for 1 h at RT. Speciﬁcations for the
primary and secondary antibodies are listed in Table 1. Membranes were scanned
using the Odyssey Infrared Imaging System (Li-Cor Biosciences). Speciﬁc bands for
pEIF2a (37 kDa), EIF2a (37 kDa), XBP1(U) (31 kDa), XBP1(S) (54 kDA), ATF6 (50 kDA)
and b-actin (42 kDa) were detected in all samples. Band intensities were determined
from two or three scans, normalised relative to loading control and quantiﬁed by
densitometric analysis using Odyssey imaging software v3.0 (Li-Cor Biosciences).
2.6. Immunohisotchemical analyses
Cellular localisation and expression of ATF6 and XBP1 in decidual tissue was
assesses using the same antibodies against XBP1 and ATF6 as used in Western blot
experiments, in combination with antibodies against cytokeratin 7 (CK7) to detect
extravillous trophoblasts (EVTs), vimentin and prolactin to detect decidual cells
(DeCs), and CD68 to detect macrophages (M4s). Double immunoﬂuorescence
staining was performed manually after deparafﬁnation in xylen, rehydration and
heat-induced antigen retrieval in TBS. Protein Block (X0909, Dako, Glostrup,
Denmark) was added for 10 min to inhibit non-speciﬁc binding, and slides were
incubated in a primary antibody mixture overnight at 4 C. The slides were incu-
bated with appropriate species-speciﬁc secondary antibodies for 30 min in a dark
chamber. Slides were examined using a ﬂuorescent microscope (Nikon Eclipse 90i
with CytoVision 3.7 software, Applied Imaging, New Milton Hampshire, UK) at
magniﬁcation600. Decidual glands, tonsil tissue and pituitary glands were used as
positive controls for CK7, vimentin/CD68 and prolactin, respectively. For negative
controls, primary antibodies were substituted with isotype-matched rabbit- (#011-
000-120, Jackson ImmunoResearch, PA) and mouse (#400102, BioLegend, CA)
immunoglobulins. Speciﬁcations for the primary and secondary antibodies are listed
in Table 1. The proportion of XBP1 and ATF6 immunopositive EVTs, DeCs and M4s
was counted in ﬁve randomly selected ﬁelds on each slide, and calculated as the
number of positive cells among the total number of CK7, vimentin/prolactin or CD68
positive cells, respectively.
2.7. Statistical analyses
Nonparametric data were analysed using ManneWhitney U test, whereas
parametric data were analysed using the Students t-test. Fisher’s exact test and c2
test were used for categorical data, and Spearman’s rank correlation was used for
correlation analyses. The signiﬁcance threshold was set to 0.05. All analyses were
performed using SPSS v15 (SPSS, Chicago, IL).
3. Results
3.1. Clinical characteristics of the study subjects
Clinical characteristics of the study subjects included in the
microarray analysis are presented in Table 2. A total of 104 samples
were included (PE, n¼ 13; FGR, n¼ 9; PEþFGR, n¼ 24 and controls,
n ¼ 58). As expected, elevated blood pressure was observed in
pregnancies with PE and PEþFGR, and lower gestational age and
birthweight were observed in all case groups (Table 2).
A total of 30 samples (PE, n ¼ 7; FGR, n ¼ 7; PEþFGR, n ¼ 8 and
controls, n ¼ 8) were included in Western blot analysis (Table 3).
Table 2
Clinical characteristics of the study subjects included in the Microarray analysis (n ¼ 104).
PE (n ¼ 13) FGR (n ¼ 9) PEþFGR (n ¼ 24) Controls (n ¼ 58)
Maternal age (y) 30.1  5.4 32.7  6.4 29.7  5.5 32.4  5.1
Systolic BP (mmHg) 153.1  17.5** 128.3  14.7* 151.0  14.9** 116.2  10.4
Diastolic BP (mmHg) 94.7  8.6** 74.4  8.3 96.2  12.1** 69.9  8.8
BMI (kg/m2)a 29.2  6.3 28.5  7.5 26.4  6.1 26.0  4.5
Primipara 8/13 4/9 16/24 29/55b
GA (weeks) 34.8  2.7** 31.9  5.0** 30.3  3.5** 38.7  0.8
Birthweight (g) 2363.9  509.7** 1224.7  672.4** 1118.2  470.1** 3608.3  491.9
Data are presented as means  SD, *p < 0.05 and **p < 0.001 comparing pre-eclampsia (PE), fetal growth restriction (FGR) and PEþFGR to controls; BP, blood pressure.
a BMI, Body Mass Index measured at ﬁrst antenatal care visit.
b No info available for three of the controls; GA, gestational age.
Table 3
Clinical characteristics of the study subjects included in the Western blot analysis (n ¼ 30).
PE (n ¼ 7) FGR (n ¼ 7) PEþFGR (n ¼ 8) Controls (n ¼ 8)
Birthweight (g) 2137.1  259.6** 1363.1  753.8** 1105.3  329.1** 3576.3  507.1
Placenta weight (g) 447.8  30.3* 269.2  115.0* 261.3  55.9** 657.9  163.9
Placenta Weight Ratioa 1.0  0.3 0.5  0.2* 0.7  0.1* 0.9  0.1
Severe PE or FGR 5/7 6/7 8/8
Early onset < 34 weeks 7/7 5/7 8/8
Mean uterine artery scoreb 2.4** 2.2* 3.5** 0
Data are presented as means  SD; *p < 0.05, **p < 0.001 comparing pre-eclampsia (PE), fetal growth restriction (FGR) and PEþFGR to controls.
a Placenta Weight Ratio was calculated as observed/expected placenta weight according to gestational age and sex according to a Norwegian normogram [42].
b Uterine artery score is based on pulsatility index and notching in Aa.uterinae [43]; Blood pressure, maternal age, gestational age, Body Mass Index and parity did not differ
statistically from that of women included in the microarray analysis (Table 2).
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Twenty-four of these were also included in the microarray study
population, whereas the remaining six were selected from our total
study population, but not included in microarray analyses due to
low RNA quality. As ER stress probably arises secondary to
ischaemia-reperfusion insults, we selected cases with clinical
characteristics suggesting vascular malperfusion, which is closely
associatedwith abnormal uterine artery Doppler ﬁndings andmore
common in early onset, severe PE [35] and severe FGR [36]. Thus,
only cases with severe clinical characteristics were included, i.e.
cases with uterine artery score  1 and/or early onset PE or FGR
(Table 3). The mean uterine artery score was higher in all case
groups compared to controls, whereas the placental weight ratio
was lower in cases with FGR and PEþFGR as compared to controls
(Table 3). Sixteen decidual samples selected from the Western blot
study population were included in immunohistochemical analyses
(PE, n ¼ 4; FGR, n ¼ 4; PEþFGR, n ¼ 4 and controls, n ¼ 4). The
clinical characteristics of these samples did not differ from those
included in Western blot analyses.
3.2. Pathway and targeted transcriptional analyses of ER stress
markers
Pathway analyses (ROAST and ROMER) showed that the ER
stress pathway was upregulated in cases with FGR and PEþFGR,
whereas in PE, a trend towards upregulation was observed
(Table 4). The targeted comparison of transcript data for XBP1, ATF6
and PERK demonstrated that cases with FGR had increased
expression of ATF6, cases with PEþFGR had increased expression of
XBP1, ATF6 and PERK, whereas XBP1 was increased in PE (Table 4).
The Illumina probe interrogating XBP1 (ILMN_1710675) detected
both the spliced and unspliced XBP1 variants. No differences
between the case groups were observed for any of these three
transcripts (data not shown).
3.3. Western blot analyses
Cases with FGR and PEþFGR showed increased phosphorylation
of EIF2a (p < 0.05), increased ratio of pEIF2a/EIF2a (p < 0.05) and
increased levels of ATF6 (p < 0.01) (Fig. 1AeC). Although cases with
PE had high mean levels of pEIF2a/EIF2a and ATF6, large variations
within this group rendered the results non-signiﬁcant in compar-
ison to controls (p¼ 0.09 and 0.43, respectively), as indicated by the
larger standard deviation bars for the PE group in Fig. 1BeC. No
differences in protein levels of the spliced form of XBP1, XBP1(S),
were observed between any of the case groups compared to
controls. However, increased levels of the unspliced form of XBP1,
XBP1(U), and a decreased ratio of XBP1(S)/XBP1(U) were observed
in isolated PE (p < 0.05 and 0.01, respectively) (Fig. 1A and C). The
levels of XBP1(U) was higher in PE compared to that of FGR, and the
ratio of XBP1(U)/XBP1(S) was lower in PE compared to FGR (all
p’s< 0.05). No differences in protein levels of pEIF2a/EIF2a, ATF6 or
XBP1(S) were observed between case groups.
3.4. Immunohistochemical analyses
Both cytoplasmic and nuclear immunoreactivity for XBP1 and
ATF6 was observed inmost (>80%) EVTs, DeCs andM4s (Fig. 2 A,A0-
R,R0). No differences in the proportion of XBP1 or ATF6 immuno-
positive cells or staining pattern were observed between the study
groups. In general, XBP1 and ATF6 immunoreactivity was present in
most cells in the decidual tissue, in contrast to tonsil tissue and
pituitary glands, inwhich only a few cells were positive (not shown).
Decidual glands displayed intense nuclear immunoreactivity for
XBP1 in both cases and controls (Fig. 2S). No differences in staining
Table 4
Pathway and targeted transcriptional analyses of ER stress related transcripts.
PE vs. controls FGR vs. controls PEþFGR vs. controls
Pathway analysisa
ROAST p ¼ 0.06 (NS) [, p < 0.05 [, p < 0.001
ROMER p ¼ 0.09 (NS) [, p < 0.05 [, p < 0.05
Microarray analysisb
XBP1 [, p < 0.01 p ¼ 0.07 (NS) [, p < 0.05
ATF6 p ¼ 0.22 (NS) [, p < 0.05 [, p < 0.001
PERK p ¼ 0.09 (NS) p ¼ 0.55 (NS) [, p < 0.05
a Rotation Gene Set Tests (ROAST) and Rotation Gene Set Enrichment Analysis
(ROMER) pathway analyses of 20 transcripts involved in the endoplasmic reticulum
(ER) stress response (Supplementary Table 1).
b A targeted comparison of transcription data for ER stress markers from each
branch of ER stress response; NS, not signiﬁcant; [, upregulation.
Fig. 1. Western blot analyses of endoplasmic reticulum (ER) stress markers in decidual
tissue from pregnancies complicated by pre-eclampsia (PE, n ¼ 7), fetal growth
restriction (FGR, n ¼ 7), PEþFGR (n ¼ 8) and controls (n ¼ 8). (A) A representative
Western blot of phosphorylated and total EIF2a, ATF6, spliced (S) and unspliced (U)
forms of XBP1 and loading control (b-actin). (B and C) Densitometry of bands
expressed relative to controls (100%), showing increased levels of pEIF2a and ATF6 in
pregnancies complicated by FGR and PEþFGR. Increased levels of XBP1(U) and
a decreased XBP1(S)/XBP1(U) ratio were observed in pregnancies complicated by PE.
Phosphorylation status of EIF2a is presented as the ratio between phosphorylated and
total level of EIF2a. No signiﬁcant differences in EIF2a were observed between any of
the study groups. Data are presented as means  SE, *p < 0.05 as compared to controls.
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intensity of XBP1 and ATF6 were observed between the study
groups in any of the evaluated cell types.
3.5. Correlation analyses
Correlation analyses demonstrated a negative correlation
between the pEIF2a/EIF2a ratio and the placental weight ratio
(rs ¼ 0.561, p < 0.05). A similar tendency was observed for ATF6
(rs ¼ 0.352, p ¼ 0.072). None of the ER stress markers were
correlated with gestational age.
4. Discussion
In this work, we have shown that decidual ER stress is increased
in pregnancies complicated by FGR and PEþFGR. Initially, this was
demonstrated by pathway analyses, showing upregulation of the
ER stress pathway in FGR and PEþFGR. In addition, targeted tran-
scriptional and protein analyses showed upregulation of the PERK-
pEIF2a and ATF6 signalling branches of the UPR. In PE, none of
these branches were signiﬁcantly altered However, a marked
increase in XBP1(U) was observed. These results indicate divergent
activation of the UPR in FGR and PEþFGR compared to isolated PE.
Consistent with our ﬁnding of increased pEIF2a in deciduas
from FGR and PEþFGR, increased placental levels of pEIF2a have
previously been reported in these cases [15]. In trophoblast-like cell
lines, increased levels of pEIF2a were associated with reduced
proliferation through suppression of protein synthesis and
decreased survival [15]. The net effect of reduced proliferation and
cell survival was proposed as a cause for reduced placental growth
in pregnancies with FGR and PEþFGR [15,16], which are charac-
terised by decreased placental villous tissue volume and surface
area [37]. Of relevance, we observed that the pEIF2a/EIF2a ratiowas
negatively correlated with placental weight ratio, with a similar
tendency for ATF6, suggesting an association between ATF6 and
PERK-pEIF2a signalling and reduced placental weight.
Cases with isolated PE only showed a trend towards upregula-
tion of the ER stress response. However, we observed increased
levels of XBP1 mRNA and XBP1(U) protein in isolated PE. It was
recently shown that XBP1(U), the constitutively expressed form of
XBP1, accumulates in the recovery phase of ER stress [38] and is
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Fig. 2. Immunoﬂuorescensce analyses of XBP1 and ATF6 in extravillous trophoblasts (EVTs), decidual cells (DeCs) and macrophages (M4s), identiﬁed using antibodies against
cytokeratin 7, vimentin/prolactin and CD68, respectively. Nuclei were counterstained with 40-6-diamidino-2-phenylindole (DAPI) (blue signal). Cytoplasmic and nuclear immu-
noreactivity of XBP1 (red signal) was observed in EVTs, DeCs and M4s in both cases with PE and/or FGR (AeI) and controls (A0eI0). A similar staining pattern was observed for ATF6
(green signal) for the same cell types in cases with PE and/or FGR (JeR) and controls (J0-R0). In decidual glands, strong nuclear immunoreactivity for XBP1 (red signal) was observed
(S). No positive staining was found in negative controls where primary antibodies were substituted with isotype-matched immunoglobulins of the appropriate species (T).
Magniﬁcation 600 in D0-F0, S and T, otherwise 1000. Scale bar 2 mm.
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able to inhibit XBP1(S) and ATF6, implying that XBP1(U) functions
as a negative regulator during ER stress [39,40]. This correlates well
with our ﬁnding of the highest level of XBP1(U) and the lowest level
of XBP1(S) in PE, and that ATF6 was not signiﬁcantly increased in
these cases. Based on this, it is tempting to speculate that IRE1-
XBP1 signalling via upregulation of XBP1(U) may protect against
or decrease the effects of ER stress in PE, which could be reﬂected
by the normal placental weigh ratio observed in this group.
Correspondingly, reduced placental weight in FGR and PEþFGR, but
not in isolated PE, was recently reported in a Norwegian cohort of
317,688 pregnancies [41].
Both nuclear and cytoplasmic immunoreactivity for XBP1 and
ATF6 was observed in EVTs, DeCs and M4s, but no differences in
the proportion of immunoreactive cells or staining pattern was
observed between the study groups. No differences in cytoplasmic
staining intensity for XBP1, representing XBP1(U), or nuclear
staining intensity of ATF6, representing cleaved ATF6, were
detected in any of these cell types between the study groups. In
general, nuclear staining intensity was difﬁcult to assess due to
photobleaching. Thus, no determination of the cellular source of
increased levels of XBP1(U) or cleaved ATF6 in decidual tissue, as
detected by Western blot, could be made by immunoﬂuorescence
analysis. However, we cannot exclude that other cell types in the
decidua, that were not evaluated in the present work may have
contributed to the increased ATF6 and XBP1(U) levels.
In summary, we found that decidua basalis is a source of ER
stress, and that ER stress is increased in pregnancies complicated by
FGRandPEþFGR. In PE,we found increased levels of XBP1(U),which
maybe a protectivemechanismagainst the detrimental effects of ER
stress. This could explain someof the observed clinical differences in
between PE and FGR. However, future studies are warranted to test
this hypothesis and elucidate the implications of our ﬁndings.
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Short title:  
Genetic risk preeclampsia and CVD
ABSTRACT 
 
Objective: Four putative single nucleotide polymorphism (SNP) risk variants at the preeclampsia 
susceptibility locus on chromosome 2q22; rs2322659 (LCT), rs35821928 (LRP1B), rs115015150 
(RND3) and rs17783344 (GCA), were recently shown to associate with known cardiovascular 
risk factors in a Mexican American cohort. This study aimed to further evaluate the pleiotropic 
effects of these preeclampsia risk variants in an independent Australian population-based cohort.  
Methods: The four SNPs were genotyped in the Western Australian Pregnancy Cohort (Raine) 
Study that included DNA, clinical and biochemical data from 1,246 mothers and 1,404 of their 
now adolescent offspring. Genotype association analyses were undertaken using the SOLAR 
software. 
Results: Nominal associations (P < 0.05) with cardiovascular risk factors were detected for all 
four SNPs. The LCT SNP was associated with decreased maternal height (P = 0.005) and 
decreased blood glucose levels in adolescents (P = 0.022). The LRP1B SNP was associated with 
increased maternal height (P = 0.026) and decreased maternal weight (P = 0.044). The RND3 
SNP was associated with decreased triglycerides in adolescents (P = 0.001). The GCA SNP was 
associated with lower risk in adolescents to be born of a preeclamptic pregnancy (P = 0.003) and 
having a mother with prior preeclamptic pregnancy (P = 0.033).   
Conclusions: Our collective findings support the hypothesis that genetic mechanisms for 
preeclampsia and CVD are, at least in part, shared, but need to be interpreted with some caution 
as a Bonferroni correction for multiple testing adjusted the statistical significance threshold 
(adjusted P < 0.001). 
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Introduction 
Women with a history of preeclampsia and offspring exposed to preeclampsia in utero are 
at increased risk of cardiovascular disease (CVD) later in life [1-3]. A large review and meta-
analysis found that women with a history of preeclampsia have approximately four-fold increased 
risk of chronic hypertension, and two-fold increased risk of coronary artery disease and stroke 
10-15 years after pregnancy [1]. The offspring of women with preeclampsia have higher mean 
systolic and diastolic blood pressure in childhood and early adult life in both genders, including 
those with normal birth weight [4-6]. Furthermore, they have almost a two-fold greater risk of 
stroke in adulthood [3]. Preeclampsia is now widely viewed as an early screening criterion for 
CVD in women. Pregnancy is a unique opportunity to identify both women and offspring at 
increased risk of premature CVD [7], and clinical risk assessments and preventive programmes 
are under development [8].  
Preeclampsia and CVD share several constitutional risk factors (e.g. hypertension and 
obesity) [9], pathological features (e.g. endothelial dysfunction and inflammation) [10, 11], and 
tend to occur in the same families [12]. These common antecedents have drawn attention to the 
likelihood of shared genetic susceptibility [13, 14]. Supporting this notion are several 
cardiovascular risk factors present years before a preeclamptic pregnancy, including increased 
blood pressure, higher levels of serum cholesterol, higher levels of low density lipoprotein 
(LDL)-cholesterol and higher levels of triglycerides [15]. Moreover, the positive association 
between preeclampsia and CVD is more dependent on these shared pre-pregnancy risk factors 
than the influence of the hypertensive disorder in the pregnancy itself [16]. This has encouraged 
the search for genetic determinants common to both disorders. However, to date only a few 
shared genetic risk factors have been identified [17-20].  
Recently, our genetic dissection of the 2q22 preeclampsia susceptibility locus identified 
four independent single nucleotide polymorphism (SNP) risk variants, residing within four genes, 
to associate with preeclampsia in an Australian family cohort [19]: lactase (LCT, rs2322659), low 
density lipoprotein receptor-related protein 1B (LRP1B, rs35821928), rho family GTPase 3 
(RND3, rs115015150) and grancalcin (GCA, rs17783344). Furthermore, these same four SNPs 
were associated with cardiovascular risk factors in an independent cohort of Mexican American 
families, suggesting pleiotropic effects for these SNPs [19]. The aim of this study was to 
determine whether these four SNPs exhibited pleiotropic characteristics with preeclampsia 
susceptibility and cardiovascular risk factors in an independent Australian population-based 
cohort consisting of mothers and their adolescents. Identifying common genetic factors 
influencing preeclampsia and CVD may provide insight into pathophysiological mechanisms 
relevant to both disorders. 
 
 
Materials and methods 
Study population 
The Western Australian Pregnancy Cohort (Raine) Study is a pregnancy cohort where 
women were recruited prior to 18 weeks’ gestation from the public antenatal clinic at King 
Edward Memorial Hospital or surrounding private clinics in Perth, Western Australia. The study 
has been described in detail elsewhere [21]. Pregnant women (n = 2,900) were enrolled between 
August 1989 and April 1992, and they gave birth to 2,868 live babies. From the original cohort of 
women, their children have been followed up over the last two decades with detailed assessments 
performed every 2-3 years. In the current study, data from the pregnant women, the neonates, and 
the 8-, 14- and 17-year cohort follow-ups were assessed, as shown in Fig. 1. Only subjects that 
had two Caucasian parents, were biologically unrelated, and who had no congenital deformities, 
were included in the current study.  
Informed written consent was obtained at recruitment and at each follow-up from the 
mother or legal guardian as well as from the adolescent during the 14- and 17-year cohort follow-
ups. Ethical approval was obtained for all protocols from the Human Ethics Committees of King 
Edward Memorial Hospital, Princess Margaret Hospital Ethics Committee, Perth, Western 
Australia and The University of Western Australia. 
 
Antenatal information 
At recruitment the mothers completed self-administrated questionnaires concerning their 
pregnancies and demographic information. The presence of preeclampsia and history of 
preeclampsia were collected from the mother at antenatal visits at the delivery units and later 
assessed from the medical records. The medical records were reviewed by obstetricians and 
research midwives to confirm a standardised diagnosis of preeclampsia as a pregnancy-induced 
increase in systolic blood pressure 140 mmHg and/or a diastolic blood pressure 90 mmHg in 
women who were normotensive before the 24th week of pregnancy, combined with significant 
new onset proteinuria ( 0.3 g/l in a 24-hour specimen) [22].  
 
Blood pressure, anthropometry and blood samples 
Detailed information on measures of blood pressure, anthropometry and biochemistry, is 
given in detail elsewhere [23, 24]. Briefly, blood pressure was measured with an automatic 
device (Dinamap Vital Signs Monitor 8100, Dinamap XL Vital Signs Monitor or Dinamap 
ProCare 100; GE Healthcare) after 5 minutes rest and using the appropriate cuff size. Six 
readings were recorded, and the average value was calculated after excluding the first reading. 
Height and weight were measured with light clothing and without shoes. Height was measured 
with Holtain Infantometer and Stadiometer (to the nearest 0.1 cm), and weight was measured on 
Wedderburn Scales (to the nearest 100 g). Fasting venous blood samples were drawn for DNA 
and biochemical analyses. Serum insulin, glucose, total cholesterol, high density lipoprotein 
(HDL)-cholesterol, LDL-cholesterol and triglycerides were measured in the PathWest Laboratory 
at Royal Perth Hospital as described previously [23, 24].  
 
Cardiovascular risk factors 
Cardiovascular risk factors assessed included resting systolic and diastolic blood pressure, 
height, weight, waist-hip ratio, abdominal skinfold, and fasting insulin, glucose, total cholesterol, 
HDL-cholesterol, LDL-cholesterol and triglycerides. Maternal data was obtained from an 
examination and blood sample taken when their children attended the 8-year cohort follow-up 
and included 1,685 mothers. Adolescent data was obtained during the 14- and 17-year cohort 
follow-ups and included 1,293 [23] and 1,053 [24] participants, respectively.  
 
DNA extraction and SNP genotyping 
DNA was extracted from blood samples taken from mothers and adolescents at the 14- or 
17-year cohort follow-ups as described elsewhere [25]. Briefly, DNA was extracted from 4 mL 
ethylenediaminetetraacetic acid (EDTA) anticoagulated blood using Qiagen PureGene chemistry 
(Qiagen, Hilden, Germany). Four independent SNPs in four genes, rs2322659 (LCT), rs35821928 
(LRP1B), rs115015150 (RND3) and rs17783344 (GCA), were genotyped for mothers and 
adolescents. For the mothers de novo genotyping of the four SNPs was performed. For the 
adolescents de novo genotyping was performed for rs35821928 and rs115015150. The rs2322659 
and rs17783344 SNPs had already been genotyped in a previously performed genome wide 
association study (GWAS) [26]. De novo genotyping was commercially performed by 
KBioscience (KBioscience, Hertfordshire, UK), with the use of their proprietary fluorescence-
based competitive allele-specific PCR genotyping assay, KASP™. Genotyping and quality 
control of GWAS data have been described in detail elsewhere [26]. Briefly, the Raine adolescent 
samples were genotyped on the Illumina Human 660W-Quad SNP Chip (Illumina Inc., San 
Diego, CA, USA) at the Centre for Applied Genomics (Toronto, Ontario, Canada). Individual 
samples were checked (and excluded accordingly) for gender inconsistencies, levels of 
heterozygosity and inter-sample relatedness.  
 
Statistical analysis 
The software package R (www.r-project.org) was used to compute descriptive statistics, 
means and 95% confidence intervals (CI). Phenotypes of interest included cardiovascular risk 
factor measurements and maternal pregnancy characteristics.  
 
SNP association analysis 
Measured genotype association analyses were undertaken for all phenotypes applying 
variance-component methods as implemented in SOLAR [27]. Because variance-component 
methods are sensitive to kurtosis, all quantitative phenotypes were transformed using SOLAR’s 
inverse normalization procedure. Genetic association was tested for each SNP under an additive 
genetic model allowing mean phenotype value to vary by minor allele. This model was compared 
with the null model of no difference in mean phenotype value by SNP genotype using a 
likelihood ratio test. Twice the difference in log-likelihoods of these models was distributed as a 
2 random variable with 1 degree of freedom. Concordance with Hardy-Weinberg proportions 
was tested using 2 goodness-of-fit statistic. A threshold of  = 0.05 was set for statistical 
significance of all computed analyses. Adjustment for multiple hypothesis testing was performed 
using Bonferroni corrections (/(total number of SNPs x total number of phenotypic traits)).  
 Cardiovascular risk factors including height, weight, blood pressure, and cholesterol, have 
consistently been demonstrated to correlate between relatives. This could reflect genetic- and/or 
shared life style effects [28]. Therefore we performed genetic association analysis to examine the 
association between total maternal genotype and total adolescent phenotype, and vice versa. We 
did not look specifically at mother-offspring pairs. In addition, we performed separate association 
analyses for girls and boys for all cardiovascular risk factors aiming to detect differences in 
genetic risk profiles between the adolescent’s genders. 
  
 
Results 
Clinical characterisation 
At the 14-year follow-up 629 (48.6%) girls and 664 (51.3%) boys participated, whereas at 
the 17-year follow-up 509 (48.3%) girls and 544 (51.7%) boys participated. Of the enrolled 
women (mothers of the adolescents) with accessible DNA for genotyping, 40 (3.2%) were 
diagnosed with preeclampsia in the index pregnancy, and 31 (2.5%) had previously experienced a 
preeclamptic pregnancy. The mean age for the index pregnancy was 28.2 years. Clinical and 
biochemical characteristics of mothers and adolescents are presented in Table 1. 
 
SNP genotyping and association analysis 
De novo DNA data was available for 1,246 of the mothers. De novo DNA data was 
available for 1,461 of the adolescents and GWAS DNA data was available for 1,494 adolescents. 
After exclusion of children with congenital deformities, siblings and non-Caucasians, DNA from 
1,246 mothers and 1,404 adolescents were included in the final analysis. We observed a high 
genotyping success rate for all four SNPs (>97%). Allele frequencies for mothers and adolescents 
are presented in Table 2, and are consistent with frequencies observed by Johnson et al. [19]. 
Except for the LCT (rs2322659) SNP for mothers, all SNPs confirmed to Hardy-Weinberg 
proportions (P > 0.05).  
Measured genotype association results were undertaken for all phenotypes and adjusted 
for sex and maternal age (raw P < 0.05). The results are presented in Table 3 and 4 for mothers 
and adolescents respectively. Carrying the A allele of LCT rs2322659 was associated with 
decreased levels of the adolescent’s blood glucose in both mothers and adolescents (P = 0.003 
and P = 0.022, respectively) and decreased maternal height (P = 0.005) in mothers. Carrying the 
T allele of LRP1B rs35821928 was associated with increased maternal height in both mothers and 
adolescents (P = 0.026 and P = 0.013, respectively) and decreased maternal weight (P = 0.044) in 
mothers. An association between the A allele of RND3 rs115015150 and decreased adolescent’s 
waist-hip ratio (P = 0.030) was observed in mothers, whereas this SNP was associated with 
decreased level of adolescent’s triglycerides (P = 0.001) in adolescents. In mothers, carrying the 
C allele of GCA rs17783344 was associated with increased adolescent’s height (P = 0.045), 
whereas in adolescents carrying the C allele was associated with lower risk to be born of a 
preeclamptic pregnancy (P = 0.003) and lower risk to have a mother who previously had 
experienced a preeclamptic pregnancy (P = 0.033). The two latter associations were related to 
male gender (P = 0.009 and P = 0.0372, respectively). However, after accounting for the four 
SNPs tested across the 14 phenotypes, none of the association results satisfy our Bonferroni-
adjusted statistical significance threshold (adjusted P < 0.001).  
 
Discussion 
The basis for this study was the recently reported shared genetic mechanisms putatively 
influencing preeclampsia and cardiovascular risk factors [19]. We have now assessed these 
independent putative pleiotropic variants representing four genes; rs2322659 (LCT), rs35821928 
(LRP1B), rs115015150 (RND3) and rs17783344 (GCA), in an independent Australian population-
based pregnancy cohort. We observed shared genetic associations between specific SNPs and 
known cardiovascular risk factors, for mothers and their offspring. However, we were unable to 
replicate many of the genetic associations previously reported by Johnson et al. [19]. To our 
knowledge, this is the first published study that has assessed possible shared genetic risk factors 
for preeclampsia and CVD in both mothers and their offspring.  
Johnson et al. found the A allele of the LCT SNP protective for preeclampsia, and 
nominally associated with oxidative stress indicators, inflammatory- and diabetic biomarkers 
[19]. Supportive of protective pleiotropic effects on preeclampsia and cardiovascular risk factors, 
we found the A allele of the LCT SNP to be nominally associated with decreased glucose levels 
in the adolescents. To date, there is limited evidence of the association between exposure to 
preeclampsia in utero and the offspring’s fasting glucose metabolism later in life [5, 6]. The LCT 
SNP was out of Hardy-Weinberg equilibrium for mothers, the same observation made by 
Johnson et al. in their Australian preeclampsia case-control cohort [19]. This could possibly be 
explained by locus-specific population stratification, and has been thoroughly discussed 
elsewhere [19, 29].  
LRP1B, a member of the LDL receptor gene superfamily, has recently been shown to be 
involved in cell migration and invasion in vitro [30], central elements in the development of 
preeclampsia. Further, SNPs in the LRP1B gene were associated with body mass index (BMI) in 
a large GWAS [31], and insulin resistance in a follow-up study [32], suggesting that this gene 
may be involved in body weight regulation. Johnson et al. found the T allele of the LRP1B SNP 
protective for preeclampsia [19]. We observed the T allele of the LRP1B SNP to be associated 
with decreased weight, and increased height. The possibility of LRP1B harbouring genetic 
variants influencing preeclampsia and CVD is possible, as obesity and short stature are risk 
factors for both preeclampsia and coronary heart disease [9, 33, 34].  
RND3 (RhoE) plays a role in human cytotrophoblast fusion, suggesting an important role 
in the regulation of trophoblast fusion in pregnancy [35]. RND3 inhibits the biological activity of 
a downstream effector protein, Rho-associated protein kinase (ROCK) [36]. ROCK proteins have 
important roles in abnormal vascular tone, endothelial dysfunction, inflammation, oxidative 
stress and vascular re-modelling, all of which are influential factors in preeclampsia and CVD 
pathogenesis. Johnson et al. found the A allele of the RND3 SNP associated with higher 
preeclampsia risk and nominally associated with increased adiponectin levels [19], a protein 
which is inversely correlated with body fat percentage in adults. In accordance with the latter, we 
found reduced levels of triglycerides and reduced waist-hip ratio for the A allele of the RND3 
SNP. Hence, these data add to the possibility of RND3 harbouring genetic variants that may have 
a role in obesity-related pathology.  
Grancalcin (GCA), a calcium binding protein, is specifically expressed in neutrophils and 
monocytes/macrophages, and displays calcium-dependent translocation to the granules and 
plasma membrane upon activation of these innate immune responders [37]. Neutrophil activation 
leads to the release of toxic factors (e.g. myeloperoxidase) promoting an inflammatory response, 
oxidative stress and vascular dysfunction [38]. While grancalcin deficiency does not adversely 
affect neutrophil function, it does however, impact their adhesive properties to fibronectin [39]. 
Plasma cellular fibronectin, a marker for endothelial and vascular injury, has been reported in 
several studies to be elevated in preeclampsia [40, 41]. Furthermore, neutrophil adhesion to 
fibronectin promotes cytokines such as IL-8 to exert their chemotactic effects, which may explain 
the pronounced abundance of neutrophils in the maternal systemic vasculature of both 
preeclamptic [38] and obese [42] women. We observed that the C allele of the GCA SNP was 
associated with lower risk to be born of a preeclamptic pregnancy and lower risk to have a 
mother who previously had experienced preeclampsia. These results showed association to male 
gender, and were not associated with preeclampsia in the mothers. This could possibly indicate a 
paternally inherited role for this SNP. However, Johnson et al. [19] assessed the maternal 
genotype, and we cannot exclude our association results to preeclampsia as false positives.  
There was only a partial replication between the results of Johnson et al. [19] and our 
study. This could be explained by differences between the studies including constitution of study 
populations (e.g. ethnicity, sex and age), sampling procedures and the undertaken biochemical 
measurements. A limitation to our study is that the number of women with preeclampsia is 
limited, which reduces the power to detect significant associations and making subgroups 
analysis assessing severe preeclampsia (e.g. early versus late onset) impossible. Severe 
preeclampsia may be associated with an even greater risk of CVD later in life [1]. However, this 
relationship was not confirmed in a recently published large review and meta-analysis [2]. 
Another limitation of our study is that we did not access paternal data due to insufficient 
information on paternal cardiovascular risk factors. On the other hand, there is no clear evidence 
of association between preeclampsia and paternal cardiovascular risk factors [43, 44], suggesting 
that influence of paternal genes for increasing preeclampsia risk differs to the influence of genes 
increasing cardiovascular risk [44]. Strengths of our study include a large homogeneous study 
population, assessment of both maternal and adolescent data, a relatively high attendance at 
cohort follow-ups, inclusion of fasting blood samples, standardized endpoint measurements and 
an accurate diagnosis of preeclampsia [21].  
 In conclusion, our study has demonstrated in an independent population that all four 
genetic variants tested (rs2322659 (LCT), rs35821928 (LRP1B), rs115015150 (RND3) and 
rs17783344 (GCA)) were nominally associated with known cardiovascular risk factors including 
height, weight, waist-hip ratio, blood glucose and triglycerides. The GCA SNP was associated 
with lower risk to be born of a preeclamptic pregnancy and lower risk to have a mother who 
previously had experienced a preeclamptic pregnancy, increasing the putative role for this gene 
locus in preeclampsia susceptibility. Our findings support the hypothesis that underlying genetic 
mechanisms for preeclampsia and CVD are, at least in part, shared. These results warrant further 
investigation to determine the potential roles of these variants in preeclampsia and CVD. The 
complex etiology of these disorders are striking, and targeted analyses and more comprehensive 
investigation strategies made possible by new technologies will be important in further revealing 
the genetic susceptibility to preeclampsia and CVD.  
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Table 1 
Clinical and biochemical characteristics of mothers at their children’s 8-year follow-up, and 
adolescents at the 14- and 17-year follow-ups.  
Trait description Mothersab Adolescents 14 yra Adolescents 17 yra 
Systolic blood pressure (mmHg) 118.8 (118.0, 119.6) 111.5 (110.9, 112.1) 118.1 (114.3, 121.9) 
Diastolic blood pressure (mmHg) 69.5 (68.9, 70.0) 58.7 (58.4, 59.1) 63.7 (59.7, 67.8) 
Height (cm) 163.9 (163.5, 164.3) 165.1 (164.6, 165.5) 174.3 (172.1, 176.4) 
Weight (kg) 70.6 (69.6, 71.5) 58.7 (57.9, 59.5) 71.5 (68.3, 74.6) 
Waist-hip ratio  - 0.83 (0.83, 0.84) 0.81 (0.80, 0.81) 
Abdominal skinfold (cm) - - 26.8 (25.3, 28.3) 
Insulin (mU/liter) 3.56 (3.45, 3.67) 12.58 (11.85-13.31) 9.49 (8.83, 10.15) 
Glucose (mmol/liter) 4.81 (4.72, 4.90) 4.81 (4.78-4.84) 4.77 (4.73, 4.80) 
Total cholesterol (mmol/liter) 5.07 (4.99, 5.16) 4.17 (4.13, 4.22) 4.12 (4.07, 4.17) 
HDL-cholesterol (mmol/liter) 1.51 (1.48, 1.55) 1.39 (1.37, 1.41) 1.30 (1.28, 1.32) 
LDL-cholesterol (mmol/liter) 3.10 (3.02, 3.18) 2.32 (2.28, 2.35) 2.34 (2.30, 2.38) 
Triglycerides (mmol/liter) 1.02 (0.96, 1.08) 1.02 (0.98, 1.05) 1.06 (1.02, 1.09) 
aData are expressed as mean (95% CI) or n (%). 
bClinical and biochemical characteristics were obtained when their children attended the 8-year 
follow-up. 
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Table 3 
SNPs nominally associated (P < 0.05) with cardiovascular risk factors for the mothers. 
Gene SNP Trait description n P valuea 
Direction of  
associationb 
LCT rs2322659 Blood glucose* 875 0.003  
Height 900 0.005  
LRP1B rs35821928 Height 902 0.026  
Weight 863 0.044  
RND3 rs115015150 Waist-hip ratio* 739 0.030  
GCA rs17783344 Height* 830 0.045  
*Associated with the adolescent phenotype. 
aObserved measured genotype P value. 
bDirection of association, for the minor allele.  
 
 
 
 
Table 4 
SNPs nominally associated (P < 0.05) with cardiovascular risk factors for the adolescents. 
Gene SNP Trait description n P valuea 
Direction of 
associationb 
LCT rs2322659 Blood glucose 969 0.022  
LRP1B rs35821928 Height* 960 0.013  
RND3 rs115015150 Triglycerides 935 0.001  
GCA rs17783344 Born of a preeclamptic pregnancy 1404 0.003  
    Mother with prior preeclampsia 1403 0.033  
*Associated with the maternal phenotype. 
aObserved measured genotype P value. 
bDirection of association, for the minor allele.  

Pregnant women, n = 2,900
Assessment of: Antenatal information (age at index pregnancy, 
preeclampsia, previously had experienced preeclampsia)
Neonates, n = 2,868
Assessment of: Born of a preeclamptic pregnancy, mother who 
previously had experienced preeclampsia
Year 8 
Mothers, n = 1,685
Assessment of: Maternal cardiovascular risk factors (blood 
pressure, biochemistry)
Year 14 
Adolescents, n = 1,293 (ngirls = 629, nboys = 664)
Assessment of: Adolescent cardiovascular risk factors (blood 
pressure, anthropometry, biochemistry)
Year 17 
Adolescents, n = 1,053, (ngirls = 509, nboys = 544)
Assessment of: Adolescent cardiovascular risk factors (blood 
pressure, anthropometry, biochemistry)
DNA mothers,
n = 1,246
DNA adolescents,
n = 1,404
 
  
 
Fig. 1. Diagram showing numbers of mothers and offspring at the cohort follow-ups which were 
included in the analysis for the current study.  
 

